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Targeted classification, identification and metabolite profiling  
of triterpenoids in the genus Gymnema and Gynostemma  
by developing a building block strategy using UHPLC-QTOF/MS 
The quality control of a medicinal plant requires a rapid, accurate, and 
comprehensive analysis of the chemical profile of the bioactive extract. Common 
HRMS-based compound annotations relied on the mass fragmentation analysis of 
detected peaks to identify the partial structure of the compounds before merging 
them together. Herein, we applied a universally accepted concept that most of the 
natural products of the same organic origin are generated by the same building blocks 
using several conservative biosynthetic processes. The detection of metabolites - 
both known and unknown - can be redefined by an inverse approach, in which, 
prebuilt natural products were predicted using key prefabricated LEGO-type 
building blocks and their biosynthetic construction rules. The conventional mass 
fragmentation pattern analysis and NMR experiments are for the confirmation of the 
existence of predicted compounds.  
Furthermore, we proposed a new idea of multilayer metabolite profiling, 
which provides simple, distinct, and comprehensive chromatogram interface with 
not only original information about retention time of metabolites, but also 
considerable insight into structure formation as well as the chemical relationship 
among plant metabolites. In this study, the building block strategy was applied 
effectively to explore the triterpenoid composition of three medicinal plants 
 ii 
including Gymnema sylvestre, Gymnema latifolium and Gynostemma longipes. 
Overall, we expect this new approach can be used, with much practicality, for 
massive structural characterization and for exploring the biosynthetic relationships 
among various compounds in medicinal plants.  
Part 1:  Discrimination of different geographic varieties of Gymnema sylvestre 
and development of a building block strategy to classification, identification and 
metabolite profiling of its oleanane triterpenoids 
The major class of bioactive metabolites in Gymnema sylvestre, a popular 
Ayurevedic medicinal plant for the treatment of diabetes mellitus, is oleanane 
triterpenoids. In this study, a targeted, biosynthesis-inspired approach using 
UHPLC-qTOF/MS was implemented to elucidate the whole chemical profile of the 
plant for the standardization of the Vietnamese G. sylvestre variety. The known 
compounds reported in the literature were first analyzed to identify the building 
blocks of the biosynthetic intermediates and the construction rules for synthesizing 
oleanane triterpenoids in the plant. These blocks were recombined to build up a 
theoretical virtual library of all reasonable compounds consistent with the deduced 
construction rules. Various techniques, including microfractionation, relative mass 
defect filtering, multiple key ion analysis, mass fragmentation analysis, and 
comparison with standard references, were applied to determine the presence of 
these predicted compounds. Conventional isolation and structure elucidation of 6 of 
the new compounds were carried out to identify new building blocks and validate 
the assignments. Consequently, 119 peaks were quickly assigned to oleanane 
triterpenoid, and among them, 77 peaks are predicted to be new compounds based 




metabolites were then classified into different layers to analyze their logical 
relationships and construct a multilayered chemical profile of the oleanane 
triterpenoids.  
Part 2: Oleanane triterpenoids from Gymnema latifolium and their PTP1B 
inhibitory activities 
Natural products are promising sources of lead compounds that play 
significant roles in the discovery of new antidiabetic agents via the mechanism of 
PTP1B inhibition. In our ongoing research to find PTP1B inhibitors from natural 
products, hundreds of plant’s extracts available in Korea Bioactive Natural Material 
Bank has been screened against this biological target. An extract of the Gymnema 
latifolium Wall. ex. Wight showed considerable PTP1B inhibitory activity. This 
result was in good agreement with the use of this plant in Vietnam as an antidiabetic 
herbal medicine, similar with its taxonomical relative G. sylvestre. It is also well-
known that most species belonging to the same genus possess similar chemical 
composition and thus exhibit similar biological activities. Further chemical 
investigation of this plant led to the isolation of 14 new oleanane triterpenes 
Gymlatinosides GL1-GL14 and 6 known oleanolic acid analogs. The structures of 
the new compounds were elucidated using diverse spectroscopic methods. Among 
them, compounds Gymlatinosides GL2 and GL3 showed significant PTP1b 
inhibitory effect. The building block strategy was also applied successfully to predict 
the structures of 54 new compounds which may have similar skeleton and 
biosynthesis construction with those isolates.  
 iv 
Part 3: 12,23-Dione dammarane triterpenes from Gynostemma longipes and 
their muscle cell proliferation activities via activation of the AMPK pathway. 
The aging population is growing rapidly around the world. Sarcopenia, 
characterized by decreased muscle mass, strength, and function, is a common feature 
of the elderly population. AMP-activated protein kinase (AMPK) is an essential 
sensor and regulator of glucose, lipid, and energy metabolism throughout the body. 
Previous studies have shown that AMPK pathway activation by regular exercise and 
appropriate dietary control have beneficial effects on skeletal muscle. In the process 
of searching for new AMPK activators from medicinal plants, we isolated and 
characterized eight new 12,23-dione dammarane triterpenoids (1–3 and 5–9), as well 
as one known gypentonoside A from Gynostemma longipes. Application of the 
building blocks and their construction rules also led to the assignment of 26 possible 
new compounds. All 9 isolated compounds were tested for their AMPK activation 
activities, seven compounds (1 and 3–8) were significantly activated AMPK 
phosphorylation in mouse C2C12 skeletal muscle cell lines. Since G. longipes 
contained a significant amount of active compound Longipenoside A1 (over 2.08% 
per dried raw plant), it suggested the potential of this plant to be developed as a 
functional food or botanical drug that enhances muscle proliferation by activating 
AMPK signaling pathways. 
Keywords: Gynostemma longipes, Gymnema sylvestre, Gymnema latifolium, 
oleanane triterpenes, dammarane triterpenes, building block strategy, PTP1B, 
muscle cell proliferation.  
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Part 1. Discrimination of different geographic varieties of Gymnema 
sylvestre and development of a building block strategy to classification, 
identification and metabolite profiling of oleanane triterpenoids in its 
Vietnamese variety using UHPLC-qTOF/MS 
1. Introduction 
Gymnema sylvestre (Retz.) R.Br. ex Sm. (GS) is a well-known Ayurvedic 
medicinal plant that has a deep root in history and is being studied extensively for its 
effectiveness in the treatment of type 2 diabetes mellitus (T2DM) (Pothuraju et al., 
2014). Preparations of this plant include a simple tea brew, tea bags, beverages and 
confectioneries (Tiwari et al., 2014).  
It has also found significant applications in various food preparations for 
regulation of sugar homeostasis, control of obesity and blood cholesterol levels. A 
food supplement based on wheat (Triticum aestivum), blended with legumes, non-
fat dry milk, vegetable oils, spices and hypoglycemic ingredients including GS, was 
formulated as a suitable supplement or meal alternative for non-insulin-dependent 
diabetes patients (Shobana et al., 2007).  
Most research on GS to date was performed on material from India, and its main 
active components are a group of gymnemic acids with a β-glucuronic acid at C-3 
and a hydroxyl substitution at C-23 on an oleane triterpene-type aglycon (Pothuraju 
et al., 2014). These gymnemic acids have been recognized for years for their role in 
suppressing selectively sweet taste sensations in humans (Warren and Pfaffmann, 
1959) (Frank et al., 1992) (Gent et al., 1999). Recently, Kashima et al. suggested that 
the subjective sweet taste intensity in GS-administered volunteers was decreased 
 2 
compared with a control group and revealed the role of a GS extract in delaying 
postprandial gastrointestinal blood flow and gastric emptying, which may affect 
subsequent glycemic metabolism (Kashima et al., 2017). 
LC-MS analysis of the GS extract after acid hydrolysis from different 
geographic distributions (India, Vietnam and China) revealed the similarity in LC 
pattern between samples from Vietnam and China but showed a significant 
discrepancy with samples of Indian origin. Specifically, gymnemagenin, a 23-
hydroxyl triterpene aglycon, was found in the Indian sample but not the Vietnamese 
and Chinese samples. This result is in good agreement with the proposed chemical 
variation of GS varieties from China, characterized by the lack of 23 hydroxyl 
functional groups, from their oleanane-type triterpene glycosides (Ye et al., 2001b). 
The advent of liquid chromatography coupled mass spectrometry (LC/MS) with 
advantages of rapid analysis, high mass accuracy, and high resolution has provided 
powerful support for the rapid identification and discovery of secondary metabolites 
in complex natural extract (Wolfender et al., 2015). However, recognition of 
metabolites in automatically acquired mass spectrometric data confront plenty of 
obstacles: (1) large amounts of interference ions often mask the ions of analyzed 
compounds; (2) plants are always comprised by hundreds of different constituents 
that belong to different group of metabolites; and (3) the availability of reference 






Figure 1: LC chromatogram of acid hydrolysis products of G. sylvestre originated 
from Vietnam, China, India and compare with standard gymnemagenin 
In recent years, several approaches to postacquisition processing techniques for 
the detection and structural assignment of the chemical constitutes in medicinal 
plants have been developed.  Traditional manual processing is generally slow, 
tedious, and likely to miss the trace metabolites (Xie et al., 2012). An improved 
method, relative mass defect (RMD) calculations, has enabled the rapid 
identification of an extensive range of different groups of metabolites in the 
complicated matrixes of plant extracts (Ekanayaka et al., 2015). Another approach 
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using key ion filtering (KIF) has been reported to be helpful in the identification of 
triterpenoid saponins that have a robust aglycone backbone and similar mass 
fragmentation patterns (Qi et al., 2012; Qiao et al., 2016; B. Yang et al., 2018). 
However, in many cases, the data from a single KIF of the total extract contained a 
substantial amount of noise, were nonselective, and were difficult to analyze. As a 
result, the multiple product ion filtering (mPIF) technique was developed and proved 
to be effective for identifying and classifying nontarget/target notoginsenosides in P. 
notoginseng extract (Xing et al., 2015). Recently, progress has been made in the 
deconvolution of complex extracts into their single constituents by the 
microfractionation of the extracts based on advanced high-performance liquid 
chromatography (HPLC) (Bohni et al., 2013). This technique is fast, simple, and 
effective for minimizing the loss of compounds of interest on the column and 
significantly amplifying the signals of low-content metabolites. 
Notably, most natural products with the same organic origin are built from 
the same precursors, which could be considered the building blocks in the 
biosynthesis process. Additionally, knowing the structures of several of the key 
building blocks is sufficient to obtain an overview of the diversity of the natural 
products and give some insights into the metabolism (Franck, 1979). To explain how 
natural products are constructed, the structures can be broken down into their basic 
building blocks, and this fragmentation can be used to propose a reasonably 
construction pathway. This approach facilitates the identification of secondary 
metabolites and can be used to rationalize the elaborated structures and thus reveals 





Any chemical composition variation can influence the pharmacological 
activity, safety and standardization of a medicinal plant, and thus, we have focused 
this study on the discrimination of two varieties of GS using different approaches, 
including morphological, anatomical and ITS1-5.8S-ITS2 DNA sequence 
comparison.  
This research was conducted in 6 steps as shown in Figure 2. (1) A virtual 
mass library of predicted oleanane triterpenoids was established using their building 
blocks and the putative biosynthesis construction. (2) Microfractionation of the total 
extract was conducted using semipreparative HPLC. (3) Untargeted data of G. 
sylvestre extract and its microfractions were acquired by UPLC/qTOF-MS. (4) 
Integrated mass analysis techniques including RMD filtering were used for the rapid 
identification of the targeted oleanane triterpenoids and the elimination of fractions 
of nontargeted group of metabolites, and key ion extraction for the predicted 
compounds was used to confirm their presence in the extract and fractions; mKIA 
recognize aglycones, and MFA was used to confirm glycosidic and acyl linkages. (5) 
The compound determinations were validated by comparison with reference 
substances and the structure elucidation of selected compounds. (6) A multilayer 
metabolite profile of the G. sylvestre extract was constructed based on all the 
compound assignments to analyze the chemical relationships among the structures.  
Purpose of research 
x Identify the differences between Vietnamese and Indian G. sylvestre 
varieties. 
x Establish a dereplication strategy to identify quickly the chemical 










2. Materials and methods 
2.1. Plant materials 
Samples of two varieties of Gymnema sylvestre originating from India (GS-I) 
and Vietnam (GS-V1 and G-V2) were cultivated in the same conditions at a WHO 
Good-Agriculture-Practice-certificated farm (GAP) in Nam Dinh and Thai Nguyen 
provinces, Vietnam. Samples were collected in September 2016. Voucher specimens 
of GS-I, GS-V1 and GS-V2 were deposited in the Medicinal Herbarium of Hanoi 
University of Pharmacy with the accession numbers HNIP-2016.05, HNIP-2016.06, 
and HNIP-2016.07, respectively. Samples of Gymnema sylvestre originating from 
Guangxi - China (GS-C) were collected in June 2017 and used in the hydrolysis 
experiment. 
2.2. Morphology and anatomy analysis 
An EZ4 Stereo Microscope (Leica, Germany) was used to analyze the 
characteristics including life form, stem, leaves, flowers, fruits and seeds. 
Photographs were obtained with a Canon SD4500IS or Canon EOS 60D + Canon 
100 mm f2.8 IS Macro (Canon Inc., Japan). For anatomical analysis, cross sections 
of fresh mature stems and leaves were prepared using a rotatory microtome and 
double-stained with methylene blue and carmine red. A light microscope MBL200 
(A.Krüss Optronic, Germany) connected to a Canon SD4500IS (Canon Inc., Japan) 
was used to visualize the results.  
2.3. ITS1-5.8S-ITS2 sequence analysis 
Total DNA was extracted from 200 mg of fresh plant leaves using a DNeasy 
Plant Mini Kit (QIAGEN, Germany) with some modifications. The internal 
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transcribed spacer sequence was amplified with forward primer ITS5 (5′-
GGAAGTAAAAGTCGTAACAAGG-3′) and reverse primer ITS4 (5′- 
TCCTCCGCTTATTGATATGC-3′) supplied by Bioneer (Bioneer Corporation, 
Korea) using a Mastercycler pro S (Eppendorf AG., Germany). PCR products were 
cleaned using a purification KIT from Thermo Fisher (USA), and sequencing was 
conducted by Macrogen Inc. (Seoul, Korea). DNA sequences were compared to 
published sequences available on GenBank (National Institutes of Health) using the 
Basic Local Alignment Search Tool (Blast) (Altschul et al., 1990). 
Internal transcribed spacer (ITS1-5.8S-ITS2) sequences of two samples of 
Gymnema sylvestre collected in different regions of Vietnam (G. sylvestre V1 and 
V2) and one of Indian origin domesticated in Vietnam (GS-I), together with 18 ITS 
sequences of five species ⎯ G. sylvestre, G. latifolium, G. inodorum, G. yunanense 
and Marsdenia tenacissima (as an outgroup) ⎯ obtained from Blast analysis were 
aligned using Geneious alignment. Finally, Geneious DNA sequencing analysis 
software (version 8.1.8, Biomatters Ltd, New Zealand) was used to construct a 
neighbor-joining phylogenetic tree with resampling bootstrap values above 75% 
(expressed as percentages of 1,000 replications) (Kearse et al., 2012).  
2.3. Establishment of a Virtual Mass Library based on Building Blocks 
A comprehensive review of all triterpenoid compounds isolated from G. 
sylvestre was retrieved from publications indexed on Scifinder, Pubmed, and Google 
scholar. However, due to the differences of chemical composition by different 
geographic distributions (Pham et al., 2018; Ye et al., 2001b), only compounds 
isolated from G. sylvestre originated from China, Vietnam, and Taiwan were used 




Taiwain is a synonym of G. sylvestre based on its morphology (HaiLong, 1998) and 
chemical composition (K. Yoshikawa et al., 1998; 1999). This database was further 
interpreted to create a library of predicted compounds by combinations of building 
blocks following construction rules deduced from the known compounds. Based on 
the molecular formulae of predicted compounds, their molecular weights were 
calculated using Masslynx 4.1 (Waters MS Technologies, Manchester, UK). 
2.4. UPLC-ESI-MSn Experiments 
An extract of the Vietnamese G. sylvestre variety was prepared by extracting 
the plant materials with70%  EtOH by Nam Duoc Pharmaceutical Jsc. (Nam Dinh 
province, Vietnam) in July 2017. In order to obtain good chromatographic peaks, 
this extract was then microfractionated into 20 subfractions (T1-T20) using 
preparative HPLC in time collection mode [Optima Pak C18, using a gradient elution 
of MeOH 55% - 90%, flow rate 2.0 mL/min, each fraction 2 min].  
The total extract and subfractions from G. sylvestre were analyzed via a 
Waters Acquity UPLC system (Waters Co., Milford, MA, USA) coupled with a 
Waters Xevo G2 QTOF mass spectrometer (Waters MS Technologies, Manchester, 
UK) that was equipped with an electrospray interface (ESI). A mobile phase (solvent 
A) was H2O containing 0.1% formic acid (v/v) and the organic phase (solvent B) 
was acetonitrile. A 20 min binary gradient elution was executed at a flow rate 0.2 
mL/min for the separation: a linear gradient from 10% to 90% solvent B in 17 min; 
then followed by an isocratic 90% B in 3 min. The mass spectrometer was operated 
in the ESI (–) MS1 and (+) MSn mode. The parameters were as follows: wave length 
range: 200 to 500 nm; analyses of the samples 5 mg/mL (2.0 μL injected into the 
partial loop in the needle overfill mode) were performed in the negative ion modes 
 10 
in the m/z 50 – 1200 range with acquisition times of 0.2 s in the centroid mode. The 
ESI conditions were set as follows: capillary voltage 2.0 kV, con voltage 20V, source 
temperature 120 °C, desolvation temperature 350 °C, and desolvation gas flow 600 
L/h.  The MSn ramp energy was set from 25.0 to 65.0 eV.  
RMD is calculated in ppm as (mass defect/measured monoisotopic mass) × 
106.  Key ion filterings applied for calculated mass of parent ions were applied in 
MS1 of both negative and positive mode for the detection of predicted target 
compounds. Multiple key ions analysis was applied in positive HRMS (65 eV) to 
determine different aglycone types. Neutral fragment mass analysis was used to 
analyze and the positive HRMS data at 25 eV to identify glycosyl and acyl 
substitutions on the aglycones. The chemical formulae of detected compounds were 
finally confirmed using a formula predictor by setting the parameters as follows: C 
(20–100), H (40–200), O (20–100), and N (0 or 1) while other elements such as P, 
S, Cl, and Br were not considered.  
2.5. Hydrolysis of Total Extract 
Total extract (100 mg) was hydrolyzed with 2.0 N HCl (70% MeOH, 10 mL) 
at 90 °C for 1 h. The solution was neutralized by 10% NaOH, dried, and suspended 
in H2O and partitioned with EtOAc. The EtOAc portion was dried, dissolved in 
MeOH, and filtered through a 0.2-µm Whatman hydrophilic membrane filter into an 
HPLC sample vials immediately before analysis by HRMS to identify different 
aglycones. The identification of each aglycone was confirmed by comparing 
retention time and HRMS with isolated references. The residual H2O layer was 
concentrated and dissolved in pyridine (1.0 mL) and 5.0 mg of L-cysteine methyl 




𝜇L of phenylisothiocyanate (Sigma, St. Louis, MO, USA) was added. This solution 
was filtered through a 0.2-µm Whatman hydrophilic membrane filter into an HPLC 
sample vials immediately before LC-MS analysis. Analysis was performed using an 
Agilent 1200 HPLC system (Agilent Technologies, Palo Alto, CA, USA) with INNO 
C18 (4.6 × 250 mm inner diameter, 5 μm particle size; Young Jin Bio Chrom Co., 
Ltd) at a column temperature of 30 °C. Chromatographic condition was carried out 
using a mobile phase of 27% CH3CN isocratic elution at a flow rate 0.6 mg/mL in 
60 min. The sugar derivatives showed the retention time at 10.9, 14.9, 17.3, and 21.5 
min, and were identical to the derivatives of authentic D-glucuronic acid, D-glucose, 
D-xylose, and L-rhamnopyranose, respectively.  
2.6. Extraction and isolation schemes  
2.6.1. General experimental procedures 
Optical rotation was measured on a JASCO P-2000 polarimeter (JASCO 
International Co. Ltd., Tokyo, Japan). IR data were recorded on a Nicolet 6700 FT-
IR spectrometer (Thermo Electron Corp., Waltham, MA, USA). The NMR data were 
analyzed using an AVANCE 500 MHz spectrometer (Bruker, Germany) or JNM-
ECA 600 MHz spectrometer (Jeol, Japan) or AVANCE III 800 HD spectrometer 
coupled with a 5-mm CPTCI cryoprobe (Bruker, Germany). The HRESIMS values 
were analyzed via an Agilent Technologies 6130 Quadrupole LC/MS spectrometer 
equipped with an Agilent Technologies 1260 Infinity LC system (Agilent 
Technologies, Inc., Santa Clara, CA, USA) and INNO C18 column (4.6 × 150 mm, 
5 Pm particle size, 12 nm, J.K.Shah & Company, Korea). Silica gel (particle size: 
63200 Pm) and RP-C18 (particle size: 40–63 Pm), which were purchased from 
Merck (Darmstadt, Germany), and Sephadex LH-20 from Sigma-Aldrich (St. Louis, 
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MO, USA) were used for column chromatography (CC). Silica gel 60 F254 and RP-
18 F254 TLC plates were from Merck (Darmstadt, Germany). A Gilson HPLC 
purification system, equipped with an Optima Pak C18 column (10 × 250 mm, 10 Pm 
particle size; RS Tech, Seoul, Korea), was used with a flow rate of 2 ml/min and UV 
detection at 205 and 254 nm. 
2.6.2. Isolation scheme  
The crude extract obtained (1 kg) was suspended in water, absorbed on 
macroporous resin HP20, and washed out with water, 50% EtOH, 95% EtOH, and 
acetone in a sequential elution process. The 95% EtOH fraction (300 g) was 
subjected to silica gel column chromatography (15 × 45 cm; 63–200 μm particle size) 
using n-hexane/EtOAc (gradient from 10:1 to 0:1) then EtOAc/CH3OH (gradient 
from 6:1 to 0:1) to give 8 fractions (A-G) based on the thin-layer chromatography 
profile. Fraction F, which was identified to be a triterpenoid-rich fraction by LC-MS 
analysis, was then chromatographed on reversed phase silica gel column eluting with 
CH3OH/H2O (v/v, from 2:3 to 1:0) to yield ten fractions (FI-FX).  
Fraction FV (12 g) was subjected to a RP-18 column separation eluted by 
CH3CN/H2O (v/v, gradient 3:7 to 7:3) to yield five fractions (FV.N1 – FV.N5). 
Fraction FV.N1 (5.0 g) was re-chromatographed on silica gel column 
chromatography (5 × 20 cm; 40–63 μm particle size) eluting with 
CH2Cl2/CH3OH(v/v, gradient from 6:1 to 0:1) to yield five sub-fractions FV.N1-A 
to FV.N1-E. Subfraction FV.N1-E was applied to a succession of Sephadex LH-20 
(100% CH3OH) and HPLC Optima Pak C18, CH3CN/H2O (2:3), flow rate 2 mL/min 




LH-20 (using 100% CH3OH) and then purified by semi-preparative HPLC (Optima 
Pak C18, 35% CH3CN, flow rate 2 mL/min) to produce compounds 2 (21.1 mg).  
Subfraction FIII (5.2 g) was re-chromatographed with silica gel column 
chromatography (5 × 20 cm; 40–63 μm particle size), eluting with CH2Cl2/CH3OH 
(v/v, gradient from 10:1 to 0:1) to yield 5 sub-fractions FIII.N1 to FIII.N5. Fraction 
FIII.N3 (520 mg) was applied to a succession of Sephadex LH-20 (CH3OH 100%) 
and HPLC (Optima Pak C18, 50% CH3CN, flow rate 2 mL/min) to afford compounds 
3 (10.6 mg). Fraction FIII.N4 (1.5 g) was developed on a reversed phase silica gel 
column chromatography, eluting with CH3CN/H2O (v/v, from 1:4 to 1:0) to yield 6 
subfractions (FIII.N4.R1-6). Subfraction F.III.N4.R3 was purified by HPLC 
(Optima Pak C18, 55% CH3CN, flow rate 1.5 mL/min) to afford compounds 4 (6.5 
mg). Subfraction F.III.N4.R5 was purified by HPLC (Optima Pak C18, 50% CH3CN, 
flow rate 1.5 mL/min) to afford compounds 5 (7.8 mg). Fraction F.III.N4.R6 was 
applied to a succession of Sephadex LH-20 (CH3OH 100%) and HPLC (Optima Pak 




Figure 3: Isolation scheme of compounds 1 ⎯ 6 from G. sylvestre  
2.6.3. Physical and chemical characteristics of isolated compounds 
Gymnemoside GS1 (1): amorphous powder; [D]25D  –24.6 (c 0.2, MeOH); IR (KBr) 
νmax: 3394, 1052, 1610 cm-1. 13C and 1H NMR data, Tables 3 and 4; HRESIMS m/z 
1089.5884 [M – H]– (calcd for C54H89O22, 1089.5845). 
Gymnemoside GS2 (2): amorphous powder; [D]25D  –26.3 (c 0.2, MeOH); IR (KBr) 
νmax: 3397, 2954, 2296, 1647, 1348, 1017 cm-1; 13C and 1H NMR data, Tables 3 and 




Gymnemoside GS3 (3): Amorphous powder; [D]25D –14.0 (c 0.2, MeOH); IR (KBr) 
νmax: 3389, 2949, 2298, 1663, 1053 cm-1; 13C and 1H NMR data, Tables 3 and 4; 
HRESIMS 753.4235 [M–H]– (calcd for C43H61O11 753.4214). 
Gymnemoside GS4 (4): Amorphous powder; [D]25D  –19.3 (c 0.2, MeOH); IR (KBr) 
νmax: 3397, 2954, 2298, 1647, 1535, 1302, 1108, 1017 cm-1; 13C and 1H NMR data, 
Tables 3 and 4; HRESIMS m/z 754.4158 [M – H]– (calcd for C42H60NO11, 754.4166).  
Gymnemoside GS5 (5): Amorphous powder; [D]25D  –22.0 (c 0.2, MeOH); IR (KBr) 
νmax: 3394, 2980, 1704, 1014 cm-1; 13C and 1H NMR data, Tables 3 and 4; HRESIMS 
m/z 731.4382  [M – H]– (calcd for C41H63O11 731.4370). 
Gymnemoside GS6 (6): Amorphous powder; [D]25D  –11.0 (c 0.2, MeOH); IR (KBr) 
νmax: 3391, 2971, 2843, 1703, 1515, 1050 cm-1; 13C and 1H NMR data, Tables 3 and 
4; HRESIMS m/z 617.4054 [M – H]− (calcd for C36H57O8  617.4053).  
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3. Results and discussion 
3.1. Discrimination of different geographic varieties of G. sylvestre  
3.1.1. Agronomical characteristics 
Two varieties of G.sylvestre, which were growth up in the same environment 
conditions, exhibited several agronomical characteristic differences. The 
Vietnamese variety has flowers two times per year including Spring (February – 
April) and autumn (September – November) while the Indian variety only has flower 
in autumn (September – November). The number of seed per fruit of the Vietnamese 
variety (30 – 50) is also much more thatn that of the Indian variety (<10) (Figure 4). 
  
  
Vietnamese variety Indian  variety 
Figure 4: Agronomical characteristics of two varieties of G. sylvestre 
3.1.2. Morphological and anatomical characteristics 
Detailed descriptions of the macroscopic and microscopic characteristics of two 




with those of Gymnema sylvestre (Retz.) R.Br. ex Sm., described in Flora of China 






Figure 5. Morphological characteristics of G. sylvestre originated from Vietnam 
(A. GS-V) and India (B. GS-I). 
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In addition to these similarities, some distinctive characteristics can be used to 
differentiate the two samples (Figure 6), including the following: (1) young 
branchlets that are glabrescent or pubescent in GS-V but densely pubescent in GS-I;  
(2) in both samples, leaf blades are diverse and can vary from obovate to ovate; 
however, they are more likely to be obovate and thick in GS-V yet ovate and thinner 
in GS-I; (3) adaxial and abaxial leaves are nearly glabrous and slightly pubescent at 
the mid-vein of GS-V, but they are found to be pubescent on both sides and densely 
pubescent at the midvein of GS-I; (4) GS-V has 4-5 pairs of lateral veins, while the 
venation system of GS-I consists of 3-4 pairs with three main veins converging at 
the base that are always more prominent; (5) follicle fruits are broadly lanceolate 
with an acuminated beak on top in GS-V; in contrast, they are smaller with narrowly 
lanceolate in outline, with no beak, in GS-I. 
 
Figure 6. Selective morphological and anatomical characteristics to differentiate 




To confirm the scientific names of these two samples, we further compared 
their morphological characteristics with TYPE specimens of Gymnema sylvestre 
deposited at the Museum National d'Histoire Naturelle, Paris. Sample GS-V was 
identified as similar to HOLOTYPE specimen MNHN-P-P04256786 (Figure 7-A) 
collected in Tonkin, Vietnam, while sample GS-I was comparable to the “TYPE” 
specimen MNHN-P-P00645841 (Figure 7-B) from India. Another SYNTYPE 
specimen MNHN-P-P00442712 from Madagascar (Africa) also matched with GS-I. 
All specimens mentioned above are identified as Gymnema sylvestre. Although the 
two studied samples were determined to be the same species, their differences were 
apparent enough to be considered two varieties of the species Gymnema sylvestre 







Figure 7. A. HOLOTYPE specimen of Gymnema sylvestre (Retz.) R.Br. ex Schult 





3.1.3. Internal transcribed spacer ITS1-5.8S-ITS2 sequence analysis 
The ITS region encompasses the two noncoding regions, ITS1 and ITS2, 
which are separated by the highly conserved 5.8S rRNA gene (White et al., 1990). 
Multiple alignment analysis of 21 samples also illustrated the conservative property 
of the 5.8S region, with only 2 single nucleotide polymorphisms (SNPs). Variations 
between samples mainly occurred in the ITS1 and ITS2 regions (Figure 8-A) and 
thus promised significant separation of closely related species. Accordingly, the 
neighbor-joining phylogenetic tree showed clear divisions for all samples at the 
inter-species level, with pairwise genetic distances by identity that varied from 90.9% 
(between GS-I and G. latifolium) to 96.4% (between GS-V and G. yunnanense) 
(Figure 8-B). At the intra-species level, G. sylvestre samples were divided into two 
groups, which strongly referred to the native origins from Vietnam and India (Figure 
8-C). The molecular differences between two groups of samples of G. sylvestre were 




          C.  
 
Figure 8. Neighbor-joining phylogenetic tree based on internal transcribed spacer 
(ITS) sequences of nuclear ribosome DNA of samples in the genus Gymnema.  
Bootstrap values expressed as percentages of 1,000 replications (>75%) are shown 
above branches. Underlined samples were directly sequenced in this study, and other 
samples sequences were obtained from GenBank via Blast analysis. Marsdenia 




3.2. Development of a building block strategy to classification, identification and 
metabolite profiling of oleanane triterpenoids in the Vietnamese G. sylvestre variety 
using UHPLC-qTOF/MS 
3.2.1. Building Blocks and Construction Rules of Triterpenoids isolated from G. 
Sylvestre.  
A comprehensive review of publications up to December 2018 on all the 
oleanane-type triterpenoids isolated from G. sylvestre indexed on SciFinder, 




No. R3 R16 R21 R22 R28 R29 CAS number 
1 -O-𝛽-glcA -OH -H -OH -CH2-O-α-rha -CH3 2253651-94-2 
2 -OH -H -H -H -COOH -CH3 508-02-1 
3 -OH -OH -H -H -CH2OH -CH3 465-94-1 
4 -OH -OH -OH -H -CH2OH -CH3 474-15-7 
5 -OH -OH -H -H -CH2OH -CH2OH 122746-52- 
6 -OH -OH -OH -H -CH2OH -CH3 53187-93-2 
7 -OH -OH -H -OH -CH2OH -COOH 862377-55-7 
8 -OH -H -H -H -CO-O-𝛽-glu -CH3 
14162-53-9 
 
9 -O-𝛽-glcA -OH -H -H -CH2OH -CH3 287390-11-8 
10 -O-𝛽-glcA -OH -OH -H -CH2OH -CH3 2229693-57-4 
11 -O-𝛽-glcA -OH -H -H -CH2OH -CH2OH 2229693-58-5 
12 -O-𝛽-glc6-O-Me* -OH -OH -H -CH2OH -CH3 1096581-47-3 
13 -O-𝛽-glcA -OH -H -H -CH2OH -COOH 
873799-50-9 
 
14 -O-𝛽-glcA -OH -O-Bz -H -CH2OH -CH3 287389-94-0 
15 -O-𝛽-glcA -OH -H -OH -CH2O-bz -CH2OH 2229693-59-6 
16 -O-𝛽-glc6-O-𝛽-glc -H -H -H -COOH -CH3 
240140-86-7 
 
17 -O-𝛽-glc -H -H -H -COO- 𝛽-glc -CH3 
78454-20-3 
 
18 -O-𝛽-glcA3-O-𝛽-glc -OH -H -H -CH3 -CH3 2229693-55-2 
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N
No. R3 R16 R21 R22 R28 R29 CAS number 
19 -O-𝛽-glcA -OH -H -H -CH2-O-𝛽-glc -CH3 256510-00-6 
20 -O-𝛽-glcA3-O-𝛽-glc -OH -OH -H -CH2OH -CH3 
330595-34-1 
 
21 -O-𝛽-glcA3-O-𝛽-glc -OH -H -OH -CH2OH -CH3 212775-47-8 
22 -O-𝛽-glcA -OH -H -OH -CH2-O-𝛽-glc -CH3 212775-48-9 
23 -[O-𝛽-glcA3-O-𝛽-glc].K -OH -H -H -CH2OH -CH2OH 
330595-36-3 
 
24 -O-𝛽-glcA3-O-𝛽-glc -OH -OH -H -CH2OH -CH3 2229693-54-1 
25 -O-𝛽-glcA -OH -H -H -CH2OH 
-CH2-O-
𝛽-glc 2229693-56-3 
26 -O-𝛽-glcA3-O-𝛽-glc -OH -H -H -CH2OH -COOH 2229693-52-9 
27 -O-𝛽-glcA3-O-𝛽-gal -OH -H -H -CH2OH -COOH 2229693-53-0 
28 -O-𝛽-glcA -OH -H -O-Ac -CH2-O-α-rha -CH3 212775-40-1 
29 -O-𝛽-glcA -O-Ac -H -OH -CH2-O-α-rha -CH3 212775-43-4 
30 -O-𝛽-glcA -OH -H -O-tga -CH2-O-𝛽-rha -CH3 
256509-97-4 
 
31 -O-𝛽-glcA3-O-𝛽-glc -OH -H -O-tga -CH2OH -CH3 
 
256509-77-0 
32 -O-𝛽-glcA3-O-𝛽-glc -OH -H -OH -CH2-O-tga -CH3 
256509-82-7 
 
33 -O-𝛽-glcA3-O-𝛽-glc -O-tga -H -OH -CH2OH -CH3 
256509-83-8 
 
34 -O-𝛽-glc6-O-𝛽-glc6-O-𝛽-xyl -H -H -H -COOH -CH3 287389-96-2 
35 -O-𝛽-glc6-O-𝛽-glc6-O-𝛽-xyl -H -H -H -COOH -CH3 
287389-96-2 
 
36 -O-𝛽-glc6-O-𝛽-glc6-O-𝛽-xyl -OH -H -H -CH2OH -CH3 
164177-55-3 
 
37 -O-𝛽-glc6-O-𝛽-glc6-O-𝛽-xyl -OH -H -OH -CH3 -CH3 1422031-87-5 
38 -O-𝛽-glcA3-O-𝛽-glc -OH -O-Bz -H -CH2OH -CH3 
330595-32-9 
 
39 -O-𝛽-man3-O-𝛽-glc6 -OH -H -OH -CH2-O-𝛽-glc -CH3 1422031-89-7 
40 -O-𝛽-glc6-O-𝛽-glc6-O-𝛽-xyl -OH -H -OH -CH2OH -CH3 
163456-79-9 
 
41 -O-𝛽-glc6-O-𝛽-glc -H -H -H -CO-O-𝛽-glc -CH3 287389-95-1 
42 -O-𝛽-glc6-O-𝛽-glc -OH -H -H -CH2-O-𝛽-glc -CH3 1096581-44-0 
43 -O-𝛽-glcA3-O-𝛽-glc -OH -H -OH -CH2-O-α-rha -CH3 212775-51-4 
44 -O-𝛽-glcA3-O-𝛽-glc -OH -H -H -CH2-O-𝛽-glc -CH3 212775-50-3 
45 -O-𝛽-glcA3-O-𝛽-glc -OH -H -OH -CH2-O-𝛽-glc -CH3 212775-45-6 
46 -O-𝛽-glcA3-O-𝛽-glc -OH -H -O-Ac -CH2-O-α-rha -CH3 212775-19-4 
47 -O-𝛽-glcA3-O-𝛽-glc -O-Ac -H -OH -CH2-O-α-rha -CH3 212775-23-0 
48 -O-𝛽-glcA3-O-𝛽-glc -O-Ac -H -OH -CH2-O-α-rha -CH3 
330595-38-5 
 
49 -O-𝛽-glcA3-O-𝛽-glc -OH -H -O-tga -CH2-O-𝛽-xyl -CH3 
256509-93-0 
 
50 -O-𝛽-glcA3-O-𝛽-glc -OH -H -O-tga -CH2-O-α-rha -CH3 212775-27-4 
51 -O-𝛽-glcA3-O-𝛽-glc -OH -H -O-tga -CH2-O-𝛽-glc -CH3 
256509-85-0 
 
52 -O-𝛽-glc6-O-𝛽-glc6-O-𝛽-xyl -H -H -H -CO-O-𝛽-glc -CH3 
287389-97-3 
 
53 -O-𝛽-glc6-O-𝛽-glc6-O-𝛽-xyl -H -H -H -CO-O-𝛽-glc -CH3 
287389-96-2 
 
54 -O-𝛽-glc6-O-𝛽-glc6-O-𝛽-xyl -OH -H -H -CH2-O-𝛽-glc -CH3 
256510-01-7 
 











Based on the literature data, we anticipated that the triterpenoid saponins of 
the Vietnamese variety of G. sylvestre were constructed from three components: a 
main aglycone, 1 or 2 glycosidic linkages at C-3 and/or C-28, and one acyl moiety 
attached to a hydroxy group of the main aglycone. The triterpenoid aglycones 
reported from G. sylvestre were longispinogenin (L), chichipegenin (C), 
sitakisogenin (S), gymnemagenol (G), 22α-hydroxygymnemagenol (HG), 
myrtilogenic acid (My), maniladiol (M), oleanolic acid (O), and 3β,16β,28-
trihydroxyolean-12-en-22,29-olide (La). The glycosidic side chains included 
glucuronic acid (glcA), glucose (glc), rhamnose (rha), and xylose (xyl). The acyl 
fragments could be acetyl, tigloyl (tig), and benzoic acid (bz). Two new building 
blocks, erythrodiol (E) and nicotinoyl (nic), were identified from three new 




Figure 10. Building blocks (A) and construction rules (B) of oleanane triterpenoids 
of G. sylvestre. 
 The presence of aglycone and glycosidic building blocks was confirmed by 
comparing the retention times of the hydrolyzed extract of G. sylvestre with 
reference aglycones and the trimethylsilyl-L-cysteine derivatives of the water-
soluble fraction of the hydrolysate with authentic sugar derivatives (Figure 11).  
 




The construction rules of oleanane triterpenoids comprising these building 
blocks were deduced from the structures of the known compounds (Figure 10). A 
library of predicted structures and their theoretical deprotonated masses ([M – H]–) 
was created using these rules (Table 1).  
Table 1. Virtual deprotonated mass [M – H]- “library” of compounds constructed 
by building block rules and their detection in extract or microfractions. 
 O E La My L CGS HG M 
 3-O-glcA         
+glcA 631.3846 617.4054 661.3588 663.3745 633.4003 649.3952 665.3901 617.4054 
+glcA+acetyl 673.3952 659.4159 703.3694 705.3850 675.4109 691.4058 707.4007 659.4159 
+glcA+tig 713.4265 699.4472 743.4007 745.4163 715.4422 731.4371 747.4320 699.4472 
+glcA+bz 735.4108 721.4316 765.3850 767.4007 737.4265 753.4214 769.4163 721.4316 
+glcA+nic 736.4081 722.4289 766.3823 768.3980 738.4238 754.4187 770.4136 722.4289 
+glcA+rha 777.4425 763.4633 807.4167 809.4324 779.4582 795.4531 811.4480 763.4633 
+glcA+acetyl+rha 819.4531 805.4738 849.4273 851.4429 821.4688 837.4637 853.4586 805.4738 
+glcA+glc 793.4375 779.4582 823.4116 825.4273 795.4531 811.4480 827.4429 779.4582 
+glcA+glc+acetyl 835.4480 821.4688 865.4222 867.4379 837.4637 853.4586 869.4535 821.4688 
+glcA+glc+tig 875.4793 861.5001 905.4535 907.4692 877.4950 893.4899 909.4848 861.5001 
+glcA+glc+benz 897.4637 883.4844 927.4379 929.4535 899.4793 915.4742 931.4691 883.4844 
+glcA+glc+nic 898.4610 884.4817 928.4351 930.4508 900.4766 916.4715 932.4664 884.4817 
+glcA+glc+glc 955.4903 941.5110 985.4644 987.4801 957.5059 973.5008 989.4957 941.5110 
+glcA+glc+glc+tig 1037.5322 1023.5529 1067.5063 1069.5220 1039.5478 1055.5427 1071.5376 1023.5529 
+glcA+glc+glc+bz 1059.5165 1045.5372 1089.4906 1091.5063 1061.5321 1077.5270 1093.5219 1045.5372 
+glcA+glc+glc+acetyl 997.5009 983.5216 1027.4750 1029.4907 999.5165 1015.5114 1031.5063 983.5216 
+glcA+glc+rha  939.4954 925.5161 969.4695 971.4852 941.5110 957.5059 973.5008 925.5161 
+glcA+acetyl +rha 981.5059 967.5267 1011.4801 1013.4958 983.5216 999.5165 1015.5114 967.5267 
+glcA+glc+tig+rha 1021.5372 1007.5580 1051.5114 1053.5271 1023.5529 1039.5478 1055.5427 1007.5580 
3-O-glc         
+glc 617.4054  603.4261  647.3795  649.3952  619.4210  635.4159  651.4108  603.4261  
+glc+glc 779.4582 765.4789 809.4324 811.4480 781.4738 797.4687 813.4636 765.4789 
+glc+glc+glc 941.5110 927.5318 971.4852 973.5008 943.5267 959.5216 975.5165 927.5318 
+glc+glc+glc+glc 1103.5638 1089.5846 1133.5380 1135.5537 1105.5795 1121.5744 1137.5693 1089.5846 
+glc+glc+glc+glc+glc 1265.6165 1251.6373 1295.5907 1297.6064 1267.6322 1283.6271 1299.6220 1251.6373 
+glc+glc+glc+glc+glc+glc 1427.6693 1413.6901 1457.6435 1459.6592 1429.6850 1445.6799 1461.6748 1413.6901 
+glc+glc+xyl  911.5005    897.5212  941.4746    943.4903  913.5161  929.5110  945.5059    897.5212  
+glc+glc+xyl+glc 1073.5533  1059.5740  1103.5275  1105.5431  1075.5689  1091.5638  1107.5587  1059.5740  
+glc+glc+xyl+glc+glc 1235.6061  1221.6268  1265.5803  1267.5959  1237.6218  1253.6167  1269.6116  1221.6268  
+glc+glc+xyl+glc+ glc+glc 1397.6589  1383.6796  1427.6331  1429.6487  1399.6746  1415.6695  1431.6644  1383.6796  
 
2B-a  2B-b  2B-c  Construction rules scheme (Figure 2B) 
 
Abbreviation:  
O: Oleanolic acid; E: Erythrodiol; M: Maniladiol; My: Myrtilogenic acid; 
La: 3β,16β,28-trihydroxyolean-12-en-29,22-olide; L: Longispinogenin;  
CGS: Chichipegenin/gymnemagenol/Sitaskisogenin; HG: 22-hydroxylgymnemagenol 
glcA: glucuronic acid; glc: glucose; rha: rhamnose; xyl: xylose; 
acetyl: acetyl; tig: tigloyl; bz: benzoyl; nic: nicotinoyl;   
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3.2.2. Relative mass filtering  
RMD filtering is a useful method for the rapid classification of various groups 
of metabolites by interpreting their chromatography-mass spectrometry data and 
calculating their molecular and fragment ions as well as their retention times 
(Ekanayaka et al., 2015). The theoretical RMD range of oleanane-type triterpenes 
of G. sylvestre was 537.4 ± 62.2 based on the calculated molecular weights of the 
triterpenoids in the predicted virtual library. A simple RMD filtering was applied to 
the predominant parent ions of all the detected compounds in negative MS1 mode to 
facilitate the exclusion of nontargeted constituents such as flavonoids and fatty acids 
in the extract. Thus, the retention times of the targeted oleanane triterpenoids were 
identified, and they ranged from 5–14 min using the chromatographic conditions of 
this study. The RMD values also provided remarkable information related to the 
structures of the triterpenoid glycosides. Conjugation with polar glycoside moieties 
(e.g., glucosylation, C6H10O5) lowered the hydrogen content, decreasing the RMD 
value as the number of attached sugars increased. On the other hand, the attachment 
of an acyl group may maintain a high hydrogen ratio and keep the RMD higher than 





Figure 12. Relative mass defect (RMD) values of predicted triterpenoids of 
G. sylvestre 
3.2.3. Identification of Targeted Metabolites by UPLC-MSn.  
The compound detection and structural assignment of the targeted triterpenoids 
were implemented by a combination of three techniques, KIF, mKIA, and MFA. It 
has been widely reported that saponins are not degraded by a single TOF in negative 
mass detection (Qi et al., 2012). Therefore, the masses of the predicted targeted 
compounds were extracted effectively and selectively in the negative MS1 mode, 
where the dominant precursor ions [M − H]− or [M + HCOO]− could be obtained 
with high specificity and sensitivity (Figure 13). In addition, the rigid polycyclic 
structures of oleanane triterpenoids in a specific plant usually vary over a limited 
number of aglycones, and each of these can be characterized by a set of key MSn 
ions produced by dehydration during mass fragmentation. As a result, the mKIA 
technique utilizing various sets of key positive MSn ions can be used to effectively 
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discriminate different aglycones in G. sylvestre. Furthermore, MFA of G. sylvestre 
in TOF-positive fragmentation mode showed the typical neutral losses of acyl and 
sugar moieties. Figure 13 illustrates an example of the integration of these 
techniques in peak picking and structure elaboration using oleanolic acid glycoside 
(peak 21). Consequently, 119 peaks of oleanane triterpenoids were quickly identified 
in the same manner, and among them, 77 peaks are predicted to be new compounds 
based on their molecular formulas and mass fragmentation patterns. To validate the 
compound assignment, three levels of assignment fidelity were proposed in this 
study (Table 2). Level (A): the compound was unambiguously determined by 
comparison with reference standard compounds or isolated and elucidated from its 
NMR data. Level (B): the compound has been previously reported from G. sylvestre 
and was consistent with the building block mass data, a rational retention time 
relationship, mKIA, and MFA. Level (C): the compound was constructed from the 
building blocks, and its structure was supported by mKIA and MFA analysis, but no 
obvious evidence to differentiate structural isomer was available. Herein, the 
compound detection and structure determination of all the targeted triterpenoids will 
be discussed. As mentioned above, the oleanane triterpenoids formed in G. sylvestre 
could be broadly classified into two major subgroups according to the existence of a 
glucuronic acid linkage at C-3 in the structure. 
3.2.3.1. Oleanane Triterpenes without Glucuronic Acid.  
These compounds were constructed following Scheme 2B-a (Figure 10). In 
brief, 1-2 glycosyl chains are formulated starting with a glucose attached to the 
aglycone at C-3 and/or C-28. These glycoside chains were then elongated by the 




C-3 glycoside chain could be either glucose or xylose. The three subgroups of 
glycosides following this construction rule were oleanolic acid glycosides, 
erythrodiol glycosides and longispinogenin glycosides. Fourteen peaks of oleanolic 
acid (O) and its analogs of this type were filtered from the data of the G. sylvestre 
extract or microfractions with mass deviations of less than 5 ppm (Figure 11). Of 
the compounds constructed following rule Figure 10B-a, 8 have been reported in 
the literature (Table 2).  
Oleanolic acid O#456 (peak 1) was confirmed by comparison with standard 
oleanolic acid. As illustrated in Figure 11, the positive mass fragmentation data of 
oleanolic acid showed a set of key ions 457, 439, 421, 411, and 393, which can be 
used to characterize this compound and its glycosides. Two oleanolic monoglucoside 
peaks, 2 and 3, possessing the molecular formula C42H68O13, were detected by ion 
extraction (663.4110 [M + HCOO]−). Both spectra showed key diagnostic ions of 
oleanolic acid as well as the loss of an O-glycosidic hexosyl moiety, resulting in their 
tentative determinations as oleanolic acid 3-O-β-D-glucopyranoside and oleanolic 
acid 28-O-β-D-glucopyranoside, respectively. The presence of oleanolic acid 28-O-
β-D-glucopyranoside (2) in G. sylvestre has been reported in the literature (Ye et al., 
2000a), while oleanolic acid 3-O-β-D-glucopyranoside (3) was confirmed by 
comparison with a reference standard.  
The targeted extraction of compounds similar of oleanolic acid diglycoside 
(C42H68O13) revealed two peaks, 4 and 5. mKIA analysis showed apparent key ions 
and mass losses corresponding to 2 glucose units. Notably, two compounds, 3-O-β-
D-glucopyranosyl-(1➝6)-β-D-glucopyranosyl oleanolic acid and 3-O-β-D-
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glucopyranosyl oleanolic acid 28-O-β-D-glucopyranosyl ester, were isolated from 
the Chinese variety of G. sylvestre (X. Liu et al., n.d.; Ye et al., 2000a). Since these 
were the only two detectable peaks with this molecular weight , it was reasonable to 
assign them to the two aforementioned compounds.  
Peak 6 (tR = 10.004 min), which showed losses of a xylose (132 Da) and two 
other glucose fragments (2 × 162), was determined as oleanolic acid 3-O-β-D-
xylopyranosyl-(1➝6)-β-D-glucopyranosyl(1➝6)-β-D-glucopyranoside by referring 
to the literature (M.-Q. Zhang et al., 2012) and comparing with a standard reference. 
Peak 6 was the only high-abundance isomer of mass extraction 911.5025 [M − H]−, 
indicating the substantial accumulation of glc6-glc6-xyl as a major glycosyl chain at 
C-3 via biosynthesis. This observation was confirmed by the detection of peaks 9 
and 12, which were identified as 3-O-β-D-xylopyranosyl (1➝6)-β-D-
glucopyranosyl-(1➝6)-β-D-glucopyranosyl oleanolic acid 28-O-β-D-
glucopyranosyl ester (K. Yoshikawa et al., 1999) and 3-O-β-D-xylopyranosyl 
(1➝6)-β-D-glucopyranosyl(1➝6)-β-D-glucopyranosyl oleanolic acid 28-O-β-D-
glucopyranosyl(1➝6)-β-D-glucopyranosyl ester, respectively. Their structrures 
were determined by mKIA and MFA and unambiguously confirmed by comparison 
with reference compounds. Using the same approach, a single peak (14, C65H106O32) 
was found by filtering by predominant ion 1397.6590 [M − H]−. The similar 
fragmentation pattern to that of 12, together with the presence of an additional 






glucopyranosyl ester.  
Peaks 10 (tR = 6.801 min) and 11 (tR = 7.108 min) can be regarded as two 
isomers. They exhibited deprotonated ions [M − H]− at 1103.5664 and 1103.5653 
and showed similar sets of key aglycone ions of oleanolic acid. The main difference 
between these two compounds is the sugar cleavage pattern. Peak 10 was identified 
as 3-O-β-D-glucopyranosyl-(1➝6)-β-D-glucopyranosyl oleanolic acid 28-O-β-D-
glucopyranosyl(1➝6)-β-D-glucopyranosyl ester by referring to the literature (Ye et 
al., 2000a) and comparing with reference compounds. Peak 11 exhibited a strong 
signal at 943.5230, suggesting an oleanolic acid core with a sugar side chain 
comprising 3 glucose units at C-3 after the loss of a glucose linkage at the carboxylic 
C-28 position. Consequently, this compound was tentatively identified as 3-O-β-D-
glucopyranosyl-(1➝6)-β-D-glucopyranosyl(1➝6)-β-D-glucopyranosyl oleanolic 





Figure 13. Application of building block strategy for the identification of oleanolic 




 Table 2. Compound assignments for detected metabolites by using building block library. 
Peak Rt (#) m/z (-) Cald. m/z (-) 
Diff 
(ppm) RMD Formula Exact mass Block-based compound assignment Assignment fidelity (*) 
CAS Number 
(&) 
1 17.194 455.3520 455.3525 -1.1 773.0 C30H48O3 456.3598 O A, Ref 508-02-1 
2  12.063 617.4038 617.4053 -2.4 654.0 C36H58O8 618.4116 O+28-(glc) B, (Ye et al., 2000a) 3391-80-8 
3 12.660 617.4016 617.4053 -3.7 650.5 C36H58O8 618.4094 O+3-(glc) A, Ref 14162-53-9 
4 10.485 779.4576 779.4582 -0.8 587.1 C42H68O13 780.4654 O+3-(glc6+glc) B, (Ye et al., 2000a) 240140-86-7 
5 10.564 779.4592 779.4582 1.3 589.1 C42H68O13 780.4670 O+3-(glc)+28-(glc) B, (X. Liu et al., n.d.) 78454-20-3 
6 10.004 911.5024 911.5004 2.2 551.2 C47H76O17 912.5102 O+3-(glc6+glc6+xyl) A, Ref, (M.-Q. Zhang et al., 2012) 287389-96-2 
7 7.485 941.5104 941.5110 -0.6 542.1 C48H78O18 942.5182 O+3-(glc6+glc6+glc) C No report 
8 7.695 941.5114 941.5110 0.4 543.2 C48H78O18 942.5192 O+3-(glc6+glc)+28-(glc) A, Ref, (Ye et al., 2000b) 287389-95-1 
9 7.441 1073.5521 1073.5532 -1.0 514.3 C53H86O22 1074.5599 O+3-(glc6+glc6+xyl)+28-(glc) A, Ref, (Ye et al., 2000a) 287389-97-3 
10 6.801 1103.5605 1103.5638 -3.3 507.9 C54H88O23 1104.5683 O+3-(glc6+glc)+28-(glc6+glc) A, Ref, (Ye et al., 2000a) 287389-98-4 
11 7.108 1103.5610 1103.5638 -2.5 508.4 C54H88O23 1104.5688 O+3-(glc6+glc6+glc)+28-(glc) C No report 
12 6.617 1235.6089 1235.6061 2.3 492.8 C59H96O27 1236.6167 O+3-(glc6+glc6+xyl)+28(glc6+glc) A, Ref, 31 Not available 
13 6.362 1265.6189 1265.6166 1.8 489.0 C60H98O28 1266.6267 O+3-(glc6+glc6+glc)+28-(glc6+glc) C No report 





15 9.318 897.5163 897.5153 1.1 575.3 C47H78O16 898.5241 E+3-(glc6+glc6+xyl) C No report 
16 7.801 927.5278 927.5317 -4.2 569.0 C48H80O17 928.5356 E+3-(glc6+glc6)+28-(glc) C No report 
17 7.915 927.5345 927.5317 3.0 576.3 C48H80O17 928.5423 E+3-(glc6+glc6+glc) C No report 
18 7.695 1059.5743 1059.574 0.3 542.0 C53H88O21 1060.5821 E+3-(glc6+glc6+xyl)+28-(glc) C No report 
19 6.994 1089.585 1089.5845 0.5 536.9 C54H90O22 1090.5928 E+3-(glc6+glc6+glc)+28-(glc) C  No report 
20 7.117 1089.5853 1089.5845 0.7 537.2 C54H90O22 1090.5931 E+3-(glc6+glc)+28-(glc6+glc) A, NMR No report 
21 6.950 1221.6289 1221.6268 1.7 514.8 C59H97O26 1,222.6367 E+3-(glc6+glc6+xyl)+28-(glc6+glc) A, NMR No report 





23 9.073 781.4726 781.4738 -1.5 604.8 C42H70O13 782.4804 L+3-(glc)+28-(glc) C No report 
24 9.301 781.4731 781.4738 -0.9 605.4 C42H70O13 782.4809 L+3-(glc6+glc) C No report 
25 7.415 913.5130 913.5161 -3.4 561.6 C47H78O17 914.5208 L+3-(glc6+glc6+xyl) B, (K. Yoshikawa et al., 1999) 164177-55-3 
26 6.046 943.5244 943.5266 -2.3 555.8 C48H80O18 944.5322 L+3-(glc6+glc)+28-(glc) B, (Zhu et al., 2008) 1096581-44-0 
27 6.257 943.5276 943.5266 1.1 559.2 C48H80O18 944.5354 L+3-(glc6+glc6+glc) C No report 
28 6.029 1075.5725 1075.5689 3.3 532.3 C53H88O22 1076.5803 L+3-(glc6+glc6+xyl)+28-(glc) A, Ref 256510-01-7 
29 5.529 1105.5813 1105.5795 1.6 525.8 C54H90O23 1106.5891 L+3-(glc6+glc)+28-(glc6+glc) C No report 
30 5.643 1105.5793 1105.5795 -0.2 524.0 C54H90O23 1106.5871 L+3-(glc6+glc6+glc)+28-(glc) C No report 
31 5.441 1237.6240 1237.6217 1.9 504.2 C59H98O27 1238.6318 L+3-(glc6+glc6+xyl)+28-(glc6+glc) C No report 
32 13.423 617.4055 617.4053 0.3 656.8 C36H58O8 618.4133 M+3-(glcA) A, NMR No report 
34 9.976 633.4016 633.4003 2.1 634.0 C36H58O9 634.4094 L+3-(glcA) A, Ref, (Ye et al., 2000a) 287390-11-8 
35 6.590 649.3959 649.3952 1.1 609.6 C36H58O10 650.4037 G+3-(glcA) A, Ref, (Pham et al., 2018) 2229693-58-5 
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Peak Rt (#) m/z (-) Cald. m/z (-) 
Diff 
(ppm) RMD Formula Exact mass Block-based compound assignment Assignment fidelity (*) 
CAS Number 
(&) 
36 7.090 649.3968 649.3952 2.5 611.0 C36H58O10 650.4046 S+3-(glcA) A, Ref, (Pham et al., 2018) 2229693-57-4 
37 7.730 649.3964 649.3952 1.8 610.4 C36H58O10 650.4042 C+3-(glcA) A, Ref, (Pham et al., 2018) No report 
38 7.564 661.3594 661.3588 0.9 543.4 C36H54O11 662.3672 La+3-(glcA) C No report 
39 7.126 663.3752 663.3744 0.2 565.6 C36H55O11 664.3830 My+3-(glcA) A, Ref, (Pham et al., 2018) 873799-50-9 
40 5.880 665.3923 665.3901 3.3 589.6 C36H57O11 666.4001 HG+3-(glcA) C No report 
41 12.643 779.4579 779.4582 -0.4 587.5 C42H68O13 780.4657 M+3-(glcA+glc) A, Ref, (Pham et al., 2018) 2229693-55-2 
42 10.112 793.4370 793.4374 -0.5 552.8 C42H66O14 794.4464 O+3-(glcA)+28-(glc) C 25406-56-8 
43 11.072 793.4386 793.4374 1.5 552.8 C42H66O14 794.4464 O+3-(glcA3+glc) 
A, Ref, 
 (Alabdul Magid et al., 2006) No report 
44 8.266 795.4545 795.4531 1.8 571.4 C42H68O14 796.4623 L+3-(glcA)+28-(glc) B, (K. Yoshikawa et al., 1999) 330595-34-1 
45 9.407 795.4545 795.4531 1.8 571.4 C42H68O14 796.4623 L+3-(glcA3+glc) A, Ref, (Ye et al., 2000a) 256510-00-6 
46 5.915 811.4473 811.4480 -0.9 551.2 C36H58O10 812.4551 G+3-glcA+29-glc A, Ref, (Pham et al., 2018) 2229693-56-3 
47 6.195 811.4482 811.4480 0.2 552.3 C36H58O10 812.4560 S+3-(glcA)+(glc) C No report 
48 6.362 811.4489 811.4480 1.1 553.2 C36H58O10 812.4567 C+3-glcA+28-glc A, (K. Yoshikawa et al., 1998) 212775-48-9 
49 6.451 811.4460 811.4480 -2.5 549.6 C36H58O10 812.4538 G+3-(glcA3+glc) A, Ref, (Ye et al., 2001a) 330595-36-3 
50 6.827 811.4477 811.4480 -0.4 551.7 C36H58O10 812.4555 S+3-(glcA3+glc) A, (Pham et al., 2018) 2229693-54-1 
51 7.319 811.4496 811.4480 2.0 554.1 C36H58O10 812.4574 C+3-(glcA3+glc) B, (K. Yoshikawa et al., 1998) 212775-47-8 
52 6.801 823.4119 823.4116 0.4 500.2 C42H64O16 824.4197 La+3-(glcA)+28-(glc) C No report 
53 6.932 823.4111 825.4234 -0.6 499.3 C42H64O16 824.4189 La+3-(glcA3+glc) C No report 
54 6.862 825.4308 825.4272 4.2 521.9 C42H66O16 826.4386 My+3-(glcA3+glc) A, Ref, (Pham et al., 2018) 2229693-52-9 
55 5.617 827.4431 827.4429 0.2 535.5 C42H68O16 828.4509 HG+3-(glcA3+glc) C No report 
56 9.204 691.4057 691.4057 -1.4 586.8 C38H60O11 692.4135 C+3-(glcA)+acetyl C No report 
57 7.476 707.4021 707.4007 2 568.4 C38H60O12 708.4099 HG+3-(glcA)+acetyl C No report 
58 11.107 731.438 731.4370 1.4 598.8 C41H64O11 732.4458 CS+3-(glcA)+tig C No report 
59 11.423 731.4382 731.4370 1.6 599.1 C41H64O11 732.4460 CS+3-(glcA)+tig C No report 
60 11.607 731.4378 731.4370 1.1 598.5 C41H64O11 732.4456 S+3-(glcA)+21-tig A, NMR No report 
61 8.161 747.4316 747.4320 -0.5 577.4 C41H64O12 748.4394 HG+3-(glcA)+tig C No report 
62 8.810 747.4351 747.4320 4.1 582.1 C41H64O12 748.4429 HG+3-(glcA)+tig C No report 
63 9.406 747.432 747.4320 0 578.0 C41H64O12 748.4398 HG+3-(glcA)+tig C No report 
64 9.266 747.433 747.4320 1.3 579.3 C41H64O12 748.4408 HG+3-(glcA)+tig C No report 
65 11.327 753.4228 753.4214 1.9 561.2 C43H62O11 754.4306 C+3-(glcA)+28-bz A, NMR No report 
66 11.555 753.4223 753.4214 1.2 560.5 C43H62O11 754.4301 CS+3-(glcA)+bz C No report 
67 11.809 753.4224 753.4214 1.3 560.6 C43H62O11 754.4302 CS+3-(glcA)+bz C No report 
68 8.634 769.4189 769.4163 3.4 544.4 C43H62O12 770.4267 HG+3-(glcA)+bz C No report 
69 9.134 769.4188 769.4163 3.2 544.3 C43H62O12 770.4266 HG+3-(glcA)+bz C No report 
70 9.599 769.4158 769.4163 3.2 540.4 C43H62O12 770.4236 HG+3-(glcA)+28-bz A, Ref, (Pham et al., 2018) 2229693-59-6 
71 9.739 769.4183 769.4163 2.6 543.7 C43H62O12 770.4261 HG+3-(glcA)+bz C No report 
72 10.555 738.4244 738.4217 3.7 574.7 C42H61NO10 739.4322 L+3-(glcA)+nic C No report 
73 8.906 754.4214 754.4166 6.4 558.6 C42H61NO11 755.4292 C+3-(glcA)+28-nic A, NMR No report 




Peak Rt (#) m/z (-) Cald. m/z (-) 
Diff 
(ppm) RMD Formula Exact mass Block-based compound assignment Assignment fidelity (*) 
CAS Number 
(&) 
75 6.994 770.4136 770.4116 2.6 536.9 C42H61NO12 771.4214 HG+3-(glcA)+nic C No report 
76 9.862 893.4913 893.4899 1.6 549.9 C47H74O16 894.4991 C+3-(glcA3+glc)+22-tig B, (K. Yoshikawa et al., 1999) 256509-77-0 
77 10.528 893.4917 893.4899 2 550.3 C47H74O16 894.4995 C+3-(glcA3+glc)+28-tig 
A, Ref,  
(K. Yoshikawa et al., 1999) 256509-82-7 
78 10.783 893.4913 893.4899 1.6 549.9 C47H74O16 894.4991 C+3-(glcA3+glc)+16-tig B, (K. Yoshikawa et al., 1999) 256509-83-8 
79 11.003 893.4940 893.4899 1.8 552.9 C47H74O16 894.5018 CS+3-(glcA3+glc)+tig C No report 
80 7.862 909.4854 909.4848 0.7 533.7 C47H74O17 910.4932 HG+3-(glcA3+glc)+tig C No report 
81 8.248 909.4849 909.4848 0.1 533.2 C47H74O17 910.4927 HG+3-(glcA3+glc)+tig C No report 
82 8.459 909.4865 909.4848 1.9 534.9 C47H74O17 910.4943 HG+3-(glcA3+glc)+tig C No report 
83 8.073 909.4852 909.4848 0.4 533.5 C47H74O17 910.4930 HG+3-(glcA3+glc)+tig C No report 
84 10.125 915.4756 915.4742 1.5 519.5 C49H72O16 916.4834 CS+3-(glcA3+glc)+bz C No report 
85 10.748 915.4756 915.4742 1.5 519.5 C49H72O16 916.4834 CS+3-(glcA3+glc)+bz C No report 
86 11.048 915.4737 915.4742 -0.5 517.4 C49H72O16 916.4815 CS+3-(glcA3+glc)+bz C No report 
87 11.107 915.4760 915.4742 2 519.9 C49H72O16 916.4838 CS+3-(glcA3+glc)+21-bz B, (Ye et al., 2001a) 330595-32-9 
88 8.169 931.4698 931.4691 0.8 504.4 C49H71O17 932.4776 HG+3-(glcA3+glc)+bz C No report 
89 8.581 931.4702 931.4691 1.2 504.8 C49H71O17 932.4780 HG+3-(glcA3+glc)+bz C No report 
90 8.774 931.4708 931.4691 1.8 505.4 C49H71O17 932.4786 HG+3-(glcA3+glc)+bz C No report 
91 9.125 931.4724 931.4691 3.5 507.2 C49H71O17 932.4802 HG+3-(glcA3+glc)+bz C No report 
92 11.265 941.5110 941.5110 0 542.7 C48H77O18 942.5188 M+3-(glcA3+glc)+28-(glc) C No report 
93 10.195 955.4911 955.4903 0.8 514.0 C48H76O19 956.4989 O+3-(glcA3+glc)+ 28-(glc) C, (Alabdul Magid et al., 2006) 26020-29-1 
94 8.755 957.5073 957.5059 1.5 529.8 C48H77O19 958.5151 L+3-(glcA3+glc)+28-(glc) 
A, Ref,  
(K. Yoshikawa et al., 1998) 212775-50-3 
95 5.740 973.5030 973.5008 2.3 516.7 C48H78O20 974.5108 C+3-(glcA3+glc)+28-(glc) B, (K. Yoshikawa et al., 1998) 212775-45-6 
96 6.134 973.5017 973.5008 0.9 515.4 C48H78O20 974.5095 G+3-(glcA3+glc)+28-(glc) C No report 
97 6.783 973.5005 973.5008 -0.3 514.1 C48H77O20 974.5083 S+3-(glcA3+glc)+28-(glc) C No report 
98 6.134 985.4604 985.4586 1.8 467.2 C48H73O21 986.4682 La+3-(glcA3+glc)+28-(glc) C No report 
99 6.117 987.4801 987.4801 0 486.2 C48H76O21 988.4879 My+3-(glcA3+glc)+28-(glc) C No report 
100 4.722 989.4953 989.4957 -0.4 500.6 C48H77O21 990.5031 HG+3-(glcA3+glc)+28-(glc) C No report 
101 9.932 900.4773 900.4745 3.1 530.1 C48H71NO16 901.4851 L+3-(glcA3+glc)+nic C No report 
102 8.441 916.4713 916.4695 2 514.3 C48H71NO16 917.4791 CS+3-(glcA3+glc)+nic C No report 
103 6.415 932.4634 932.4644 -1.1 497.0 C48H70NO17 933.4712 HG+3-(glcA3+glc)+nic C No report 
104 7.432 837.4810 837.4789 2.5 574.3 C44H70O15 838.4888 C+3-(glcA)+28-(rha)+22-acetyl 
B, (K. Yoshikawa et al., 1998) 
212775-43-4 
105 7.670 837.4770 837.4789 -2.3 569.6 C44H70O15 838.4848 C+3-(glcA)+28-(rha)+ 16-acetyl 
B, (K. Yoshikawa et al., 1998) 
212775-43-4 
106 6.134 999.5154 999.5165 -1.1 515.6 C50H80O20 1000.5232 C+3-(glcA3+glc)+28-(rha)+22-acetyl 
B, (K. Yoshikawa et al., 1998) 
212775-19-4 
107 6.801 999.5170 999.5165 0.5 517.2 C50H80O20 1000.5248 C3-(glcA3+glc)+28-(rha)+16-acetyl 
B, (K. Yoshikawa et al., 1998) 
212775-23-0 
108 5.862 1015.5121 1015.5114 0.7 504.3 C50H80O21 1016.5199 C+3-(glcA3+glc)+28-(glc)+acetyl C No report 
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Peak Rt (#) m/z (-) Cald. m/z (-) 
Diff 
(ppm) RMD Formula Exact mass Block-based compound assignment Assignment fidelity (*) 
CAS Number 
(&) 
109 9.783 1055.5441 1055.5427 1.3 515.5 C53H83O21 1056.5519 CS+3-(glcA3+glc)+28-(glc)+tig C No report 
110 10.143 1055.5457 1055.5427 2.8 517.0 C53H83O21 1056.5535 CS+3-(glcA3+glc)+28-(glc)+22-tig B, (K. Yoshikawa et al., 1998) 256509-85-0 
111 7.283 1071.5386 1071.5376 0.9 502.6 C53H83O22 1072.5464 HG+3-(glcA3+glc)+28-(glc)+tig C No report 
112 7.380 1071.5381 1071.5376 0.5 502.2 C53H83O22 1072.5459 HG+3-(glcA3+glc)+28-(glc)+tig C No report 
113 7.678 1071.5393 1071.5376 1.6 503.3 C53H83O22 1072.5471 HG+3-(glcA3+glc)+28-(glc)+tig C No report 
114 10.310 1077.5294 1077.5270 2.2 491.3 C55H82O21 1078.5372 CS+3-(glcA3+glc)+28-(glc)+bz C No report 
115 9.248 1077.5298 1077.5270 2.6 491.7 C55H82O21 1078.5376 CS+3-(glcA3+glc)+28-(glc)+bz C No report 
116 8.722 1093.5260 1093.5219 3.7 481.0 C55H82O22 1094.5338 HG+3-(glcA3+glc)+28-(glc)+bz C No report 
117 8.327 1093.5243 1093.5219 2.2 479.5 C55H82O22 1094.5321 HG+3-(glcA3+glc)+28-(glc)+bz C No report 
118 7.888 1093.5231 1093.5219 1.1 481.0 C55H82O22 1094.5338 HG+3-(glcA3+glc)+28-(glc)+bz C No report 
119 7.695 1039.5466 1039.5478 -1.2 525.8 C53H84O20 1040.5544 C+3-(glcA3+glc)+28-(rha)+22-tig B, (K. Yoshikawa et al., 1998) 212775-27-4 
  
(#) Rt : Retention time. 
(&) CAS number: Chemical Abstract Service registration number. The compounds with “No report” were presumed to be new compounds after 
looking up its possible structures on Scifinder by chemical formula and no result was found to have similar building block components and mass 
fragmentation patterns. Structure of peak 12 was reported but has not been indexed with a CAS number. 
(*) Rate of assignment fidelity:  
(A) Unambiguous identification by reference compounds (Ref) from KBNMB or structure isolation and elucidation of new compounds 
(NMR).  
(B) Evidence of building block mass data, mKIA, MFA, and retention time analysis; Compound should be reported isolated from G. 
sylvestre. The assignment can be interchanged between unidentified isomers of the same molecular weight and mass behavior characteristics. 




3.2.3.2. Erythrodiol Glycosides 
Peaks 20 (tR = 7.117 min) and 21 (tR = 6.950 min) displayed mass 
fragmentations of glucoside chains similar to those of the oleanolic acid glycosides, 
but they each possessed a set of key ions at 425 and 407. Because the structures of 
the compounds reported in the literature could not explain these key ions, direct 
isolation by conventional column chromatography and structure elucidation by 
NMR spectroscopy were performed for these two peaks. Consequently, peaks 20 




glucopyranoside, respectively (Figure 14). These findings highlight the existence of 
erythrodiol (E) as an aglycone of G. sylvestre, and its glycosides followed a 
construction rule similar to Figure 10B-a with oleanolic acid. Similar target ion 
filtrations of predicted compounds led to the detection of 6 other peaks (15-19 and 
22) from erythrodiol glycosides, and their structures were tentatively assigned. All 
these assumed erythrodiol glycosides were suggested to be new compounds by 
searching for their molecular formulas and structures in SciFinder. 
3.2.3.3. Longispinogenin (L) Glycosides 
Longispinogenin has been reported as the main aglycone of the Chinese and 
Vietnamese varieties of G. sylvestre  (Pham et al., 2018),(Ye et al., 2001b) and it can 
be practically recognized by based on its characteristic skeleton ions at m/z 441, 423, 
and 405. Nine peaks of longispinogenin derivatives (23–31) displayed the same type 
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of glycoside construction as was seen with oleanolic acid and erythrodiol (Figure 
10-a). Peak 28 (tR = 6.029 min) was determined to be alternoside XIX (K. Yoshikawa 
et al., 1999) by comparison with a reference compound. Peak 31 (tR = 5.441 min) 
was expected to be a new compound with one additional glucose compared to 28. 
Peaks 25 and 26 were tentatively assigned as sitakisoside X (Y. Liu et al., 2014) and 
gymnemoside W1 (Zhu et al., 2008), respectively.  
Three new compounds, longispinogenin 3-O-β-D-glucopyranosyl-(1➝6)-β-
D-glucopyranosyl-(1➝6)-β-D-glucopyranoside (27), 3-O-β-D-glucopyranosyl 
(1➝6)-β-D-glucopyranosyl longispinogenin 28-O-β-D-glucopyranosyl-(1➝6)-β-D-
glucopyranoside (29) and 3-O-β-D-glucopyranosyl-(1➝6)-β-D-
glucopyranosyl(1➝6)-β-D-glucopyranosyl longispinogenin 28-O-β-D-
glucopyranoside (30), were deduced similarly. Considering oleanolic acid and 
erythrodiol (Figure 21-B), the carboxylic group at C-28 of oleanolic acid (layer 1) 
caused a weak increase in the polarities of all compounds compared to their 
erythrodiol counterparts (layer 2), which had the same glycoside pattern except for 
the modification of the hydroxy group at C-28. In addition, longispinogenin 
glycosides (layer 3), which have one addition hydroxy group on the aglycone at C-
16 relative to erythrodiol (layer 2), showed remarkably higher polarities. 
3.2.3.4. Oleanane Triterpenes with Glucuronic Acid 
These compounds characterized by a glucuronic acid attached to C-3, and 
they were diversified by two factors: glycosylation and acylation. Glycosylation 
frequently occurs at C-3' and C-28 of glucuronic acid (Figure 10B-b), while 




the oleanane skeleton (Figure 10B-c). The key characteristic of the nonacylated 
triterpene glycosides is the presence of a glucuronic acid at C-3 of the main aglycone. 
The building block model for [aglycone + glcA] predicted 7 possible deprotonated 
mass values (Figure 11), and their key ion extraction led to the detection of peaks 
32-41 (Table 2). Among them, peaks 33-36 and 39 were unambiguously identified 
by comparison with reference compounds, and three peaks 37, 38, and 40 were 
tentatively assigned based on their mass fragmentation patterns. The ion at m/z 
617.4057 of peak 32 can be the 3-O-β-D-glucuronopyranosyl analogue of either 
erythrodiol or maniladiol because they share the same molecular formula (C36H58O8). 
NMR spectroscopy was used to clarify the structure of peak 32, and it was revealed 
to be maniladiol 3-O-β-D-glucuronopyranoside.  
Considering that all these detected glycosides possess similar glucuronic 
acid linkages at C-3, the difference in their polarities would be related to the structure 
of their aglycones. As seen in Figure 21 (layer 4), the retention times of these peaks 
were in the following order of their aglycones, and the order matched the number of 
hydroxy or carboxylic groups in their structure: 22𝛼-hydroxygymnemagenol (5 × 
OH) > gymnemagenol (4 × OH) > sitakisogenin (4 × OH) > myrtilogenic acid (3 × 
OH + COOH)  > 3β,16β,28-trihydroxyolean-12-en-22,29-olide (3 × OH + C=O) > 
chichipegenin (4 × OH) > longispinogenin (3 × OH) > oleanolic acid (OH + COOH) 
> maniladiol (2 × OH). Similarly, the 9 possible deprotonated mass values predicted 
for [aglycone + glcA + glc] were extracted (Figure 11), resulting in the detection of 
15 peaks (41-55) (Figure 21-B). The structure of compounds 41, 43-45, 47, 48, 50, 
and 54 (confirmed by comparison with reference standards) and compounds 46 and 
49 (tentatively assigned by comparing with literature data) suggested that an 
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additional glucose can be attached to C-3' of the glucuronic acid moiety to extend 
the C-3 linkage or connected to the aglycone skeleton at C-28 (or C-29 in 
gymnemagenol).  
An investigation of 3 known glycoside peaks (34, 44, and 45) of the same 
aglycone longispinogenin showed a shift in the retention time of compound 44, 
which has a second glucose unit attached to C-28 (-1.7 min), to a time much earlier 
than that of compound 45, in which the second sugar is linked to C-3' of glucuronic 
acid (-0.6 min). A low variation in the retention times (0.4-0.8 min) was also 
observed in aglycones in which the second sugar was connected to C-3' of the 
glucuronic acid, and these included maniladiol (peaks 32 and 41, -0.8 min), 
myrtilogenic acid (peaks 39 and 54, -0.4 min), and sitakisogenin (peaks 36 and 48, 
-0.7 min) (Figure 21). On the other hand, the large shift in the retention time (-1.7 
min) of peak 42, which is known to have the structure [O + 3-(glcA) + 28-(glc)] 
relative to that of peak 33 [O + 3-(glcA)], further suggested that unknown peak 43 
was [O + 3-(glcA3-glc)] based on the difference between its retention time with that 
of peak 33 (0.7 min). For longer sugar chains, three compounds have been reported 
to be constructed from three units following the construction rule [aglycone + 3-
(glcA3-glc) + 28-(glc)] (K. Yoshikawa et al., 1998). Building block analysis and 
peak extraction resulted in the detection of 8 peaks (Figure 21-B, layer 12). The 
difference between the retention times of the reference compound 94 [L + 3-(glcA3-
glc) + 28-(glc)] and 45 [L + 3-(glcA3-glc)] suggested a polar shift of approximately 
1.3 min due to the new glucose linkage at C-28. As a result, a range of retention time 
shifts of 1-1.4 min was observed between peaks 92 (M), 93 (O), 98 (My), and 100 




(glcA3-glc)]. Peaks 41 (M), 42 (O), 54 (My), and 45 (HG) (Figure 21-B, layer 5) 
were assigned as aglycone + 3-(glcA3-glc) + 28-(glc). 
3.2.3.5. Triterpenes Glycosides with Tigloyl and Benzoyl Substituents 
The acylation of the glycosides of 22𝛼-hydroxygymnemagenol, 
chichipegenin, and sitakisogenin by tigloyl and benzoyl moieties following Figure 
10B-c has been reported. The acylation of the triterpenoid glycoside core structure 
significantly reduces the polarity of the compound. As illustrated in Figure 21-B, 
three peaks (58-60) were assigned to CS + 3-(glcA) + tigloyl derivatives and 4 peaks 
(61-64) were assigned to HG + 3-glcA + tigloyl derivatives (layer 7). The other 
isomers with the same molecular weight were presumed to be aglycone variants or 
be acylated at different positions. Interestingly, a corresponding number of benzoyl 
derivatives (peaks 65-71, Figure 21-B, layer 8) were observed, and they showed 
slight reductions in polarity (0.2 min) compared with their tigloyl derivatives 
(Figure 21-B, layer 7). Since compound 65 was elucidated as 28-benzoyl-
chichipegenin 3-O-β-D-glucopyranoside, it is likely that peak 58 was 28-tigloyl-
chichipegenin 3-O-β-D-glucopyranoside. A similar analysis of peak 67 suggested 
that it was 21-O-tigloyl-sitaskisogenin 3-O-β-D-glucuronopyranoside based on the 
assignment of 60 as 21-O-tigloyl-sitaskisogenin 3-O-β-D-glucuronopyranoside, 
which was determined from NMR evidence. Peak 70 was confirmed as 28-benzoyl-
22𝛼-hydroxygymnemagenol 3-O-β-D-glucopyranoside by comparison to reference 
compounds, so its tigloyl analogue (peak 63) could be assigned as 28-tigloyl-22𝛼-
hydroxygymnemagenol 3-O-β-D-glucopyranoside (Figure 21-B, layers 10 and 11). 
3.2.3.6. Triterpenes Glycosides with Nicotinoyl Substituents. 
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The determination that peak 73 had an odd exact mass suggested that the 
compound possessed a nitrogen moiety attached to the aglycone. Because no similar 
compound has been reported from G. sylvestre, the compound was isolated and 
elucidated to be 28-nicotinoyl chichipegenin 3-O-β-D-glucuronopyranoside. This 
finding suggested that the nicotinoyl moiety is another biosynthetic building block 
for G. sylvestre compounds. Building block peak extraction was then applied and 
revealed 7 nicotinoyl derivatives of longispinogenin, chichipegenin, myrtilogenic 
acid and 22𝛼-hydroxygymnemagenol (peaks 72-75 and 101-103)  (Figure 21-B, 
layers 9 and 13). The construction rule and shift in retention times suggested that 
their structures can be tentatively assigned as [aglycone + 3-(glcA) + 28-(nic)] and 
[aglycone + 3(glcA3-glc) + 28-(nic)] derivatives, respectively (Table 2). 
3.2.3.6. Triterpenes Glycosides with Acetyl Substituents 
Four acylated compounds were reported from G. sylvestre, with the main 
aglycone being chichipegenin (K. Yoshikawa et al., 1998). The deprotonated ion 
mass extraction also suggested the presence of these compounds in the fractionated 
matrixes (peaks 104-107). Building block prediction suggested that acetylation is 
not common in this plant, and the derivatives of chichipegenin and 22𝛼-
hydroxygymnemagenol were observed in low quantities. The following building 
block structures could be found on the basis of the determined construction rules: 
peaks 56 and 57 [aglycone + 3-(glcA) + acetyl], peaks 104 and 105 [aglycone + 3-
(glcA3-glc) + 28-(rha) + acetyl], and peaks 106-108 [aglycone + 3-(glcA3-glc) + 28-
(glc) + acetyl]. Substitution on a rhamnose moiety occurred only with an acetyl or 
tigloyl moiety was available since the extraction of the predicted glycosides 




3.3. Structure elucidation of selective isolation of new compounds predicted by 
virtual block library 
 
Figure 14. Structures of new isolated compounds 1⎯6 (A) and key 2D-NMR 
correlations (B) of new isolated compounds 1, 4, and 6. 

















1 39.1, CH2 39.1, CH2 39.1, CH2 39.1, CH2 39.1, CH2 39.1, CH2 
2 27.0, CH2 27.0, CH2 26.9, CH2 26.8, CH2 27.0, CH2 27.0, CH2 
3 89.4, CH 89.4, CH 89.3, CH 89.3, CH 89.3, CH 89.4, CH 
4 39.8, C 39.8, C 39.9, C 39.8, C 39.9, C 39.9, C 
5 56.0, CH 56.0, CH 55.9, CH 55.9, CH 56.0, CH 56.0, CH 
6 18.8, CH2 18.8, CH2 18.7, CH2 18.7, CH2 18.8, CH2 18.8, CH2 
7 33.0, CH2 33.0, CH2 33.2, CH2 33.1, CH2 33.3, CH2 33.4, CH2 
8 40.4, C 40.4, C 40.6, C 40.6, C 40.5, C 40.6, C 
9 48.3, CH 48.2, CH 47.4, CH 47.4, CH 47.4, CH 47.4, CH 
10 37.1, C 37.1, C 37.0, C 37.0, C 37.1, C 37.1, C 
11 24.0, CH2 24.1, CH2 24.2, CH2 24.2, CH2 24.2, CH2 24.2, CH2 
12 123.1, CH 123.1, CH 124.2, CH 124.4, CH 123.5, CH 122.8, CH 
13 144.9, C 144.8, C 142.3, C 142.3, C 143.1, C 144.9, C 
14 42.1, C 42.1, C 42.9, C 42.9, C 44.1, C 44.3, C 
15 26.5, CH2 26.5, CH2 36.5, CH2 36.4, CH2 36.3, CH2 36.8, CH2 
16 22.4, CH2 22.3, CH2 66.6, CH 66.6, CH 67.2, CH 64.8, CH 
17 37.4, C 37.3, C 44.8, C 44.7, C 43.5, C 38.4, C 
18 43.4, CH 43.4, CH 44.2, CH 44.2, CH 44.1, CH 49.9, CH 
19 47.0, CH2 47.0, CH2 46.4, CH2 46.3, CH2 47.4, CH2 47.5, CH2 
20 31.4, C 31.4, C 32.4, C 32.4, C 37.1, C 31.5, C 
21 34.7, CH2 34.7, CH2 44.4, CH2 44.3, CH2 76.7, CH 35.1, CH2 
22 33.0, CH2 33.0, CH2 69.9, CH 69.9, CH 30.3, CH2 31.6, CH2 
23 28.5, CH3 28.5, CH3 28.5, CH3 28.5, CH3 28.6, CH3 28.5, CH3 
24 17.3, CH3 17.3, CH3 17.3, CH3 17.3, CH3 17.3, CH3 17.3, CH3 
25 16.1, CH3 16.0, CH3 16.0, CH3 15.9, CH3 16.1, CH3 16.0, CH3 
26 17.4, CH3 17.3, CH3 17.5, CH3 17.4, CH3 17.3, CH3 17.4, CH3 
27 26.5, CH3 26.5, CH3 28.0, CH3 28.0, CH3 27.4, CH3 27.8, CH3 
28 77.3, CH2 77.3, CH2 63.6, CH2 64.1, CH2 67.2, CH2 22.8, CH3 
29 33.7, CH3 33.7, CH3 33.7, CH3 33.6, CH3 29.6, CH3 33.9, CH3 
30 24.3, CH3 24.3, CH3 25.2, CH3 25.2, CH3 19.1, CH3 24.5, CH3 
GlcA-1'   107.6, CH 107.4, CH 107.4, CH 107.6, CH 
GlcA-2'   75.8, CH 75.8, CH 75.8, CH 75.9, CH 
GlcA-3'   78.5, CH 78.5, CH 78.6, CH 78.6, CH 
GlcA-4'   73.9, CH 73.9, CH 73.6, CH 73.9, CH 
GlcA-5'   78.5, CH 78.4, CH 78.5, CH 78.0, CH 
GlcA-6'   172.6, COOH 173.9, COOH 173.2, COOH 173.4, COOH 
Glc-SA1-1' 107.2, CH 107.2, CH     
Glc-SA1-2' 75.9, CH 75.9, CH     
Glc-SA1-3' 78.8, CH 78.7, CH     
Glc-SA1-4' 72.0, CH 71.9, CH     
Glc-SA1-5' 77.5, CH 77.5, CH     
Glc-SA1-6' 70.8, CH2 70.6, CH2     
Glc-SA2-1' 105.7, CH 105.7, CH     
Glc-SA2-2' 75.5, CH 75.4, CH     
Glc-SA2-3' 78.7, CH 78.8, CH     
Glc-SA2-4' 71.9, CH 71.9, CH     
Glc-SA2-5' 77.3, CH 77.3, CH     
Glc-SA2-6' 63.0, CH2 70.0, CH2     
Xyl-SA3-1'  106.3, CH     
Xyl-SA3-2'  75.2, CH     
Xyl-SA3-3'  78.4, CH     
Xyl-SA3-4'  71.4, CH     
Xyl-SA3-5'  67.3, CH2     
Glc-SB1-1' 105.8, CH 105.6, CH     
Glc-SB1-2' 75.5, CH 75.4, CH     
Glc-SB1-3' 78.7, CH 78.7, CH     
Glc-SB1-4' 72.0, CH 71.9, CH     
Glc-SB1-5' 77.3, CH 77.3, CH     
Glc-SB1-6' 70.3, CH2 70.3, CH2     
Glc-SB2-1' 105.7, CH 105.2, CH     


















Glc-SB2-3' 78.7, CH 78.7, CH     
Glc-SB2-4' 71.9, CH 71.8, CH     
Glc-SB2-5' 77.3, CH 77.3, CH     
Glc-SB2-6' 63.0, CH2 63.0, CH2     
 
# 28-O-benzoyl substitution: Bz-1 (δC167.1, C), Bz-2 (δC131.5, C), Bz-3,7 (δC130.0, CH), Bz-4,6 (δC129.3, CH), 
Bz-5 (δC133.7, CH). 
## 28-O-nicotinoyl substitution: COO- (δC167.1, C); Nic-2 (δC151.1, CH); Nic-3 (δC127.1, C);  Nic-4 (δC137.3, CH); 
Nic-5 (δC123.1, CH); Nic-6 (δC154.2, CH). 
* 21 O-tigloyl moiety:  -COO- (δC167.9, C); Tig-2 (δC 130.0, CH); Tig-3 (δC137.1, C); Tig-4 (δC14.6, CH); Tig-5 




Table 4. 1H NMR Spectroscopic Data for Gymnemosides GS1–6 (in Pyridine -d5). 
position 
1 2 3# 4## 5 6 
GH (J in Hz), 
600 Mhz 
GH (J in Hz), 
600 Mhz 
GH (J in Hz), 
500 Mhz 
GH (J in Hz), 
800 Mhz 
GH (J in Hz), 
600 Mhz 
GH (J in Hz), 
500 Mhz 































3.36, dd (4.0, 
11.5) 
5 0.72, d (11.7) 0.72, d (11.7) 0.74, overlap 0.77, overlap 0.80, d (12.0) 0.77, d (11.7) 






















9 1.58, overlap 1.59, overlap 1.57, overlap 1.56, overlap 1.58, overlap 1.57, overlap 











12 5.17, br s 5.17, br s 5.33, br s 5.36, br s 5.33, br s 5.30, br s 
15 1.80, overlap 0.90, overlap 
1.80, overlap 
0.90, overlap 


















(11.3. 4.5) 4.57, overlap 










































2.12, t (13.0) 
2.45, td (14.0, 
2.6) 
1.14, overlap 
23 1.01, s 1.01, s 0.97, s 1.09, s 1.02, s 1.00, s 
24 1.26, s 1.26, s 1.30, s 1.30, s 1.34, s 1.30, s 
25 0.88, s 0.87, s 0.80, s 0.80, s 0.85, s 0.86, s 
26 0.96, s 0.95, s 1.10, s 1.11, s 0.98, s 1.02, s 
27 1.21, s 1.21, s 1.43, s 1.43, s 1.35, s 1.38, s 









5.43, d (10.5) 
4.80, d (10.5) 
4.35, d (10.5) 
3.83, d (10.5) 1.14, s 
29 0.91, s 0.91, s 1.15, s 0.97, s 1.05, s 0.97, s 
30 0.94, s 0.94, s 1.03, s 1.02, s 1.23, s 0.92, s 
GlcA-1'   4.97, d (7.7) 4.91, d (7.7) 5.01, d (7.7) 5.01, d (7.7) 
GlcA-2'   4.12, overlap 4.08, overlap 4.13, overlap 4.13, overlap 
GlcA-3'   4.32, t (7.7) 4.29, t (7.7) 4.33, t (7.7) 4.33, t (7.7) 
GlcA-4'   4.58, t (7.7) 4.49, t (7.7) 4.58, overlap 4.58, overlap 
GlcA-5'   4.66, d (7.7) 4.55, d (7.7) 4.66, d (7.7) 4.66, d (7.7) 
Glc-SA1-1' 4.89, d (7.5) 4.87, d (7.5)     
Glc-SA1-2' 3.97, overlap 3.97, overlap   
  
Glc-SA1-3' 4.10, overlap 4.10, overlap     
Glc-SA1-4' 4.16, overlap 4.16, overlap     
Glc-SA1-5' 3.99, overlap 3.99, overlap     
Glc-SA1-6' 4.29, overlap 4.89, overlap 
4.29, overlap 
4.89, overlap   
  
Glc-SA2-1' 5.14, d (7.5) 5.10, d (7.5)     
Glc-SA2-2' 3.96, overlap 3.96, overlap     
Glc-SA2-3' 4.16, overlap 4.16, overlap     
Glc-SA2-4' 4.09, overlap 4.09, overlap     
Glc-SA2-5' 3.99, overlap 3.99, overlap     





1 2 3# 4## 5 6 
GH (J in Hz), 
600 Mhz 
GH (J in Hz), 
600 Mhz 
GH (J in Hz), 
500 Mhz 
GH (J in Hz), 
800 Mhz 
GH (J in Hz), 
600 Mhz 
GH (J in Hz), 
500 Mhz 
4.30, overlap 4.30, overlap 
Xyl-SA3-1'  4.94, d (7.5)      
Xyl-SA3-2'  3.97, overlap     
Xyl-SA3-3'  4.10, overlap     
Xyl-SA3-4'  4.16, overlap     
Xyl-SA3-5'  4.29, overlap  3.62, t (7.5)   
  
Glc-SB1-1' 4.83, d (8.0) 4.76, d (7.5)     
Glc-SB1-2' 4.12, overlap 4.12, overlap     
Glc-SB1-3' 4.17, overlap 4.17, overlap     
Glc-SB1-4' 4.29, overlap 4.29, overlap     
Glc-SB1-5' 4.09, overlap 4.09, overlap     
Glc-SB1-6' 4.33, overlap 4.33, overlap   
  
Glc-SB2-1' 5.14, d (7.5) 5.04, d (7.5)     
Glc-SB2-2' 3.96, overlap 3.96, overlap     
Glc-SB2-3' 4.09, overlap 4.09, overlap     
Glc-SB2-4' 4.16, overlap 4.16, overlap     













# 28-O-Benzoyl substitution: Bz-3,7 [each 1H, δH 8.25, (d, J= 7.5 Hz)], Bz-4,6 [each 1H, δH 7.43, (t, J= 7.5 Hz)], 
Bz-5 [1H, δH 7.52, (t, J= 7.5 Hz)]. 
## 28-O-nicotinoyl substitution:  Nic-2 (1H, δH 9.50, s); Nic-4 [1H, δH 8.36, (d, J= 7.5 Hz)]; Nic-5 [1H, δH 7.35 (dd, 
J= 7.5, 1.8 Hz)]; Nic-6 [1H, δH 8.85 (d, J= 1.8 Hz)]. 




3.3.1. Gymnemoside GS1 - Compound 1  
Compound 1 (peak 20) was obtained as an amorphous powder with [α]25 D
24.6 (c 0.1, MeOH). The IR absorption bands at 3394, 1052, and 1610 cm-1 indicated 
the presence of a hydroxy group and an olefin. Its molecular formula (C54H90O22), 
which corresponds to 10 indices of hydrogen deficiency (IDHs), was deduced based 
on its HRESIMS ion peak at m/z 1089.5884 [M – H]– (calcd for C54H89O22, 
1089.5845). The HPLC-MS fragment ions obtained in positive mode suggested the 
presence of 4 glucoses (4 ×162 Da) and an aglycone with a molecular weight of 422 
with 2 hydroxy groups, which was indicated by the three key ions at 443, 425 and 
407. The 1H, 13C, and HSQC NMR spectra showed seven methyl proton singlets at 
δH 1.26, 1.21, 1.01, 0.96, 0.94, 0.91, and δH 0.88 (each 3H, s), and these signals 
corresponded to the carbon signals at δC 17.3, 26.5, 28.5, 17.4, 24.3, 33.7, and 16.1, 
respectively. Furthermore, one broad singlet at δH 5.17 (1H, br s) for an olefinic 
proton and two olefinic carbon signals at δC 144.9 and 123.1 were observed. These 
NMR resonances, together with the HMBC and NOESY correlations (Figure 15), 
suggested that 1 was an erythrodiol aglycone due to the olefinic linkage at C12-C13 
and the presence of the seven methyl groups of an oleanane triterpenoid backbone. 
A β-oriented hydroxy group at C3 (δC 89.4) was determined from the HMBC cross 
peaks from H-23 (δH 1.26, s) and H-24 (δH 1.01, s) to C3 (δC 89.4) and the NOESY 
correlation between H-3𝛼 (δH 3.31, dd, J=11.5, 4.3 Hz) and H-5𝛼 (δH 0.72, d, J=11.7 
Hz). The assignment of the aglycone was confirmed by comparison with the NMR 
data of erythrodiol glycosides reported in the literature (Ito et al., 2004). The 
presence of four sugar residues was clearly indicated by the four anomeric 
resonances at [δC 107.2, δH 4.89 (1H, d, J = 7.5 Hz)], [δC 105.8, δ 4.83(1H, d, J = 7.5 




The acid hydrolysis of 1 yielded a sugar that was identified as D-glucose by 
comparison with an authentic sugar standard. The coupling constants (all J = 7.5 Hz) 
of the anomeric protons suggested that these glucose moieties were in the β isomer 
form. Importantly, the shifts of the glycosylated carbons were observed at C3 (δC 
89.4) and C28 (δC 77.3), which supported the substitution of sugar chains at C-3 
(GlcSA) and C-28 (GlcSB). These connections were confirmed by the HMBC cross 
peaks between H-1GlcSA1 [δH 4.84 (1H, d, J = 7.5 Hz)] and C-3 (δC 89.4) and between 
H-1GlcSB1 [δH 4.83 (1H, d, J = 7.5 Hz)] and C-28 (δC 77.3). Additional investigation 
of the saccharide portion by 13C NMR spectroscopy (Table 3) revealed that only two 
of the four CH2OH groups of the glucose residues were remarkably downfield 
shifted (δC 70.8, and 70.3), suggesting 1→6 linkages between the glucose units. 
Furthermore, the HMBC spectrum of 1 showed clear correlations between H-1GlcSA2 
[δH 5.12 (1H, d, J = 7.5 Hz)] and C-6GlcSA1 (δC 70.8) and between H-1GlcSB2 [δH 5.14 
(1H, d, J = 7.5 Hz)] and C-6GlcSB1 (δC 70.3). Taken together, compound 1 was 
elucidated to be 3-O-β-D-glucopyranosyl-(1➝6)-O-β-D-glucopyranosyl erythrodiol 
28-O-β-D-glucopyranosyl-(1➝6)-O-β-D-glucopyranoside. This is the first reported 
erythrodiol analogue in G. sylvestre and thus suggests erythrodiol is a building block 
in this system and its glycosides would be constructed in a manner similar to 
oleanane glycosides (Figure 10-B). 
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3.3.1. Gymnemoside GS2 - Compound 2  
Compound 2 (peak 21) was obtained as an amorphous powder with [D]25D  26.3 
(c 0.2, MeOH). Its molecular formula was determined to be C59H98O26 based on its 
HRESIMS peak at m/z 1221.6298 [M – H]– (calcd for C59H97O26, 1221.6268). 
Evidence from KIA, MFA, and the construction rule in Figure 10B-a suggested that 
the structure of 2 may be erythrodiol + 3-(glc6-glc6-xyl) + 28-(glc6-glc). The 1H and 
13C NMR spectroscopic data of 2 (Tables 3 and 4) were similar to those of 1, except 
for the addition of one xylose unit based on the signals of an anomeric proton Xyl-
SA3-1' (δH 4.92, d, J = 7.5 Hz) and 6 carbons at Xyl-SA3-1' (δC 106.3), Xyl-SA3-2' 
(δC 75.2), Xyl-SA3-3' (δC 78.4), Xyl-SA3-4' (δC 71.4), and Xyl-SA3-5' (δC 67.3). 
Furthermore, a downfield shift of Glc-SA2-6' (δC 70.0, +7.0 ppm) was observed 
relative to 1, which supported the elongation of the sugar chain by continuing the 
1→6 linkage pattern through the attachment of a xylopyranosyl unit to C-6 of Glc-
SA2. Further HMBC analysis indicated a connection between Xyl-SA3-1' (δH 4.92, 
d, J = 7.5 Hz) and C-Glc-SA2-6' (δC 70.0). Accordingly, compound 2 was elucidated 
to be 3-O-β-D-xylopyranosyl-(1➝6)-O-β-D-glucopyranosyl(1➝6)-O-β-D-
glucopyranosyl erythrodiol 28-O-β-D-glucopyranosyl-(1➝6)-β-D-glucopyranoside. 
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Figure 16. Gymnemoside GS2 
3.3.3. Gymnemoside GS3 - Compound 3 
Compound 3 (peak 65) was obtained as an amorphous powder with [D]25D   14.0 
(c 0.2, MeOH). It possessed the molecular formula C41H62O11, as determined from 
its negative ion HRESIMS peak [M – H]– at m/z 753.4235 (calcd for C43H61O11, 
753.4214). Its molecular formula and fragmentation were consistent with the 
structure of CS + (3-glcA) + bz formulated from the building block library. The 1H 
NMR spectrum showed seven methyl singlets at δH 1.43, δH 1.30, δH 1.15, δH 1.10, 
δH 1.03, δH 0.97, and δH 0.80 (each 3H, s). The 13C NMR spectrum showed signals 
for 42 carbons, including two carboxylic groups at δC 172.6 and 167.1, one anomeric 
carbon, 8 aromatic and olefinic carbons, 7 oxygenated carbons, and 24 methine or 
methylene carbons. The signals of a double bond at C12-13 δC 123.3 and 143.4 and 




which are similar to the characteristic peaks of chichipegenin.(K. Yoshikawa et al., 
1999; 1994a) The shift in the resonance of C-3 due to glycosylation (δC 89.4, +10.9 
ppm) relative to the same carbon in chichipegenin (K. Yoshikawa et al., 1994a) and 
the HMBC cross peak from GlcA-H1′ δH 4.97 (d, J = 7.7 Hz) to C-3 (δC 89.4) 
confirmed the structure and linkage of the sugar portion to C-3. The presence of a 
benzoyl group was evident by comparing the aromatic signals [bz-1 (δC167.1, C), 
bz-2 (δC131.5, C), bz-3,7 (δC130.0, CH), bz-4,6 (δC129.3, CH), and bz-5 (δC133.7, 
CH)] to those in the literature (Pham et al., 2018; Ye et al., 2001a) and the location 
of this group at C-28 on the aglycone was deduced from the HMBC correlation 
between H-28 (δH 5.41, d, J = 10.5 Hz; δH 4.93, d, J = 10.5 Hz) and bz-1 (δC 167.1). 
Based on these data, compound 3 was elucidated as 28-O-benzoyl-chichipegenin 3-
O-β-D-glucopyranoside. 
 
Figure 17. Gymnemoside GS3 
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3.3.4. Gymnemoside GS4 - Compound 4 
Compound 4 (peak 73) was obtained as an amorphous powder with [α]25 D 19.3 
(c 0.1, MeOH), and its molecular formula of C42H61NO11 was determined based on 
its negative HRESIMS ion peak m/z 754.4158 [M – H]− (calcd for C42H60NO11, 
754.4166). HPLC-MS experiments in positive mode suggested the existence of a 
glucuronic acid moiety (corresponding to a loss of 176 Da), a nitrogen-containing 
acyl moiety (107 Da) and 4 hydroxy groups on the triterpene skeleton 
(corresponding to 4 × 18 Da). Comparison of the 1H and 13C NMR data of 4 with 
those of 3 revealed that the two compounds were structurally similar in their 
aglycone and glycosyl portions, and the benzoyl group was replaced by a 3-
nicotinoyloxy group, as indicated by the NMR data (nic-1 [δC 167.1], nic-2 (δC 151.1), 
nic-3 (δC 124.3), nic-4 (δC 137.3), nic-5 (δC 123.1) and nic-6 (δC 154.2)). The 3-
nicotinoyloxy linkage at C-28 was established by the HMBC cross peaks from the 
carbonol protons H-28a (δH 5.40, d, J = 10.5 Hz) and H-28b (δH 4.90, d, J = 10.5 Hz) 
to nic-1 (δC 165.7). Therefore, compound 4 was identified as 28-O-(3-
nicotinoyloxy)-chichipegenin-3-O-β-D-glucuropyranoside. This is the first time a 
compound bearing a nicotinoyl moiety has been found in G. sylvestre, and it can be 





Figure 18. Gymnemoside GS4 
3.3.5. Gymnemoside GS5 – Compound 5  
Compound 5 (peak 60) was obtained as an amorphous powder with [D]25D  22.0 
(c 0.2, MeOH). Its molecular formula (C41H64O11) was determined from its 
quasimolecular ion peak at m/z 731.4382 [M – H]– (calcd for C41H63O11, 731.4370) 
in HRESIMS. The 1H, 13C, and HSQC NMR spectroscopic data of 5 (Tables 3 and 
4) were similar to those of gymnemoside ND6 with an additional tigloyl unit, which 
was indicated by the resonances of tig-1 (δC 167.9), tig-2 (δC 130.0), tig-3 (δC 137.1), 
tig-4 (δC 14.6), and tig-5 (δC 12.7) as well as the downfield shift of C-21 (δC 76.7) 
compared with the corresponding carbon in gymnemoside ND6 and the HMBC cross 
peak from H-21 (δH 5.51) to tig-1 (δC 167.9). Consequently, compound 5 was 
elucidated as 21-O-tigloyl-sitaskisogenin 3-O-β-D-glucuronopyranoside. 
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Figure 19. Gymnemoside GS5 
3.3.6. Gymnemoside GS6 - Compound 6 
Compound 6 (peak 32) was obtained as an amorphous powder with [D]25D 11.0 
(c 0.2, MeOH), and it possessed a molecular formula of C36H58O8 based on its 
HRESIMS peak at m/z 617.4054 [M – H] – (calcd for C36H57O8, 617.4053). The 1H 
and 13C NMR data (Table 3) together with the HSQC and HMBC data suggested 
that 6 was structurally similar to gymnemoside ND4 (Pham et al., 2018) but lacked 
a glucose in the glycoside chain. Thus, compound 6 was elucidated as maniladiol-3-
O-β-D-glucuronopyranoside. The elucidation of 6 and the detection of gymnemoside 
ND4 in the extract suggested that these compounds and maniladiol glycosides were 
constructed by Figure 10B-b (unlike erythrodiol glycosides which were constructed 





Figure 20. Gymnemoside GS6 
3.4. Metabolite Profiling of Oleanane Triterpenoids  
The shortcomings of conventional metabolite profiling by manual 
investigation of chromatographic spectra have been clearly recognized as 
unsystematic, untargeted, and time-consuming (Wolfender et al., 2015; Xie et al., 
2012; Xing et al., 2015). Our new approach to metabolite assignment in this study 
provided a clear improvement on the current method. The remarkable advantage of 
the simple microfractionation technique using in this study was the ability to 
magnify signals of minor or trace compounds, led to the detection of 119 peaks while 
only 60 peaks could be found in a single UPLC-MS scan of the total extract.  
A new concept of multilayer metabolite profiling – MMP was developed as 
an addition to the typical total ion chromatography (TIC) chemical profile (Figure 
21). The advantage of MMP is that it not only displayed the retention time of 
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compounds in a straightforward chromatogram interface but also provided the 
information of the structural formation of metabolites. Another strength of MMP is 
its ability to underline considerable insight into the chemical relationship of oleanane 
saponins by categorization of all detected peaks into homogeneous structural sub-
groups (layers). The relationship between detected peaks can be analyzed on each 
layer or comparing peaks of different layers. 
 






The quality control of a medicinal plant requires a rapid and accurate analysis 
of the comprehensive chemical profile of the active extract (Mohn et al., 2009). In 
this study, we described a new, reliable, and generally applicable approach to 
analyze the 70% EtOH extract of G. sylvestre by ultra-performance liquid 
chromatography (UPLC) with quadrupole-time-of-flight mass spectroscopy 
(UHPLC/qTOF-MS). This strategy is realized by integrating building blocks 
analysis with rapid HPLC microfractionation of extract, and multiple key ion 
analysis (mKIA), and mass fragmentation analysis (MFA) to allowing a systematic 
structure assignment and dereplication of the triterpenoids saponins of G. sylvestre. 
Spectra and mass data, which are obtained from the 24 standard reference 
compounds isolated from Vietnamese G. sylvestre variety available in Korea 
Bioactive Natural Material Bank (KBNMB), provided unambiguous evidence for 
the metabolite profiling. Targeted isolation for selective compounds was also 
implemented to confirm the structural annotations. Finally, all identified compounds 
were categorized into multiple structural layers to examine the biosynthesis 




Part 2. Oleanane triterpenoids from Gymnema latifolium and their 
PTP1B inhibitory activities 
1. Introduction 
Type 2 diabetes mellitus (T2DM) has emerged as a global health issue which 
correlates closely to the widespread occurrence of obesity. The International 
Diabetes Federation estimated that there were 382 million patients of T2DM aged 
20–70 years worldwide in 2013, and the number was anticipated to surge up to 592 
million by 2035 (DeFronzo et al., 2015). T2DM is defined as a complex metabolic 
disorder characterized by high blood glucose levels caused by insulin deficiency, 
insulin resistance or both (DeFronzo et al., 2015). Poor glycaemic control may lead 
to a variety of diabetes complications, including cardiovascular disease, diabetic 
nephropathy, diabetic neuropathy, diabetic retinopathy, stroke, and lower limb 
amputations (Hossain et al., 2007; Marcovecchio et al., 2019; J. L. Yang et al., 2017). 
Protein tyrosine phosphatases (PTPs) are considered as drug targets to treat 
type 2 diabetes and obesity by their role in regulating the tyrosine phosphorylation 
of target proteins (Fischer et al., 1991; He et al., 2014). PTP1B, a member of the 
PTP superfamily, has been proven to be a promising therapeutic target in the 
treatment of T2DM  by regulating insulin and leptin signaling pathways (Zabolotny 
et al., 2002). PTP1B gene deletion also protected mice against the development of 
obesity, diabetes, and cardiovascular dysfunction (Cho, 2013; Coquerel et al., 2014).  
Natural products are promising sources of lead compounds that play a 
significant role in the discovery of new antidiabetic agents via the mechanism of 
PTP1B inhibition. Approximately 300 new or known natural products from various 




exhibited promising in vitro, in vivo activities and selectivity profiles (Jiang et al., 
2012). Among them, naturally occurring triterpenes isolated from Astibilbe koreana, 
Symplococos paniculata, Gynostemma pentaphyllum displayed remarkable PTP1B 
inhibition activities (Hung et al., 2009; Na et al., 2006a; 2006b). These inhibitors, 
therefore, could be considered for further research and development as clinical drug 
candidates for treating diabetes, obesity and related metabolic syndromes (Jiang et 
al., 2012). 
In our ongoing research to find PTP1B inhibitors from natural products, 
hundreds of plant extracts available in Korea Bioactive Natural Material Bank have 
been screened against this biological target. An extract of the Gymnema latifolium 
Wall. ex Wight showed considerable PTP1B inhibitory activity (>70% inhibition at 
30 µg/mL). The result was in agreement with the use of this plant in Vietnam as an 
antidiabetic herbal medicine. Some studies have recommended that 3𝛽-hydroxy 
oleanane derivatives were potential PTP1B inhibitor (Qian et al., 2010; Y.-N. Zhang 
et al., 2008). Various varieties of Gymnema sylvestre,  a species of the same genus 
Gymnema, have been studied intensively on their extracts and their oleanane 
triterpenoid composition for the hypoglycaemic effects (Leach, 2007; Pham et al., 
2018; Tiwari et al., 2017). It is also well-known that most species belonging to the 
same genus possess similar chemical composition and thus exhibit similar biological 
activities (Jürgens and Dötterl, 2004). As expected, in this study, we isolated 14 new 




Purpose of research 
x Authenticate the scientific name of the medicinal plant 
x Identify the the chemical composition of Gymnema latifolium.  





2. Materials and methods 
2.1. Plant materials 
Plant materials were cultivated in an herb farm in the Thai Nguyen province of 
Vietnam (GPS 21°52'47.5"N 105°44'35.7"E) and collected in August 2017. A 
voucher specimen was deposited in the Medicinal Herbarium of Hanoi University 
of Pharmacy with the accession number HNIP/18068.  
2.2. Extraction and isolation schemes  
2.2.1. General experimental procedures 
 Optical rotations were measured on a JASCO P-2000 polarimeter using a 1-
cm cell (JASCO International Co. Ltd., Tokyo, Japan). IR data were recorded on a 
Nicolet 6700 FT-IR spectrometer (Thermo Electron Corp., Waltham, MA, USA). 
NMR data were analyzed using an AVANCE 500 MHz spectrometer (Bruker, 
Billerica, MA USA) or a JNM-ECA 600 MHz spectrometer (JEOL Ltd., Tokyo, 
Japan). HRESIMS were analyzed using an Agilent Technologies 6130 Quadrupole 
LC/MS spectrometer equipped with an Agilent Technologies 1260 Infinity LC 
system (Agilent Technologies, Inc., Santa Clara, CA, USA) and an INNO C18 
column (4.6 × 150 mm, 5 Pm particle size, 12 nm, J.K. Shah & Company, Korea). 
Silica gel 60 F254 and RP-18  TLC plates and deuterated pyridine for NMR analysis 
were purchased from Merck (Darmstadt, Germany). Sephadex LH-20 from Sigma-
Aldrich (St. Louis, MO, USA) was used for column chromatography (CC). A Gilson 
HPLC semi-preparative purification system, equipped with an Optima Pak C18 
column (10 × 250 mm, 10 µm particle size; RS Tech, Seoul, Korea), was used at a 
flow rate of 2 mL/min and UV detection at 205 or 254 nm. Extra-pure grade solvents 
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for extraction, fractionation, and isolation were purchased from Dae Jung Pure 
Chemical Engineering Co. Ltd. (Siheung, Korea). 
2.2.2. Isolation scheme  
The aerial parts of G. latifolium (5.0 kg) were powdered and extracted with 
70% EtOH (3 times × 10 L, for 3 h each) with ultrasonication, and the extract was 
concentrated in vacuo. The crude extract obtained (900 g) was suspended in water, 
absorbed onto Sephabeads SP70 resin and washed with water, 50% EtOH, 100% 
EtOH, and acetone, in a sequential elution process. The 100% EtOH fraction (150 g) 
GL.100 was subjected to silica gel column chromatography (15 × 45 cm; 63–200 
μm particle size) using n-hexane/EtOAc (gradient from 10:1 to 0:1) and then 
EtOAc/MeOH (gradient from 10:1 to 0:1) to give 6 fractions (N1-N6) based on the 
thin-layer chromatography profile. Fraction N3 was chromatographed over C18-
reversed phase silica gel (RP-C18) column chromatography, eluted with CH3OH/H2O 
(2:3 to 4:1) to obtain 12 fractions N3.M1-M12.   
 Fraction N3.M7 (800 mg) was applied to a Sephadex LH-20, eluted with 
CH3OH/H2O (7:10) to yield 7 subfractions N3.M7.L1⎯L7. Subfraction N3.M7.L3 
(258 mg) was subjected to semi-preparative reversed-phase HPLC on an Optima Pak 
C18 column, CH3OH/H2O (4:6 to 7:10), flow rate 2 mL/min, to yield compound 15 
(24.7 mg) and 17 (12.6 mg).   
Fraction N3.M8 (850 mg) was applied to a sequential separation by 
Sephadex LH-20 (MeOH 70%) to yield 3 subfractions N3.M8.L1⎯L3. Subfraction 
N3.M8.L3 (520 mg) over C18-reversed phase silica gel (RP-C18) column 
chromatography, eluted with CH3CN/H2O (3:7 to 1:1) to obtain 5 fractions 




HPLC using a CH3CN/H2O (3:7) solvent system from fraction N3.M8.L3.A1 (90 
mg). Compounds 18 (22.5 mg) and 19 (15.5 mg) were purified from fraction 
N3.M8.L3.A2 (150 mg) by semi-preparative HPLC using CH3CN/H2O (4:6), flow 
rate 2 mL/min.  Subfraction N3.M8.L3.A3 (200 mg) was applied to a HPLC (Optima 
Pak C18, CH3CN/H2O (gradient 2:8 to 4:6, flow rate 2 mL/min) to produce 
compounds 12 (16.5 mg) and 13 (9.5 mg). Subfraction N3.M8.L3.A4 (80 mg) was 
subjected to a  HPLC (Optima Pak C18, CH3CN/H2O (isocratic 4:6, flow rate 2 
mL/min) to produce compounds 14 (8.2 mg) and  16 (10.2 mg).  
Fraction N3.M9 (320 mg) was applied to a Sephadex LH-20, eluted with 
CH3OH/H2O (7:10) to yield 5 subfractions N3.M9.L1-L5.  Compounds 5 (19.1 mg) 
were obtained by semi-preparative HPLC using a CH3CN/H2O (4:6) solvent system 
from fraction N3.M9.L3 (200 mg).  
Fraction N3.M10 (500 mg) was applied to a sequential separation by 
Sephadex LH-20 (MeOH 70%) and HPLC (Optima Pak C18, CH3CN/H2O (gradient 
3:7 to 5:5, flow rate 2 mL/min) to produce compounds 6 (22.5 mg) and 7 (15.5 mg). 
Compound 8 (5.0 mg) were purified from fraction N3.M10.L2 (150 mg) by semi-
preparative HPLC using CH3CN/H2O (9:11), flow rate 2 mL/min.  
Fraction N3.M12 (500 mg) was applied to a Sephadex LH-20, eluted with 
CH3OH/H2O (7:10) to yield 7 subfractions N3.M12.L1-L7. Subfraction N3.M12.L2 
(180mg) was subjected to semi-preparative reversed-phase HPLC on an Optima Pak 
C18 column, CH3CN/H2O (6:4), flow rate 2 mL/min, to yield compound 1 (21.4 mg) 
and 2 (15.5 mg).  Subfraction N3.M12.L3 (120 mg) was purified by reversed-phase 
HPLC on an Optima Pak C18 column, using sequential separation by CH3OH/H2O 
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(3:1), flow rate 2 mL/min, to yield compound 3 (12.5 mg) and 4 (13.2 mg).  
Subfraction N3.M12.L4 (80 mg) was separated by another semi-preparative HPLC 





Figure 22. Isolation scheme of compounds 1 – 20 from G. latifolium 
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2.2.3. Physical and chemical characteristics of isolated compounds 
Gymlatinoside GL1 (1): White amorphous powder, [D]25D  +15.2 (c 0.2, MeOH); 
IR (KBr) vmax 3389, 2948, 2898, 1711, 1641, 1266, 1008  cm–1; 1H and 13C NMR 
data, Tables 5 and 6; HRESIMS m/z 967.4896 [M − H]− (calcd for C49H75O19,  
967.4903). 
Gymlatinoside GL2 (2): White amorphous powder, [D]25D  +9.6 (c 0.2, MeOH); 
IR (KBr) vmax 3389, 2948, 1711, 1646, 1441, 1389, 1266, 1140  cm–1; 1H and 13C 
NMR data, Tables 5 and 6; HRESIMS m/z 965.4752 [M − H]− (calcd for C49H73O19, 
965.4746). 
Gymlatinoside GL3 (3): White amorphous powder, [D]25D  +10.1 (c 0.2, MeOH); 
IR (KBr) vmax 3384, 2893, 2307, 1716, 1275, 1095  cm–1; 1H and 13C NMR data, 
Tables 5 and 6; HRESIMS m/z 987.4581 [M − H]− (calcd for C51H71O19, 987.4590).  
Gymlatinoside GL4 (4): White amorphous powder, [D]25D  +22.1 (c 0.2, MeOH); 
IR (KBr) vmax 3429, 2948, 1726, 1080, 1040  cm–1; 1H and 13C NMR data, Tables 5 
and 6; HRESIMS m/z 1007.4826 [M − H]− (calcd for C51H75O20, 1007.4852). 
Gymlatinoside GL5 (5): White amorphous powder, [D]25D  +13.4 (c 0.2, MeOH);  
IR (KBr) vmax 3399, 2943, 1075, 1035  cm–1; 1H and 13C NMR data, Tables 5 and 6; 






Gymlatinoside GL6 (6): White amorphous powder, [D]25D  +5.4 (c 0.2, MeOH);  
IR (KBr) vmax 3454, 2953, 1736, 1250, 1030 cm–1; 1H and 13C NMR data, Tables 5 
and 6; HRESIMS m/z 791.4225 [M − H]− (calcd for C42H63O14, 791.4218). 
Gymlatinoside GL7 (7): White amorphous powder, [D]25D  +12.4 (c 0.2, MeOH); 
IR (KBr) vmax 3386, 2957, 2891, 1743 cm–1; 1H and 13C NMR data, Tables 5 and 6; 
HRESIMS m/z 847.4508 [M − H]− (calcd for C45H67O15, 847.4480).  
Gymlatinoside GL8 (12): White amorphous powder, [D]25D  +35.4 (c 0.2, MeOH); 
UV (MeOH) λmax (log ε) 325 nm (3.2); IR (KBr) vmax 3364, 2957, 2891, 1743 cm–1; 
1H and 13C NMR data, Tables 7 and 8; HRESIMS m/z 1121.5549 [M − H]− (calcd 
for C57H85O22, 1121.5532). 
Gymlatinoside GL9 (13): White amorphous powder, [D]25D  +24.3 (c 0.2, MeOH); 
UV (MeOH) λmax (log ε) 325 nm (3.5);  IR (KBr) vmax 3361, 2957, 2881, 1733 cm–1; 
1H and 13C NMR data, Tables 7 and 8; HRESIMS m/z 1151.5658  [M − H]− (calcd 
for C58H87O23,  1151.5638). 
Gymlatinoside GL10 (14): White amorphous powder, [D] 25D  +10.1 (c 0.2, 
MeOH); UV (MeOH) λmax (log ε) 325 nm (3.1); IR (KBr) vmax 3365, 2955, 2884, 
1733, 1232 cm–1; 1H and 13C NMR data, Tables 7 and 8; HRESIMS m/z 827.4585 
[M − H]− (calcd for C46H67O13, 827.4582). 
Gymlatinoside GL11 (15): White amorphous powder, [D] 25D  +26.3 (c 0.2, 
MeOH); UV (MeOH) λmax (log ε) 325 nm (3.4); IR (KBr) vmax 3429, 2948, 1726, 
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1080, 1040  cm–1; 1H and 13C NMR data, Tables 7 and 8; HRESIMS m/z 973.5167 
[M − H]− (calcd for C52H77O17, 973.5161).  
Gymlatinoside GL12 (16): White amorphous powder, [D] 25D  +15.2 (c 0.2, 
MeOH); UV (MeOH) λmax (log ε) 325 nm (3.5);  IR (KBr) vmax 3455, 2948, 1737, 
1252, 1030 cm–1; 1H and 13C NMR data, Tables 7 and 8; HRESIMS m/z 1149.5629 
[M − H]− (calcd for C52H77O17, 973.5161). 
Gymlatinoside GL13 (17): White amorphous powder, [D] 25D  +25.9 (c 0.2, 
MeOH); UV (MeOH) λmax (log ε) 325 nm (3.5); IR (KBr) vmax 3366, 2957, 2884, 
1733, 1232, 1030 cm–1; 1H and 13C NMR data, Tables 7 and 8; HRESIMS m/z 
1267.6147 [M − H]− (calcd for C63H95O26, 1267.6147). 
Gymlatinoside GL14 (18): White amorphous powder, [D] 25D  +12.5 (c 0.2, 
MeOH); IR (KBr) vmax 3454, 2953, 1250, 1030  cm–1; 1H and 13C NMR data, Tables 
7 and 8; HRESIMS m/z 1091.5645 [M − H]− (calcd for C53H87O23, 1091.5638). 
2.3. Acid Hydrolysis 
The total extract (100 mg) was hydrolyzed with 2.0 N HCl (70% MeOH, 10 
mL) at 90 °C for 1 h. The solution was neutralized with 10% NaOH, dried, suspended 
in H2O and partitioned with EtOAc. The residual H2O layer was concentrated and 
dissolved in pyridine (1.0 mL), and 5.0 mg of L-cysteine methyl ester hydrochloride 
was added. The mixture was kept for 1 h at 60 °C, and then 4.4 𝜇L of 
phenylisothiocyanate (Sigma, St. Louis, MO, USA) was added. This solution was 
filtered through a 0.2-µm Whatman hydrophilic membrane filter into an HPLC 
sample vial and immediately analyzed by LC-MS. The analysis was performed using 




INNO C18 (4.6 × 250 mm inner diameter, 5 μm particle size; Young Jin Bio Chrom 
Co., Ltd), and the column temperature was 30 °C. The chromatographic separations 
were carried out using a mobile phase of 27% CH3CN with isocratic elution at a flow 
rate of 0.6 mg/mL over 60 min. The sugar derivatives showed retention times of 
10.9, 14.9 min, which were identical to the derivatives prepared with authentic D-
glucuronic acid, D-glucose, respectively. Similar procedures also applied to 
identified the sugar portions of compound 1, 5, 6, 7, 12 . 
2.4. PTP1B Assay 
PTP1B (human, recombinant) was purchased from BIOMOL International LP 
(Plymouth Meeting, PA). The enzyme activity was measured using p-nitrophenyl 
phosphate (pNPP), as described previously. To each of 96 wells in a microtiter plate 
(final volume: 100 µL) was added 2 mM pNPP and PTP1B (0.05-0.1 µg) in a buffer 
containing 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA, and 1 mM 
dithiothreitol (DTT), with or without test compounds. Following incubation at 37 °C 
for 30 min, the reaction was terminated with 10 M NaOH. The amount of produced 
p-nitrophenol was estimated by measuring the absorbance at 405 nm. The 
nonenzymatic hydrolysis of 2 mM pNPP was corrected by measuring the increase 
in absorbance at 405 nm obtained in the absence of PTP1B enzyme.  
For the enzyme kinetic determination, Lineweaver-Burk was used to determine 
the inhibition type of PTP1B. On the basis of Lineweaver-Burk double reciprocal 
plots, the PTP1B inhibition mode was obtained at various concentrations of p-NPP 
substrate (1, 2, 4, and 8 mM) without or with different test compound concentrations 
(10, 20, 30, and 40 μM). The 50% inhibition concentration (IC50) and the inhibition 
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type were evaluated using the Sigma Plot Statistical Analysis software (11.0 
software, SPCC Inc., Chicago, IL, USA). Data were represented as a mean of 





3. Results and discussion 
3.1. Authentication of Gymnema latifolium Wall ex. Wight 
Lianas are up to 6 m high. Stems corky lenticellate, old stems basally wing-
like corky.  The whole plant contains bright, yellow latex. Young branchlets 
yellowish green, densely pubescent, stalks densely hairy. Leaves opposite, broadly 
ovate, 8⎯13 cm × 5⎯8 cm, apex acute, base truncate to rounded, margin entire, 
orange-yellow pubescent abaxially, 5⎯7 lateral veins per side; petiole 1.5⎯4 cm long, 
densely pubescent. Inflorescences paired at node, multi-flowered, umbrella-shape 
cymes, pubescent. Peduncle, 3⎯8 mm long. Flowers yellow, 3 mm × 3 mm. Sepals 
ovate, puberulous outside. Corolla yellowish, campanulate, outside glabrous, 
densely pubescent inside. Gynostegium concealed in corolla, 
cylindrical with slightly swollen base, laterally with ten oval nectary patches; anther 
appendages shorter than stigma head. Pollinia oblong, erect, top enlargement; ovary 
densely pubescent, stigma conical divided into two. Follicles are in pair or solitary, 
lanceolate cylindrical, beaked, 7⎯10cm long, 0.3⎯0.6 cm in diameter, apex 
acuminate, base dilated, densely pubescent. Seeds many, oblong-lanceolate, 
winged with a thin edge; coma 3–4 cm long, white (Figure 23-A).   
The morphology is closely matched the description 
of Gymnema latifolium by Flora of China (Wu and Raven, 1995) with a slight 
difference on the fruit shape (7-10 cm x 0,3-0.6 cm) compared with 4.5-5.5 × 1.5-2 
cm. Also, the special characteristic of the wing-like corky can be found in the 
description of Gymnema khadalense by Subhash (Deokule et al., 
2013) and Gymnema kollimalayanum by Ramachandran (Ramachandran and 
Viswanathan, 2009). However, two species 
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Gymnema khandalense and Gymnema kollimalayanum were considered as 
synonyms of Gymnema latifolium by Meve and Alejandro (Meve and Alejandro, 
2011). In this study, by comparing the morphological characteristics with the 
specimens of syntype K000872841 (Figure 23-B) and lectotype specimen 
K000872839 (Figure 23-C) of Gymnema latifolium stored in the herbarium at the 
Royal Botanic Gardens Kew and the description by Meve and Alejandro, we 
identified the sample in Vietnam as Gymnema latifolium Wall. ex Wight. A DNA 
sequence of the ITS1-5.8S-ITS2 internal transcribed spacer of the sample was also 
deposited at GeneBank (National Institutes of Health) with the accession number 




   
A. B. C. 
Figure 23. A. Morphological characteristics of the studied Gymnema latifolium Wall. ex. Wight; B. Lectotype specimen of Gymnema 
latifolium Wall. ex. Wight (K000872839); C.  Lectotype specimen of Gymnema latifolium Wall. ex. Wight (K000872839)   
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3.2. Oleanane triterpenoids isolated from G.latifolium  
A 70% EtOH extract of G. latifolium was subjected to various 
chromatographic columns and then to purification by preparative high-performance 
liquid chromatography (HPLC) to afford 14 new oleanane triterpenoid glycosides, 
Gymlatinosides GL1-GL14 (1-7, 12-18) and 6 known compounds Gymnemic acid 
IX (8) (Liu et al., 1992), Gymnemic acid IV (9) (K. Yoshikawa et al., 1989), 
Gymnemasaponin I (K. Yoshikawa et al., 1991)(10), and Gymnemagenin (11) (Liu 
et al., 1992) , Gymnemoside-d and Gymnemosid-e (K. Yoshikawa et al., 1991). The 
structures of new compounds were elucidated by 2D-NMR, while known 
compounds were determined using 1D NMR analysis and comparing the physical 
and spectroscopic data with those in the literature. 
 






Figure 25. Key HMBC (H→C), COSY (H→H) and NOESY (H→H) of 
compound 1, 5, 6, 12, 18 isolated from G. latifolium 
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Table 5. 13C NMR spectroscopic data for new compounds Gymlatinosides GL1⎯7 
(in Pyridine-d5) 
position 















1 39.0, CH2 39.0, CH2 39.1, CH2 39.0, CH2 39.2, CH2 39.0, CH2 39.1, CH2 
2 26.4, CH2 26.4, CH2 26.4, CH2 26.4, CH2 27.0, CH2 26.9, CH2 26.4, CH2 
3 82.1, CH 82.2, CH 82.2, CH 82.2, CH 89.2, CH 89.1, CH 82.2, CH 
4 43.8, C 43.9, C 43.9, C 43.9, C 39.9, C 39.8, C 43.9, C 
5 47.2, CH 47.3, CH 47.5, CH 47.3, CH 56.1, CH 55.8, CH 47.7, CH 
6 18.3, CH2 18.4, CH2 18.4, CH2 18.3, CH2 18.8, CH2 18.6, CH2 18.3, CH2 
7 32.8, CH2 32.8, CH2 32.9, CH2 32.8, CH2 33.1, CH2 33.0, CH2 32.8, CH2 
8 40.5, C 40.6, C 40.6, C 40.6, C 40.5, C 40.5, C 40.6, C 
9 47.6, CH 47.6, CH 47.7, CH 47.6, CH 47.3, CH 47.2, CH 47.9, CH 
10 36.7, C 36.7, C 36.7, C 37.1, C 37.3, C 36.9, C 36.9, C 
11 24.2, CH2 24.3, CH2 24.3, CH2 24.2, CH2 24.2, CH2 24.1, CH2 24.2, CH2 
12 124.9, CH 124.9, CH 125.0, CH 125.0, CH 123.3, CH 125.0, CH 125.0, CH 
13 141.5, C 141.6, C 141.6, C 140.9, C 143.8, C 140.8, C 140.9, C 
14 43.0, C 43.0, C 43.0, C 43.2, C 44.3, C 43.1, C 43.2, C 
15 36.8, CH2 36.9, CH2 37.0, CH2 33.9, CH2 37.3, CH2 33.8, CH2 33.9, CH2 
16 67.8, CH 67.8, CH 67.9, CH 68.7, CH 66.5, CH 68.6, CH 68.7, CH 
17 46.0, C 46.0, C 46.0, C 47.9, C 41.7, C 47.8, C 47.4, C 
18 42.8, CH 42.8, CH 42.9, CH 42.5, CH 45.1, CH 42.4, CH 42.5, CH 
19 46.0, CH2 46.1, CH2 46.2, CH2 46.1, CH2 47.1, CH2 46.0, CH2 46.1, CH2 
20 36.9, C 37.0, C 37.0, C 37.0, C 37.0, C 36.8, C 37.1, C 
21 78.6, CH 79.2, CH 80.3, CH 76.7, CH 34.5, CH2 76.7, CH 76.7, CH 
22 71.7, CH 71.9, CH 71.9, CH 72.0, CH 27.5, CH2 71.9, CH 72.0, CH 
23 64.5, CH2 64.5, CH2 64.5, CH2 64.5, CH2 28.6, CH2 28.4, CH2 64.7, CH2 
24 13.9, CH3 13.9, CH3 14.0, CH3 14.0, CH3 17.4, CH3 17.2, CH3 14.0, CH3 
25 16.5, CH3 16.5, CH3 16.6, CH3 16.5, CH3 16.1, CH3 15.8, CH3 16.5, CH3 
26 17.4, CH3 17.4, CH3 17.5, CH3 17.3, CH3 17.4, CH3 17.1, CH3 17.3, CH3 
27 27.7, CH3 27.8, CH3 27.8, CH3 27.7, CH3 27.5, CH3 27.6, CH3 27.7, CH3 
28 62.6, CH2 62.7, CH2 62.7, CH2 58.2, CH2 78.7, CH2 58.2, CH2 58.2, CH2 
29 29.7, CH3 29.7, CH3 29.7, CH3 29.5, CH3 33.3, CH3 29.4, CH3 29.5, CH3 
30 20.9, CH3 20.1, CH3 20.2, CH3 20.1, CH3 24.4, CH3 20.0, CH3 20.1, CH3 
1st sugar  3-O-GlcA 3-O-GlcA 3-O-GlcA 3-O-GlcA 3-O-Glc 3-O-GlcA 3-O-GlcA 
1ʹ 106.8, CH 106.8, CH 106.9, CH 106.8, CH 107.3, CH 107.5, CH 106.6, CH 
2ʹ 72.5, CH 72.5, CH 72.5, CH 72.5, CH 76.2, CH 75.8, CH 75.8, CH 
3ʹ 74.2, CH 74.2, CH 74.2, CH 74.2, CH 78.7, CH 78.5, CH 78.5, CH 
4ʹ 69.9, CH 69.9, CH 69.9, CH 69.9, CH 72.2, CH 73.8, CH 73.8, CH 
5ʹ 75.6, CH 75.6, CH 75.7, CH 75.6, CH 79.1, CH 77.9, CH 78.2, CH 













28-O-Glc   
1ʹʹ 97.4, CH 97.5, CH 97.5, CH 97.5, CH 106.2, CH   
2ʹʹ 94.1, CH 94.2, CH 94.2, CH 94.2, CH 75.4, CH   
3ʹʹ 80.2, CH 80.2, CH 80.2, CH 80.2, CH 78.4, CH   
4ʹʹ 70.1, CH 70.1, CH 70.2, CH 70.1, CH 72.0, CH   
5ʹʹ 79.9, CH 80.0, CH 80.0, CH 80.0, CH 79.1, CH   
6ʹʹ 63.2, CH2 63.2, CH2 63.3, CH2 63.2, CH2 63.1, CH2   
16-Acyl    16-Ac  16-Ac 16-Ac 
1ʹʹʹ    170.2, C  170.5, C 170.3, C 
2ʹʹʹ    21.4, CH3  21.3, CH3 21.9, CH3 
21-acyl 21-Mba 21-Tig 21-Bz 21-Tig  21-Ac 21-Tig 
1 176.8, C 168.4, C 167.2, C 167.6, C  170.3, C 167.6, C 
2 42.4, CH 129.9, C 131.9, C 129.3, C  21.8, CH3 129.3, C 
3 27.6, CH2 137.2, CH 130.4, CH 137.9, CH   137.9, CH 
4 12.3, CH3 12.8, CH3 129.2, CH 12.6, CH3   12.6, CH3 
5 17.5, CH3 14.5, CH3 133.5, CH 14.6, CH3   14.6, CH3 
6   129.2, CH     
7   130.4, CH     
22-Acyl    22-Ac  22-Ac 22-Ac 
1ʹʹʹ    170.8, C  170.8, C 170.8, C 
2ʹʹʹ    21.9, CH3  21.0, CH3 21.4, CH3 
28-Acyl 28-Ac 28-Ac 28-Ac     
1ʹʹʹ 171.1, C 171.2, C 170.8, C     
2ʹʹʹ 20.0, CH3 21.1, CH3 21.0, CH3     




Table 6. 1H NMR spectroscopic data for compounds Gymlatinosides GL1⎯7 (in 
Pyridine-d5) 
position 
1 2 3 4 5 6 7 
GH (J in Hz) 
600 Mhz 
GH (J in Hz) 
600 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
600 Mhz 


























3 4.26, dd (12.3, 4.5) 
4.28, dd 
(12.3, 4.5) 




3.40, dd (11.5, 
4.5) 
3.41, dd (11.5, 
4.5) 
4.36, dd (12.3, 
4.5) 
5 1.64, overlap 1.64, overlap 1.65, overlap 1.64, overlap 0.78, overlap 0.75, overlap 1.64, overlap 


























9 1.63, overlap 1.63 overlap 1.63, overlap 1.63, overlap 1.56, t (9.0) 1.52, t (9.0) 1.63, overlap 













12 5.36, t (3.3) 5.38, t (3.3) 5.37, t (3.3) 5.37, t (3.3) 5.24, t (3.0) 5.39, t (3.0) 5.38, t (3.0) 











1.88, overlap  
1.42, overlap 






(11.5,5.5) 4.57, overlap 6.31, overlap 
6.30, dd (11.0, 
5.5) 
18 2.84, dd (13.7, 3.9) 
2.87, dd 
(13.7, 3.9) 




2.30, dd (13.8, 
4.0) 
3.27, dd (14.0, 
4.0) 
3.30, dd (14.4, 
4.0) 











2.26, t (14.0) 
1.34, overlap 
21 5.67, d (10.5) 
5.76, d 




1.63, overlap 5.61, d (11.0) 
5.69, d (11.0) 




1.35, overlap 5.16, d (11.0) 
6.23, d (11.0) 
23 3.70, d (10.5) 









1.32, s 1.32, s 
4.36, overlap 
3.73, d (10.4) 
24 0.92, s 0.93, s 0.91, s 0.95, s 1.03, s 0.99, s 0.96, s 
25 0.90, s 0.89, s 0.87, s 0.88, s 0.87, s 0.78, s 0.89, s 
26 1.05, s 1.06, s 1.05, s 0.90, s 0.98, s 0.86, s 0.90, s 
27 1.27, s 1.28, s 1.28, s 1.35, s 1.35, s 1.41, s 1.37, s 














29 1.04, s 1.04, s 1.04, s 0.95, s 0.93, s 0.96, s 0.98, s 
30 1.20, s 1.23, s 1.23, s 1.23, s 0.95, s 1.20, s 1.24, s 
1st sugar  3-O-GlcA 3-O-GlcA 3-O-GlcA 3-O-GlcA 3-O-Glc 3-O-GlcA 3-O-GlcA 
1ʹ 5.17, d (7.5) 5.20, d (7.5) 5.15, overlap 5.19, d (7.5) 4.97, d (7.5) 5.19, d (7.5) 5.27, d (7.5) 
2ʹ 4.20, overlap 4.20, overlap 4.21, overlap 4.21, overlap 4.01, overlap 4.21, overlap 4.18, t (6.8) 
3ʹ 4.89, t (9.5) 4.91, t (9.5) 4.89, t (9.5) 4.91, t (9.5) 4.26, overlap 4.91, t (9.5) 4.26, overlap 
4ʹ 5.21, overlap 5.24, t (9.5) 4.36, overlap 5.21, t (9.5) 4.22, overlap 5.21, t (9.5) 4.59, overlap 
5ʹ 4.52, overlap 4.54, d (9.5) 4.54, overlap 4.55, d (9.5) 4.02, overlap 4.55, d (9.5) 4.59, overlap 
6ʹ 




2nd sugar 3ʹ-O-2-oxoglc 3ʹ-O-2-oxoglc 3ʹ-O-2-oxoglc 
3ʹ-O-2-
oxoglc 28-O-Glc   
1ʹʹ 5.32, s 5.34, s 5.31, s 5.34, s 4.94, d (7.5)   
2ʹʹ     4.01, overlap   
3ʹʹ 4.21, overlap 4.24, overlap 4.22, overlap 4.23, overlap 4.26, overlap   
4ʹʹ 4.35, overlap 4.38, overlap 5.21, overlap 4.36, overlap 4.22, overlap   
 5ʹʹ 4.02, t (7.5) 4.04, overlap 4.03, t (7.5) 4.02, overlap 4.02, overlap   
6ʹʹ 4.33, d (10.5) 
4.61, d (10.5) 
4.36, overlap 






16-Acyl    16-Ac  16-Ac 16-Ac 
2    2.02, s  2.11, s 2.03, s 
21-acyl 21-Mba 21-Tig 21-Bz 21-Tig  21-Ac 21-Tig 
2 2.56, sextet (6.0)    
 2.17, s  
3 1.53, overlap 1.86, overlap 7.03, q (7.0) 8.27, d (7.5) 7.04, q (7.0)   7.04, q (6.8) 
4 0.97, t (7.0) 1.88, s 7.43, t (7.5) 1.90, s   1.90, s 
5 1.23, d (7.0) 1.61, d (7.0) 7.51, t (7.5) 1.63, d (7.0)   1.63, d (7.2) 
6   7.43, t (7.5)     
7   8.27, d (7.5)     
22-Acyl    22-Ac  22-Ac 22-Ac 
2    2.12, s  2.08, s 2.13, s 
28-Acyl 28-Ac 28-Ac 28-Ac     




Figure 26. Comparison of key 13C NMR signals of new compound 1⎯7 isolated 
from G. latifolium 
3.2.1. Gymlatinoside GL1 (1) 
Gymlatinoside GL1 (1), obtained as a white amorphous powder, with [D]25D  
+15.2 (c 0.2, MeOH), was found to possess a molecular formula of C49H76O19 and 
and 12 indices of hydrogen deficiency (IHDs) based on the high-resolution 
electrospray ionization mass spectrometry (HRESIMS) ion peak at m/z 967.4896 [M 
− H]− (calcd for C49H75O19,  967.4903). The broad IR peak at 3389 cm–1 indicated the 
presence of hydroxy groups, and the peaks at 1641 cm–1 revealed the existence of 
carboxylic moieties. The 1H NMR spectrum exhibited seven methyl singlets at δH 
1.94, 1.27, 1.20, 1.05, 1.04, 0.92 and 0.90 (each 3H). The most downfield resonance 
(δH 1.94) is the signal of an acetoxymethyl, and the others suggested an oleanane 
backbone. Two other methyls can be observed at  δH 1.23 (3H, d, J = 7.0 Hz) and δH 
0.97 (3H, t, J = 7.0 Hz) (Table 6). The 13C NMR spectrum showed signals for 49 
carbons, including three carboxylic groups at δC 176.8, 171.6 and 171.1; two olefinic 




oxygenated carbons in the range from δC 62.6 to 94.1, and others are methine, 
methylene and methyl signals (Table 5). The COSY, HSQC and HMBC spectra 
indicated a planar structure of oleanane-type triterpene possessing 6 hydroxy groups 
substituted at C-3, 16, 21, 22, 23 and 28 for the main aglycone of 1 (Figure 27). 
Comparing chemical shifts of 1 with gymnemic acid VIII and gymnemic acid X 
suggested gymnemagenin to be the main aglycone (Liu et al., 1992). A series of 
NOESY correlations between H-3 (δH 4.26  dd, J = 12.3, 4.5 Hz), H-23 (δH 3.70 d, 
J = 10.5 Hz); δH 4.32 d, J = 10.5 Hz), H-5 (δH 1.64, overlap), H-9 (δH 1.64, overlap), 
H-27 (δH 1.27, s), H-16 [δH 5.09, dd, J = 11.0, 5.2 Hz), H-21 [δH 5.67, d, J = 10.5 
Hz) and H-29 (δH 1.04, s) confirmed the 𝛼 configuration for these protons. 
Meanwhile, the series of NOESY cross peaks between H-24 (δH 0.92, s), H-25 (δH 
0.92, s), H-26 (δH 1.05, s), H-28 [δH 4.57, overlap; δH 4.99 d, J = 10.5 Hz), H-18 [δH 
2.84, dd, J = 13.7, 3.9 Hz), H-22 [δH 4.50, overlap] and H-30 (δH 1.20, s) 
demonstrated their 𝛽 configurations (Figure 27). Furthermore, the acid hydrolysis 
of 1 afforded an aglycone which exhibited the same retention time and mass 
fragmentation with the standard gymnemagenin on LC-MS analysis. Two carboxylic 
groups were identified to be an (S)-2-methylbutyric acid (δC 176.8) and an acetyl (δC 
171.1) substitutions by comparing with those reported in literature (Yoshikawa et al., 
1992). Compared with gymnemagenin, the acylation shifts can be observed at C-28 
(δC 62.6, +4.1 ppm) and C-21 (δC 78.6, +1.4 ppm) (Liu et al., 1992). The protons at 
C-21 and C-28 also showed significant downfield shifts from those of 
gymnemagenin (H-21: δH 4.04 → δH 5.67 and H-28: δH 4.07 → δH 4.57; δH 4.71 → 
δH 4.99). The HMBC correlations from H-21 (δH 5.67, d, J = 10.5 Hz) to C-1M-21 (δC 
176.8), and H-28 [δH 4.99, d, J = 10.5 Hz); δH 4.57, overlap] to C-1A-28 (δC 171.1) 
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confirmed the linkages of the (S)-2-methylbutyric acid to C-21 and the acetyl to C-
28. The COSY and dimensional (2D) J-resolved NMR spectra allowed the detection 
of two sugar chains, and the precise assignment of the coupling constants of their 
sugar protons (Figure 27). A doublet signal at δH 5.18 (d, J = 7.5 Hz) can be assigned 
to a 𝛽-isomer anomeric proton H-1′, corresponding to the anomeric carbon signal at 
C-1′ (δC 106.8).  The appearance of proton H-5′ (δH 4.51) as a doublet (J = 10.5 Hz) 
and its HMBC cross peak with C-6′ (δC 171.6) suggested that the first sugar moiety 
is a glucuronic acid. The second anomeric proton H-1′′ (δH 5.32) which correlated 
with C-1′′  δC 97.4 on HSQC spectrum and the signal of the quaternary carbon C-2′′ 
(δC 94.1) are the characteristics of a  2-oxo-hexose which is forming an 
intramolecular hemiacetal with another hydroxy group (Liu et al., 1992). The 
existence of this 2-oxo-glucose portion was also recognizable by a fragment loss of 
160 Da in the positive mass fragmentation. Furthermore, the 13C-NMR data of the 
sugar portions were almost identical to those of gymnemic acid VIII (Liu et al., 
1992). The HMBC correlation from H4′ (δH 5.21, t,  J = 10.5 Hz) to C-2′′, which was 
not detected by Liu, but finally could be observed in a high resolution HMBC NMR 
experiment. This HMBC correlation further confirmed the existence dioxane ring 
between two sugar moieties (Figure 27). Coupling constants and NOESY 
correlations confirmed the β configurations for H-2′ and 4′, and 𝛼 orientations for 
H-1′, 3′, 5′, 1′′, 3′′ and 5′′. The 3J coupling constant (J = 10.5 Hz) observed by 
dimensional (2D) J-resolved NMR indicated the antiperiplanar conformation 
between H-3′′ and H-4′′ and thus verified the axial orientation of H-4′′. Taken 







Figure 27. Gymlatinoside GL1 
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3.2.2. Gymlatinoside GL2 (2) 
Gymlatinoside GL2 (2) was obtained as a white amorphous powder, with [D]25D  
+9.6 (c 0.2, MeOH). Its HRESIMS showed a pseudo molecular ion peak at m/z 
965.4752 [M − H]− (calcd for C49H73O19, 965.4746), indicating a molecular formula 
of C49H74O19 and 13 IHDs. The 1H and 13C NMR spectroscopic data of 2 (Tables 5, 
6) showed similar resonances to those of 1, apart from the signals of the O-(S)-
2methylbutyloyl moiety which were replaced by the chemical shifts of a tigloyl 
moiety (Pham et al., 2018) (Figure 26). A neutral fragmentation loss of 82 Da 
observed in positive mode of mass spectrum also established the occurrence of the 
tigloyl and its linkage to C-21 was demonstrated by the HMBC correlation from H-
21 [δH 5.76, d(10.5)]  to C-1T-21 (δC 168.4) (Figure 28). Therefore, compound 2 was 
defined as 21-O-tigloyl-28-O-acetyl-gymnemagenin 3-O-β-D-arabino-2-
hexulopyranosyl-(1→3)-β-D-glucuronopyranoside. 
 




3.2.3. Gymlatinoside GL3 (3) 
Gymlatinoside GL3 (3) was obtained as a white amorphous powder, with [D]25D  
+10.1 (c 0.2, MeOH). Its HRESIMS showed a pseudo molecular ion peak at m/z 
987.4581 [M − H]− (calcd for C51H71O19, 987.4590), indicating a molecular formula 
of C51H71O19 and 16 indices of hydrogen deficiency. The 1H and 13C NMR 
spectroscopic data of 3 (Tables 5, 6) exhibited similar resonances to those of 1, 
except for the replacement of signals of the O-(S)-2methylbutyloyl moiety with the 
chemical shifts of a benzoyl moiety (Figure 26). The positive mass fragment loss 
∆m/z = 104 Da observed in 3 confirmed the existence of benzoyl. The downfield shift 
of C-21 (δC 80.3) and the HMBC cross peak from H-21 [δH 5.77, d(10.5)] to C-1B-21 
(δC 167.2) established the connection of the benzoyl to C-21 (Figure 29). Therefore, 
compound 3 was elucidated as 21-O-benzoyl-28-O-acetyl-gymnemagenin 3-O-β-D-
arabino-2-hexulopyranosyl-(1→3)-β-D-glucuronopyranoside. 
 
Figure 29. Gymlatinoside GL3 
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3.2.4. Gymlatinoside GL4 (4) 
Gymlatinoside GL4 (4) was obtained as a white amorphous powder, with [D]25D  
+ 22.1 (c 0.2, MeOH), was found to possess a molecular formula of C51H76O20 and 
14 IHDs based on the high-resolution electrospray ionization mass spectrometry 
(HRESIMS) ion peak at m/z 1007.4826 [M − H]− (calcd for C51H75O20, 1007.4852). 
Mass fragmentation in the positive mode showed the neutral losses of 2 acetyls (2 × 
42 Da) and 1 tigloyl (82 Da). The 1H and 13C NMR data of 4 (Tables 5, 6) showed 
comparable resonances to those of 2 in the aglycone and glycosyl moieties (Figure 
26) with some differences  occurred in the positions of acyl substitutions. Further 
investigation of the acylation shifts and HMBC spectra revealed that the tigloyl was 
attached to C-21 (δC 76.7) and two acetyls were substituted at C-16 (δC 68.7), C-22 








3.2.5. Gymlatinoside GL5 (5) 
Gymlatinoside GL5 (5) was obtained as an amorphous powder with [D]25D  
+13.4 (c 0.2, MeOH). The molecular formula C42H70O13 was determined by a 
quasimolecular ion peak at m/z 781.4746 [M – H]– (calcd for C42H69O13, 781.4738) 
in HRESIMS. 1H, 13C, and HSQC NMR spectroscopic data of the aglycone (Tables 
5, 6) exhibited signals for seven methyl groups: (δH 0.87, δC 16.1), (δH 0.93, δC 33.3), 
(δH 0.95, δC 24.4), (δH 0.98, δC 17.4), (δH 1.03, δC 17.4), (δH 1.32, δC 28.6), and (δH 
1.35, δC 27.5). The double bond at C12-13 was demonstrated by signals of olefinic 
group [δH-12 5.24 (br s), δC-12 123.3] and δC-13 143.8. Signals of 15 oxygenated carbons 
can be observed including 2 anomeric carbons at δC 107.3, 106.2, 10 other glycosyl 
carbons and 3 others of the main skeleton. These NMR data suggested the structure 
of a longispinogenin moiety with two attached sugars (Pham et al., 2018).  Sugar 
analysis and NMR data suggested the sugar type of this structure is glucose which 
is identified to be in β-configuration by the coupling constant J=7.5 Hz of their 
anomeric protons. Their positions at C-3 and C-28 were evident by the HMBC 
correlations from H-1′ [4.97, d (7.5)] to C-3 (δC 89.2) and H-1′′ [4.94, d (7.5)] to C-
28 (δC 78.7). Consequently, compound 5 was elucidated as 3-O-β-D-glucopyranosyl 




Figure 31. Gymlatinoside GL5 
3.2.6. Gymlatinoside GL6 (6) 
Gymlatinoside GL6 (6), obtained as an amorphous powder with [D]25D  +5.4 (c 
0.2, MeOH). The HRESIMS of this compound revealed an ion peak at m/z 791.4225 
[M – H]– (calcd for C42H63O14, 791.4218). It suggested a molecular formula 
C42H64O14 and indicated the presence of 11 IHDs. The 1H-NMR spectrum of 6 
showed seven methyl groups (δH 0.78, 0.86, 0.96, 0.99, 1.20, 1.32 and 1.41), and 12 
oxymethine protons (Table 6). The signals in the 13C NMR spectrum together with 
HSQC analysis could be assigned as 11 quaternary carbons (4 carboxylic acids at δC 
173.3, 170.8, 170.5, 170.3 and one olefinic at δC 140.8), 13 tertiary carbons (9 
oxygenated methines, one olefinic carbon at δC 125.0), 8 secondary carbons (1 
oxygenated methylene at δC 68.6) and 10 methyl carbons (Table 5). Compared its 
resonances with literature, together with the NOESY experiment (Figure 32), 




hydroxyl group substituted at C-16, C-21 and one 𝛼-oriented hydroxyl group at C-
22 (K. Yoshikawa et al., 1994b).  Furthermore, positive fragment ions exhibited a 
glucuronic fragment loss (176 Da) and 3 acetyl substitutions (3 × 42 Da). The HMBC 
correlations from H-16 (6.31, overlap) to C-1A-16 (δC 179.5), H-21 [δH  5.61, d (11.0)] 
to C-1A-21 (δC 170.3), and H-22 [δH  5.16, d (11.0)] to C-1A-22 (δC 170.8) confirmed 
the acylated linkage positions at C-16, 21 and 22. The connection of the β glucuronic 
acid to C-3 was determined by the coupling constant J = 7.5 Hz of the anomeric 
proton, the glycosylated chemical shift of C-3 (δC 89.1, +11.1) and the HMBC 
correlation from H-1′ (δH 4.97) to C-3. Therefore, compound 6 was elucidated as 
16,21,22-O-triacetyl marsglobigerin 3-O-β-D-glucuronopyranoside. 
 
Figure 32. Gymlatinoside GL6 
3.2.7. Gymlatinoside GL7 (7) 
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Gymlatinoside GL7  (7), obtained as an amorphous powder with [D]25D +12.4 
(c 0.2, MeOH), possessed a molecular formula of C45H68O15 based on HRESIMS ion 
peaks at m/z 847.4508 [M – H]– (calcd for C45H67O15, 847.4480). The LC-MS 
experiment in positive mode showed key ions of gymnemagenin (489, 471, 453 and 
435) and neutral losses of a glucuronic acid (176 Da), a tigloyl (82 Da) and two 
acetyls (2 × 42 Da). 1H, 13C, and HSQC NMR spectroscopic data confirmed the 
structure of aglycone gymnemagenin similar with compound 1 (Tables 5, 6). 
Meanwhile,  its 13C-NMR showed similar acylation chemical shifts for C-16 (δC 
68.7), C-21 (δC 76.7) and C-22 (δC 72.0) compared with 4 and the sugar portion 
showed superimposability with compound 6. The glycosylated chemical shift of C-
3 (δC 82.2) and HMBC cross peak from anomeric proton H-1′ [δH 5.27, d (7.5)] 
indicated the presence of a β-D-glucuronic acid substituted at C-3. Accordingly, 
compound 7 was determined as 21-O-tigloyl-16,22-O-diacetyl gymnemagenin 3-O-
β-D-glucuronopyranoside. 
 




Table 7. 13C NMR spectroscopic data for compounds Gymlatinosides GL12-18 (in 
Pyridine-d5) 
Position 













GC, , type 
150 Mhz 
1 38.6, CH2 38.5, CH2 38.7, CH2 38.6, CH2 38.6, CH2 38.6, CH2 39.0, CH2 
2 28.0, CH2 28.0, CH2 28.1, CH2 28.0, CH2 28.0, CH2 28.0, CH2 27.7, CH2 
3 71.5, CH 71.4, CH 71.5, CH 71.4, CH 71.6, CH 71.4, CH 71.4, CH 
4 43.6, C 43.6, C 43.6, C 43.6, C 43.5, C 43.6, C 43.2, C 
5 47.3, CH 47.3, CH 47.3, CH 47.3, CH 47.2, CH 47.3, CH 47.5, CH 
6 18.7, CH2 18.7, CH2 18.8, CH2 18.7, CH2 18.7, CH2 18.7, CH2 18.8, CH2 
7 32.9, CH2 32.8, CH2 32.9, CH2 32.6, CH2 32.5, CH2 32.7, CH2 32.9, CH2 
8 40.5, C 40.5, C 40.5, C 40.4, C 40.5, C 40.5, C 40.4, C 
9 47.4, CH 47.3, CH 47.5, CH 47.4, CH 47.2, CH 47.3, CH 47.5, CH 
10 37.2, C 37.2, C 37.2, C 37.2, C 36.9, C 37.2, C 37.3, C 
11 24.2, CH2 24.2, CH2 24.2, CH2 24.1, CH2 24.1, CH2 24.1, CH2 24.1, CH2 
12 123.1, CH 123.1, CH 123.1, CH 123.4, CH 123.5, CH 123.4, CH 123.2, CH 
13 144.0, C 144.2, C 144.0, C 144.2, C 144.6, C 144.2, C 144.0, C 
14 44.4, C 44.3, C 44.4, C 44.5, C 44.5, C 44.5, C 44.3, C 
15 37.3, CH2 37.3, CH2 37.2, CH2 37.4, CH2 37.1, CH2 37.5, CH2 37.2, CH2 
16 68.0, CH 68.0, CH 68.0, CH 66.5, CH 66.7, CH 66.5, CH 66.5, CH 
17 44.3, C 44.0, C 44.4, C 41.7, C 41.7, C 41.4, C 41.6, C 
18 44.4, CH 44.2, CH 44.1, CH 45.2, CH 44.5, CH 45.2, CH 45.0, CH 
19 48.3, CH2 48.3, CH2 48.3, CH2 47.4, CH2 47.4, CH2 47.3, CH2 47.5, CH2 
20 37.2, C 37.1, C 37.2, C 31.3, C 31.3, C 31.3, C 31.3, C 
21 73.1, CH 73.0, CH 73.1, CH 34.4, CH 34.4, CH2 34.4, CH2 34.4, CH 
22 35.4, CH2 35.3, CH2 35.4, CH2 28.0, CH2 28.0, CH2 28.0, CH2 27.7, CH2 
23 73.5, CH2 73.4, CH2 73.5, CH2 73.4, CH2 73.7, CH2 73.4, CH2 75.3, CH2 
24 13.2, CH3 13.2, CH3 13.3, CH3 13.2, CH3 13.1, CH3 13.2, CH3 13.6, CH3 
25 16.4, CH3 16.4, CH3 16.5, CH3 16.5, CH3 16.5, CH3 16.5, CH3 16.6, CH3 
26 17.2, CH3 17.2, CH3 17.3, CH3 17.4, CH3 17.1, CH3 17.4, CH3 17.5, CH3 
27 28.2, CH3 28.3, CH3 28.2, CH3 28.3, CH3 28.2, CH3 28.3, CH3 27.6, CH3 
28 68.7, CH2 68.5, CH2 68.7, CH2 78.3, CH2 78.3, CH2 78.4, CH2 78.3, CH2 
29 30.4, CH3 30.4, CH3 30.5, CH3 33.8, CH3 33.7, CH3 33.8, CH3 33.7, CH3 
30 18.3, CH3 18.4, CH3 18.4, CH3 24.5, CH3 24.6, CH3 24.5, CH3 24.4, CH3 
A-Glc-1' 104.1, CH 104.1, CH 104.2, CH 104.1, CH 104.0, CH 104.1, CH 105.3, CH 
A-Glc-2' 75.4, CH 75.4, CH 75.7, CH 75.7, CH 75.6, CH 75.5, CH 75.4, CH 
A-Glc-3' 76.2, CH 76.1, CH 76.4, CH 76.4, CH 76.3, CH 76.2, CH 78.7, CH 
A-Glc-4' 71.8, CH 71.8, CH 72.2, CH 72.2, CH 72.1, CH 71.8 CH 71.9, CH 
A-Glc-5' 77.5, CH 77.4, CH 79.1, CH 79.1, CH 79.0, CH 77.5, CH 77.4, CH 
A-Glc-6' 69.9, CH2 69.8, CH2 62.9, CH2 62.9, CH2 62.9, CH2 70.3, CH2 70.5, CH2 
A-Acyl-1 126.8, C 125.5, C 126.8, C 126.8, C 126.8, C 126.8, C  
A-Acyl-2 124.1, CH 106.9, CH 124.2, CH 124.1, CH 124.1, CH 124.1, CH  
A-Acyl-3 149.3, C 149.6, C 149.3, C 149.3, C 149.2, C 149.2, C  
A-Acyl-4 151.4, C 141.0, C 151.5, C 151.4, C 151.4, C 151.4, C  
A-Acyl-5 117.2, CH 149.6, C 117.2, CH 117.1, CH 117.1, CH 117.1, CH  
A-Acyl-6 111.6, CH 106.9, CH 111.6, CH 111.5, CH 111.6, CH 111.6, CH  
A-Acyl-7 146.2, CH 146.4, CH 146.2, CH 146.2, CH 146.4, CH 146.2, CH  
A-Acyl-8 116.0, CH 116.3, CH 116.0, CH 116.0, CH 115.9, CH 116.0, CH  






56.3, CH3 56.3, CH3 56.3, CH3 56.3, CH3  
A–glc-1'' 105.8, CH 105.8, CH    105.9, CH 105.7, CH 
A–glc-2'' 75.3, CH 75.3, CH    75.3, CH 75.4, CH 
A–glc-3'' 78.7, CH 78.7, CH    78.7, CH 78.5, CH 
A–glc-4'' 71.8, CH 71.8, CH    71.8, CH 71.9, CH 
A–glc-5'' 77.4, CH 77.3, CH    77.4, CH 77.4, CH 
A–glc-6'' 70.5, CH2 70.2, CH2    69.8, CH2 70.5, CH2 
A–xyl-1''' 106.5, CH 106.4, CH    106.5, CH 106.3, CH 
A–xyl-2''' 75.3, CH 75.2, CH    75.3, CH 75.2, CH 
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Position 













GC, , type 
150 Mhz 
A–xyl-3''' 78.5, CH 78.5, CH    78.5, CH 78.3, CH 
A–xyl-4''' 71.5, CH 71.5, CH    71.7, CH 71.4, CH 
A–xyl-5''' 67.5, CH 67.4, CH    67.5, CH 67.4, CH 
B-Glc-I-1'    106.2, CH 103.4, CH 106.2, CH 106.2, CH 
B-Glc-I-2'    75.4, CH 75.6, CH 75.3, CH 75.3, CH 
B-Glc-I-3'    78.3, CH 76.5, CH 78.4, CH 78.5, CH 
B-Glc-I-4'    72.0, CH 72.2, CH 72.0, CH 71.9, CH 
B-Glc-I-5'    79.1, CH 78.9, CH 79.1, CH 79.0, CH 
B-Glc-I-6'    63.1, CH2 62.9, CH2 63.1, CH2 63.1, CH2 
 
#Acyl-2: 1F-2 (126.8, C); 1F-2 (124.2, CH); 3F-2 (149.3, C); 4F-2 (151.5, C); 5F-2 (117.1, CH); 6F-2 (111.6, CH); 7F-2 (146.4, CH); 
8F-2 (115.7, CH); 9F-2 (167.0, C); O-CH3 (56.3, C). 






Table 8. 1H NMR spectroscopic data for compounds Gymlatinosides GL12-18 (in Pyridine-d5) 
Position 
12 13 14 15 16# 17 18 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
600 Mhz 
GH (J in Hz) 
600 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
500 Mhz 


























3 4.08, overlap 4.08, overlap 4.12, dd (11.5, 4.5) 4.07, overlap 4.02, overlap 4.05, overlap 4.18, overlap 
5 1.56, overlap 1.54, overlap 1.56, overlap 1.56, overlap 1.56, overlap 1.56, overlap 1.56, overlap 
6 1.36, overlap 1.39, overlap 1.36, overlap 1.36, overlap 1.36, overlap 1.36, overlap 1.36, overlap 













9 1.79, overlap 1.82, overlap 1.79, overlap 1.79, overlap 1.79, overlap 1.79, overlap 1.79, overlap 
11 1.76, overlap 1.77, overlap 1.76, overlap 1.76, overlap 1.76, overlap 1.76, overlap 1.76, overlap 
12 5.28, br s 5.28, br s 5.28, br s 5.17, br s 5.19, br s 5.17, br s 5.21, br s 
15 2.27, t (11.5)  2.24, t (11.5)  2.27, t (11.5)  2.25, t (11.5)  2.28, t (11.5)  2.22, t (11.5)  2.30, t (11.5)  
16 4.81, overlap  4.81, overlap  4.77, dd (11.5, 5.0) 4.58, overlap 4.52, overlap 4.60, overlap 4.52, overlap 
18 2.61, dd (13.5, 4.5) 2.63, dd (13.5, 4.5) 2.62, dd (13.5, 4.5) 2.83, dd (13.5, 4.5) 2.61, dd (13.5, 4.5) 2.62, dd (13.5, 4.5) 2.61, dd (13.5, 4.5) 













21 4.19, overlap  4.19, overlap  4.19, dd (13.0, 4.5)  4.19, overlap 4.19, overlap 4.19, overlap 4.19, overlap 
22 3.30, dd (13.0, 4.5) 2.11, overlap 
3.30, dd (13.0, 4.5) 
2.13, overlap 
3.23, dd (13.0, 4.5) 
2.04, t (13.0) 
3.30, dd (13.0, 4.5) 
2.11, overlap 
3.23, dd (13.0, 4.5) 
2.04, t (13.0) 
3.30, dd (13.0, 4.5) 
2.13, overlap 
3.30, dd (13.0, 4.5) 
2.13, overlap 
23 4.03, overlap 3.87, overlap 
4.03, overlap 
3.95, overlap 
4.03, d (10.5) 









24 0.84, s 0.84, s 0.86, s 0.85, s 0.87, s 0.84, s 1.02, s 
25 0.87, s 0.87, s 0.89, s 0.88, s 0.88, s 0.87, s 0.94, s 
26 1.01, s 1.01, s 1.02, s 0.97, s 1.00, s 0.98, s 0.98, s 
27 1.68, s 1.68, s 1.65, s 1.61, s 1.53, s 1.64, s 1.22, s 
28 4.42, d (10.5) 3.76, d (10.5) 
4.42, d (10.5) 
3.76, d (10.5) 
4.42, d (10.5) 









29 1.31, s 1.28, s 1.31, s 0.95, s 0.88, s 0.95, s 0.89, s 
30 1.28, s 1.31, s 1.28, s 0.93, s 0.96, s 0.93, s 0.93, s 
A-Glc-1' 5.05, d (8.5) 5.05, d (8.5) 5.05, d (8.5) 5.12, d (8.5) 5.09, d (8.5) 5.04, d (8.5) 4.81, d (7.5) 
A-Glc-2' 5.68, t (8.5) 5.68, t (8.5) 5.71, t (8.5) 5.77, t (8.5) 5.74, t (8.6) 5.66, t (8.5) 4.03, overlap 
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Position 
12 13 14 15 16# 17 18 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
600 Mhz 
GH (J in Hz) 
600 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
500 Mhz 
GH (J in Hz) 
500 Mhz 
A-Glc-3' 4.27, overlap 4.29, overlap 4.29, overlap 4.27, overlap 4.29, overlap 4.27, overlap 4.15, overlap 
A-Glc-4' 4.22, overlap 4.21, overlap 4.21, overlap 4.22, overlap 4.21, overlap 4.22, overlap 4.23, overlap 
A-Glc-5' 4.07, overlap 4.07, overlap 4.07, overlap 4.07, overlap 4.07, overlap 4.07, overlap 4.00, overlap 














A-Acyl-2 7.20, overlap 6.98, overlap 7.20, overlap 7.20, overlap 7.20, overlap 7.19, overlap  
A- Acyl -5 7.19, overlap  7.19, overlap 7.19, overlap 7.19, overlap 7.18, overlap  
A- Acyl -6 7.21, overlap 6.98, overlap 7.21, overlap 7.21, overlap 7.20, overlap 7.19, overlap  
A- Acyl -7 7.99, d (16.0) 7.99, d (16.0) 8.01, d (16.0) 7.98, d (16.0) 7.99, d (16.0) 7.97, d (16.0)  
A- Acyl -8 6.62, d (16.0)  6.67, d (16.0)  6.64, d (16.0)  6.64, d (16.0)  6.70, d (16.0)  6.60, d (16.0)   
A- Acyl -
OCH3 
3.85, s 3.89, s 3.84, s 3.82, s 3.85, s 3.82, s  
A–glc-1'' 4.97, d (7.5) 4.97, d (7.5)    5.00, d (7.5) 4.94, d (7.5) 
A–glc-2'' 4.05, overlap 4.03, overlap    4.05, overlap 4.03, overlap 
A–glc-3'' 4.15, overlap 4.15, overlap    4.15, overlap 4.15, overlap 
A–glc-4'' 4.24, overlap 4.23, overlap    4.24, overlap 4.23, overlap 
A–glc-5'' 4.00, overlap 4.00, overlap    4.00, overlap 4.00, overlap 








A–xyl-1''' 5.00, d (7.5) 5.00, d (7.5)    4.98, d (7.5) 5.03, d (7.5) 
A–xyl-2''' 4.04, overlap 4.02, overlap    4.04, overlap 4.02, overlap 
A–xyl-3''' 4.15, overlap 4.15, overlap    4.15, overlap 4.15, overlap 
A–xyl-4''' 4.25, overlap 4.23, overlap    4.25, overlap 4.23, overlap 
A–xyl-5''' 4.35, overlap 
3.68, t (10.5) 
4.35, overlap 
3.67, t (10.5) 
   4.32, overlap 
3.66, t (10.5) 
4.35, overlap 
3.67, t (10.5) 
B-Glc-I-1'    4.96, d (7.5) 4.93, d (7.5) 4.97, d (7.5) 4.94, d (7.5) 
B-Glc-I-2'    4.05, overlap 5.71, t (8.6) 4.05, overlap 4.05, overlap 
B-Glc-I-3'    4.15, overlap 4.15, overlap 4.15, overlap 4.15, overlap 
B-Glc-I-4'    4.24, overlap 4.24, overlap 4.24, overlap 4.24, overlap 
B-Glc-I-5'    4.00, overlap 4.00, overlap 4.00, overlap 4.00, overlap 
B-Glc-I-6'    4.52, overlap 
4.43, dd (12.0, 5.0) 
4.59, overlap 
4.44, dd (12.0, 5.0) 
4.59, overlap 
4.44, dd (12.0, 5.0) 
4.56, overlap 
4.43, dd (12.0, 5.0) 




3.2.8. Gymlatinoside GL8 (12) 
Gymlatinoside GL8 (12) obtained as a white amorphous powder, with [D]25D  
+35.4 (c 0.2, MeOH), was found to possess a molecular formula of C57H86O22 based 
on the high-resolution electrospray ionization mass spectrometry (HRESIMS) ion 
peak at m/z 1121.5549 [M − H]− (calcd for C57H85O22,  1121.5532). The broad IR 
peak at 3364 cm–1 indicated the presence of hydroxy groups. The 1H NMR spectrum 
displayed six methyl singlets at δH 1.70, 1.30, 1.28, 1.01, 0.86 and 0.84 (each 3H) 
one olefinic broad singlet at δH 5.28, which were characteristics of a oleanane 
skeleton.  Three anomeric proton signals at δH 5.07, d (7.5); 4.97, d (7.5) and 5.01, 
d (7.5) suggested the presences of three sugars moieties. Also, three other signals of 
overlapped olefinic protons at δH 7.19, 7.20, 7.21 revealed by HSQC correlations, 
together with one methoxy singlet at δH 3,89 and two trans olefinic doublets at δH 
7.99 and 6.66  (both have J =16.0 Hz) suggested the existence of a feruloyl 
substituent. The 13C NMR spectrum showed signals for 57 carbons, including 
resonances of 1 carboxylic group at δC 167.0;  10 aromatic or olefinic carbons; 3 
anomeric and 19 oxygenated carbons ranging from δC 67.5 to 78.7, and others are 
methine, methylene and methyl signals. Inspection of COSY, HSQC and HMBC 
spectra determined a planar structure of oleanane-type triterpene possessing 5 
hydroxy groups substituted at C-3,16, 21, 23 and 28 for the main aglycone of 12 
(Figure 34). Comparing chemical shifts of 12 with gymnemoside-d revealed that 
they shared an aglycone, gymnestrogenin and a glycosyl chain, -glc6-glc6-xyl at C-
23 in common (M. Yoshikawa et al., 1997). The additional feruloyl at C-2' was 
confirmed by the HMBC correlation from H-2' [δH 5.69, t (8.6)] to C-9F (167.0). The 
relative configuration of the aglycone Gymnestrogenin was analysed by NOESY 
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experiments which illustrated in Figure 34. Consequently, the structure of 12 was 
identified as Gymnestrogenin 23-O-β-D-xylopyranosyl-(1→6)-β-D-glucopyranosyl-
(1→6)-(2′-O-trans-feruloyl)-β-D-glucopyranoside. 
 




3.2.9. Gymlatinoside GL9 (13) 
 Gymlatinoside GL9 (13) obtained as a white amorphous powder, with [D]25D  
+24.3 (c 0.2, MeOH), was found to possess a molecular formula of C58H88O23 based 
on the high-resolution electrospray ionization mass spectrometry (HRESIMS) ion 
peak at m/z 1151.5658 [M − H]− (calcd for C58H87O23,  1151.5638). Comparison of 
the molecular formula with compound 12 suggested that 13 has one more methoxy 
(OCH3) unit. The chemical shifts in 1D-NMR and correlations in the  2D-NMR 
spectra of 12 and 13 were mostly comparable; the exception was the resonances of 
the acyl unit connected to C-2ʹ (Tables 7, 8). The existences of two methoxy groups 
attached to two symmetry-equivalent carbons of the acyl portion were suggested by 
the proton singlet signal of 6 protons at δH 3.89.  The 1H and 13C chemical shifts 
revealed the structure of a sinapyol moiety for the acyl substitution by comparing 
with literature (Abe et al., 1995) and analysis of HMBC correlations (Figure 35). Its 
trans configuration was identified by the coupling constant J =16.0 Hz of two 
adjacent olefinic doublet protons at δH 7.99 and δH 6.66. The position of this 
substituent was determined from the HMBC cross peak correlations from H-2ʹ [δH 
5.68, d (8.5)] to C-9S (δC 166.9) and C1' (δC 104.1). Accordingly, compound 13 was 




Figure 35. Gymlatinoside GL9 
3.2.10. Gymlatinoside GL10 (14) 
Gymlatinoside GL10 (14) was obtained as a white amorphous powder, with 
[D]25D  +10.1 (c 0.2, MeOH). Its HRESIMS showed a pseudo molecular ion peak at 
m/z 827.4585 [M − H]− (calcd for C46H67O13, 827.4582), indicating a molecular 
formula of C46H68O13. The 1H, 13C, HSQC and HMBC NMR spectroscopic data of 
14 could be discriminated with 12 by the lack of resonances of the xylopyranosyl 
and the glucopyranosyl units attached to C-6ʹ and the shielded chemical shift of this 
carbon C-6ʹ (δC 62.9) (Tables 7, 8). HMBC correlations H-2ʹ [δH 5.71, d (8.5)] to C-
9F (δC 167.1) and C1' (δC 104.2) confirmed the structure of Gymlatinoside GL10 as 






Figure 36. Gymlatinoside GL10 
3.2.11. Gymlatinoside GL11 (15) 
Gymlatinoside GL11 (15) was obtained as a white and amorphous powder with 
[D]25D  +26.3 (c 0.2, MeOH). It gave a molecular formula of C52H78O17 as determined 
according to the negative ion peak [M − H]− at m/z 973.5167 (calcd for C52H77O17, 
973.5161) in the HRESIMS corresponding to 14 IDHs. The 1H, 13C NMR (Tables 
7, 8), and HSQC spectroscopic data of 15 displayed 6 methyl singlet resonances at 
δH 0.85, 0.88, 0.97, 1.61, 0.95, 0.93 which corresponding to the carbon resonances 
at δC 13.2, 16.5, 17.4, 28.3, 33.8 and 24.5, respectively. Furthermore, signals of an 
olefinic proton at δH 5.17 (1H, br s) and two olefinic carbon signals at δC 144.2 and 
123.4 were observed. These resonances revealed the aglycone structure to be 23-
hydroxy longispinogenin by referring to NMR data of  Gymnemoside-e (K. 
Yoshikawa et al., 1991). The presence of the additional β-glucopyranosyl unit was 
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evident by the resonances of 6 oxygenated carbons at C-1ʹʹ (δC 106.2), C-2ʹʹ (δC  75.4), 
C-3ʹʹ (δC 78.3), C-4ʹʹ (δC 72.0), C-5ʹʹ (δC 79.1), and C-6ʹʹ (δC 63.1). When compared 
with 14, a downfield shift of C-28 (δC 78.3, +9.6 ppm) and a HMBC correlation 
between anomeric proton H-1ʹʹ (δH 4.96) and C-28 (Figure 37) were observed, which 
supported the attachment of the second glucopyranosyl unit to C-28. Accordingly, 
compound 15 was determined to be 28-O-β-D-glucopyranosyl 23-hydroxy-
longispinogenin 23-O-(2′-O-trans-feruoyl)-β-D-glucopyranoside.  
 
Figure 37. Gymlatinoside GL11 
3.2.12. Gymlatinoside GL12 (16) 
Gymlatinoside GL12 (16) was obtained as an amorphous powder with [D]25D  
+15.2 (c 0.2, MeOH). Its molecular formula was determined to be C62H86O20 based 
on its HRESIMS peak at m/z 1149.5629 [M – H]- (calcd for C62H85O20, 1149.5634). 
The HRMS positive mode showed an extra neutral loss of one feruloyl (176 Da) 




were comparable with those of 15, except for the addition of resonances of one 
feruloyl unit which attached to C-2''. Further HMBC analysis confirmed the structure 
of compound 16 as shown in Figure 38. Accordingly, compound 16 was elucidated 
to be 28-O-(2′-O-trans-feruoyl)-β-D-glucopyranosyl 23-hydroxy-longispinogenin 
23-O-(2′-O-feruoyl)-β-D-glucopyranoside. 
 
Figure 38. Gymlatinoside GL12 
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3.2.13. Gymlatinoside GL13 (17) 
Gymlatinoside GL13 (17) was isolated as an amorphous powder with [D]25D  
+25.9 (c 0.2, MeOH). The HRESIMS of this compound revealed an ion peak at m/z 
1267.6147 [M − H]− (calcd for C63H95O26, 1267.6147). It suggested a molecular 
formula C63H96O26 and indicated the presence of 16 IHDs. NMR data of compound 
17 showed partial similarities compared with compounds 13 and 15 (Tables 7, 8). 
The first glycosyl portion at C-23, which was identical to that part of compound 13, 
comprised of a feruloyl moiety attached to C-2' of a sugar chain of glc6-glc6-xyl. The 
main aglycone and the second sugar at C-28 were identified to be 23-hydroxy 
longispinogenin and glucose, respectively by comparing NMR data of this portion 
with those of compound 15 (Figure 39). Finally, the structure of 17 was identified 
as 28-O-β-D-glucopyranosyl 23-hydroxy-longispinogenin 23-O-β-D-xylopyranosyl 
(1→6)-β-D-glucopyranosyl-(1→6)-(2′-O-trans-feruloyl)-β-D-glucopyranoside.  
 




3.2.14. Gymlatinoside GL14 (18) 
Gymlatinoside GL14 (18) was purified as an amorphous powder with [D]25D  
+12.5 (c 0.2, MeOH). Its molecular formula was identified as C53H88O23 based on 
the negative ion peak at m/z 1091.5645 [M − H]− (calcd for C53H87O23, 1091.5638). 
The 1H and 13C NMR spectroscopic data of 18 (Tables 7, 8) showed the same 
structrure with 17 with the disappearance of the feruloyl moiety. Also, no maximum 
absorption at 325 on UV spectrum and no mass fragment 176 Da can be observed 
on possitive mass fragmentation. Further HMBC analysis confirmed the structure of 
compound 18 as shown in Figure 40. Hence, compound 18 was elucidated as 28-O-
β-D-glucopyranosyl 23-hydroxy-longispinogenin 23-O-β-D-xylopyranosyl-(1→6)-
β-D-glucopyranosyl-(1→6)-β-D-glucopyranoside.   
 
Figure 40. Gymlatinoside GL14 
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3.3. PTP1B inhibitory activities of isolated compounds  
All isolates (1–20) were evaluated for their PTP1b inhibitory effects and 
compound 2, 3 showed considerable inhibitory activities with IC50 values of 28.66 
± 2.57 mM and 19.83 ± 0.40 mM, respectively. Based on the inhibitory activities, 
compounds 2 and 3 were selected for further investigation of their PTP1B enzyme 
kinetics. Consequently, the compound 2, 3 were found to be competitive PTP1B 
inhibitors as shown in Lineweaver-Burk plots (Figure 41). 
 
Figure 41. Lineweaver-Burk plots for determination of the type of PTP1B 
inhibition of compounds 2 and 3 using pNPP assay.  
The conditions were as follows: 4 mM substrate, 0.05–0.1 μg/mL of PTP1B enzyme, 
50 mM Tris (pH 7.5), at room temperature. In the presence of different 
concentrations of compounds for lines from bottom to top: A. Compound 2 (20, 30, 
and 40 μM); B. Compound 3 (10, 20, 30 μM). The data were evaluated in three 
replicates at each substrate concentration. 
3.4. Building block assignments for oleanane glycosides in G.latifolium  
3.4.1. 3-β-hydroxy oleanane glycosides 
The isolated compounds suggested 3-β-hydroxy oleanane glycosides from 




including a aglycone (gymnemagenin, marsglobiferin, longisopinogenin), a glycosyl 
chain at C-3 (β-D-arabino-2-hexulopyranosyl-(1→3)-β-D-glucuronopyranosyl, 
glucuronic acid or glucose) and 1⎯3 acyl moieties (acyl, tigloyl, Mba, benzoyl) 
posisted at C-16,21, 22, 28. A list of predicted structures was proposed using the 
combination of these main building block components following its construction 
rules. As a result, 75 peaks matched with the masses in the predicted list were 
extracted successfully from the total extract of G. latifolium or its microfractions 
with mass deviations of less than 5 ppm.  
The extracted peaks were then analyzed in the MSn TOF-positive mode by 
using the multiple key ion analysis (mKIA) and mass fragmentation analysis (MFA) 
techniques (Figure 42). The sturdy polycyclic structures of various oleanane 
triterpenoids can be characterized by different sets of dehydrated key MSn ions 
during mass fragmentation. Therefore, the mKIA technique utilizing various sets of 
key positive MSn ions can be used to effectively discriminate different aglycones in 
G. latifolium. In this study, gymnemagenin and its glycosides showed a set of key 
ions at m/z 453, 435, 417, 399, marsglobiferin and its analogs exhibited ions at m/z 
473, 455, 437, 419 and longispinogenin display ions at m/z 441, 423, 405. On the 
other hand, the MFA technique was applied in qTOF-positive fragmentation mode 
to confirm the glycosyl and acyl moieties. Specifically, the  β-D-arabino-2-
hexulopyranosyl-(1→3)-β-D-glucuronopyranosyl (Ahg) portion was defined by a 
neutral loss of 336 Da, while the two sugars glucuronic acid and glucose were 
detected by the mass losses of 176 Da and 162 Da, respectively. The acyl moieties 
can be identified similarly by their neutral losses, such as acetyl (42 Da), tigloyl (82 
Da), 2(S)-methylbutyloyl (84 Da) and benzoyl (104 Da).  
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Figure 42. HRMS-based building block strategy to assign constituents in G. 
latifolium. 
Figure 42A, B illustrated the application of building block strategy to detect 
target peaks for the predicted deprotonated ion mass at m/z 967.4902 of the 




Gymenagenin+Ahg+Ac+Mba. The peak peaking resulted in the detection of  2 peaks 
16 and 17 from the total extract, and 4 peaks 15⎯18 in the microfraction 10. The 
increase of the number of detected peaks and the better mass resolution were two 
major advantages of the microfractionation applied in this strategy. Structure of peak 
20 (compound 1) was analyzed in detailed by using mKIA analysis (Figure 42C) 
and MFA analysis (Figure 42D). 3 other peaks were expected to be structural 
isomers of compound 1 with the variation of the two acyl moeties at positions 16, 
21, 22 and 28.  
Finally, 56 of the 76 extracted peaks were confirmed using the same 
approach. These peaks included 7 previously undescribed compounds which were 
isolated in this study, 15 peaks can be assigned to reported compounds in the 
literature, and 34 peaks can be predicted as previously undescribed compounds 
because no compound indexed in SciFinder can match both of their molecular 
formulas and mass fragmentation patterns (Table 9). 
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Table 9. Compound assignments for 3-β-hydroxy oleanane glycosides G. 
latifolium using the building block strategy 
Peak  Rt m/z (-) Cald. m/z (-) 
Diff 







1 7.283 505.3527 505.3529 -0.4 C30H49O6 506.3605 G 22467-07-8 
2 5.17 841.4216 841.4216 -0.7 C42H66O17 842.4294 G+Ahg No report 
3 5.862 883.4313 883.4327 -1.6 C44H68O18 884.4391 G+Ahg+Ac No report 
4 5.994 883.4352 883.4327 2.8 C44H68O18 884.443 G+Ahg+Ac No report 
5 6.529 883.4337 883.4327 1.1 C44H68O18 884.4415 G+Ahg+Ac No report 
6 6.801 883.4327 883.4327 1.4 C44H68O18 884.4405 G+Ahg+Ac No report 
7 8.362 923.4655 923.464 1.6 C47H71O18 924.4733 G+Ahg+Tig 131653-20-8 
8 8.661 945.4488 945.4484 0.4 C49H70O18 946.4566 G+Ahg+Bz No report 
9 8.704 925.4807 925.4797 1.1 C47H74O18 926.4885 G+Ahg+Mba  131653-19-5 
10 8.266 925.4448 925.4433 1.6 C46H70O19 926.4526 G+Ahg+Ac+Ac No report 
11 9.204 965.4755 965.4746 0.9 C49H74O19 966.4833 G+Ahg+Ac+Tig No report 
12 9.31 965.4757 965.4746 1.1 C49H74O19 966.4835 G+Ahg+Ac+Tig No report 
13 9.695 965.4771 965.4746 2.6 C49H74O19 966.4849 G+Ahg+Ac+Tig No report 
14 10.028 965.4753 965.4746 0.7 C49H74O19 966.4831 G+Ahg+Ac+Tig Compd. 2 
15 9.528 987.46 987.459 1 C51H72O19 988.4678 G+Ahg+Ac+Bz No report 
16 9.695 987.4575 987.459 -1.5 C51H72O19 988.4653 G+Ahg+Ac+Bz No report 
17 10.23 987.4595 987.459 0.5 C51H72O19 988.4673 G+Ahg+Ac+Bz Compd. 3 
18 9.362 967.4921 967.4903 1.9 C49H76O19 968.4999 G+Ahg+Ac+Mba  No report 
19 9.765 967.4899 967.4903 -0.4 C49H76O19 968.4977 G+Ahg+Ac+Mba  No report 
20 10.362 967.4896 967.4903 -0.7 C49H76O19 968.4974 G+Ahg+Ac+Mba  Compd. 1 
21 10.827 967.4894 967.4903 -0.9 C49H76O19 968.4972 G+Ahg+Ac+Mba  No report 
22 8.792 967.4571 967.4539 3.3 C48H72O20 968.4649 G+Ahg+Ac+Ac+Ac No report 
23 10.625 1007.4833 1007.4852 -1.9 C51H76O20 1008.4911 G+Ahg+Ac+Ac+Tig Compd. 4 
24 10.818 1007.4844 1007.4852 1.4 C51H76O20 1008.4922 G+Ahg+Ac+Ac+Tig No report 
25 5.284 681.3831 681.385 -2.8 C36H58O12 682.3909 G+glcA 121686-42-8 
26 6.801 723.3965 723.3956 1.2 C38H60O13 724.4043 G+glcA+Ac 147934-05-2 
27 6.968 723.3975 723.3956 2.6 C38H60O13 724.4053 G+glcA+Ac No report 
28 8.792 763.4274 763.4269 0.7 C41H63O13 764.4352 G+glcA+tig 121903-96-6,  155023-62-4 
29 9.108 785.4127 785.4158 1.9 C43H62O13 786.4205 G+glcA+Bz 154977-77-2, 154977-76-1 
30 8.959 765.4434 765.4425 1.2 C41H65O13 766.4512 G+glcA+Mba 122074-65-1 
31 9.195 765.4443 765.4425 2.4 C41H65O13 766.4521 G+glcA+Mba 155023-61-3 
32 7.406 765.4057 765.4061 -0.5 C40H62O14 766.4135 G+glcA+Ac+Ac No report 
33 8.528 765.4079 765.4061 2.4 C40H62O14 766.4157 G+glcA+Ac+Ac No report 
34 9.625 805.4387 805.4374 1.6 C43H66O14 806.4465 G+glcA+Ac+Tig 175033-15-5 
35 9.801 805.4376 805.4374 0.2 C43H66O14 806.4454 G+glcA+Ac+Tig 122168-40-5 
36 10.406 805.4397 805.4374 2.9 C43H66O14 806.4475 G+glcA+Ac+Tig 174232-51-0 
37 9.862 827.4237 827.4218 2.3 C45H64O14 828.4315 G+glcA+Ac+Bz No report 
38 10.169 827.4219 827.4218 0.1 C45H64O14 828.4297 G+glcA+Ac+Bz 199618-65-0 
39 10.73 827.4203 827.4218 -1.8 C45H64O14 828.4281 G+glcA+Ac+Bz No report 
40 9.897 807.4528 807.4531 -0.4 C43H68O14 808.4606 G+glcA+Ac+Mba No report 
41 10.108 807.4529 807.4531 0.2 C43H68O14 808.4607 G+glcA+Ac+Mba 122144-48-3 
42 10.95 807.453 807.4531 -0.1 C43H68O14 808.4608 G+glcA+Ac+Mba No report 
43 8.296 807.4177 807.4167 1.2 C42H64O15 808.4255 G+glcA+Ac+Ac+Ac No report 
44 9.011 807.4182 807.4167 1.2 C42H64O15 808.426 G+glcA+Ac+Ac+Ac No report 
45 9.195 807.4167 807.4167 0 C42H64O15 808.4245 G+glcA+Ac+Ac+Ac No report 
46 11.000 847.4492 847.448 1.4 C45H68O15 848.457 G+glcA+Ac+Ac+tig Compd. 7 
47 11.081 869.4357 869.4323 3.9 C47H66O15 870.4435 G+glcA+Ac+Ac+Bz No report 
48 11.301 849.4658 849.4636 2.6 C45H70O15 850.4736 G+glcA+Ac+Ac+Mba No report 
49 9.537 489.3574 489.358 -1.2 C30H50O5 490.3652 M 147395-99-1 
50 6.143 665.3894 665.3901 -1.1 C36H58O11 666.3972 M+glcA No report 
51 7.415 707.4018 707.4007 1.6 C38H60O12 708.4096 M+glcA+Ac No report 
52 7.529 707.3998 707.4007 -1.3 C38H60O12 708.4076 M+glcA+Ac No report 
53 8.301 749.4099 749.4112 -1.7 C40H62O13 750.4177 M+glcA+Ac+Ac No report 
54 9.072 749.4119 749.4112 0.9 C40H62O13 750.4197 M+glcA+Ac+Ac No report 
55 9.862 791.4228 791.4218 1.3 C42H64O14 792.4306 M+glcA+Ac+Ac+Ac Compd. 6 
56 9.318 781.4746 781.4738 1 C42H70O13 762.4824 L+glc+glc Compd. 5 
 
All of the detected peaks were 56 peaks of 3𝛽-hydroxy oleanane 
triterpenoids were quickly identified and mapped on the plant metabolite fingerprint. 




extract is typically noisy and limited in the number of metabolites (only 37/56 peaks 
can be detected in the total extract of G. latifolium). All the 56 peaks of 3𝛽-hydroxy 
oleanane triterpenoids were effectively identified and mapped on a multilayer plant 
metabolite fingerprint (Figure 43-B).  
 
 
Figure 43. Metabolite profiling for 3𝛽-hydroxy oleanane triterpenoids in G. 
latifolium 
3.4.2. 23-hydroxy oleanane glycosides 
 Similar approach was applied for 23-hydroxy oleanane glycosides led to the 
assignment of 22 peaks as shown in Table 10 and 20 peaks were expected to be new 
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compounds. Among them, the structure of 9 compounds (7 new and 2 known) were 
isolated and confirmed in this study.   
Table 10. Compound assignments for 23-hydroxy oleanane glycosides in G. 
latifolium using the building block strategy 
Peak Compd assignment Rt m/z (-) Cald m/z (-) 
Diff 
(ppm) RMD Formula Mass 
1 GP+2×glc+xyl 6.231 991.5110 991.5114 -0.4 515.4 C47H78O19 946.5133 
2 GP+3×glc+xyl 5.362 1107.5583 1107.5587 -0.4 504.1 C53H88O24 1108.5661 
3 GP+glc+fer 7.494 827.4602 827.4582 2.4 556.2 C46H68O13 828.4680 
4 GP+glc+fer 8.362 827.4585 827.4582 0.4 554.1 C46H68O13 828.4663 
5 GP+2×glc+fer 6.029 989.5095 989.5110 -1.5 514.9 C52H78O18 990.5173 
6 GP+2×glc+fer 6.862 989.5118 989.5110 0.8 517.2 C52H78O18 990.5196 
7 GP+2×glc+fer 7.757 989.5129 989.5110 1.9 518.3 C52H78O18 990.5207 
8 GP+2×glc+xyl+fer 7.512 1121.5549 1121.5532 1.5 494.8 C57H86O22 1122.5627 
9 GP+2×glc+xyl+syn 6.485 1151.5658 1151.5638 1.7 491.3 C58H88O23 1152.5736 
10 GT+3×glc 7.073 959.5219 959.5216 0.3 543.9 C48H80O19 960.5297 
11 GT+2×glc+xyl 8.450 975.5170 975.5165 0.5 530.0 C47H78O18 930.5193 
12 GT+3×glc+xyl 6.862 1091.5645 1091.5638 0.6 517.1 C53H88O23 1092.5723 
13 GT+4×glc+xyl 5.661 1253.6143 1253.6166 -1.8 490.0 C59H98O28 1254.6221 
14 GT+glc+fer 10.309 811.4618 811.4633 -1.8 569.1 C46H68O12 812.4696 
15 GT+glc+fer 11.248 811.4628 811.4633 -0.6 570.3 C46H68O12 812.4706 
16 GT+2×glc+fer 7.503 973.5175 973.5161 1.4 531.6 C52H78O17 974.5253 
17 GT+2×glc+fer 8.266 973.5176 973.5161 1.5 531.7 C52H78O17 974.5254 
18 GT+2×glc+fer 8.528 973.5167 973.5161 0.6 530.8 C52H78O17 974.5245 
19 GT+2×glc+xyl+fer 9.695 1105.5579 1105.5583 -0.4 504.6 C57H86O21 1106.5657 
20 GT+3×glc+xyl+fer 7.862 1267.6147 1267.6147 -1.8 484.9 C63H96O26 1268.6225 
21 GT+2×glc+2×fer 9.503 1149.5629 1149.5634 -0.4 489.7 C62H86O20 1150.5707 







To the best of our knowledge, this is the first report on chemical composition 
and bioactivities of Gymnema latifolium Wall. ex Wight.  Consequently, the 
authentication using conventional morphological technique together with DNA 
sequencing using the universally accepted sequence ITS1-5.8S-ITS2 will help the 
use of this new plant material correctly in the future studies. 20 oleanane analogs 
isolated from G. latifolium highlighted the chemical similarities of species in the 
same genus. Also, all the known compounds (including 6 isolated and 18 assigned 
structures) found in this study were reported from the genus Gymnema. The building 
block strategy using UPLC-MSn qTOP also applied to identify quickly 78 structures, 
including 14 new compounds isolated in this study and 40 other oleanane glycosides 
which can be assigned as previously undescribed structures. Among them, the total 
extract of G. latifolium and compounds Gymlatinosides GL2 and GL3 showed 
considerable PTP1B inhibitory effect and can be study further for their antidiabetic 
activity.
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Part 3:  12, 23-Dione dammarane triterpenoids from 
Gynostemma longipes and their muscle cell proliferation 
activities via activation of the AMPK pathway. 
1. Introduction 
One of the most distinctive effects of aging is the involuntary loss of muscle 
mass, strength and function, which is termed sarcopenia (Charlier et al., 2016). 
Skeletal muscle decreases approximately 3-8% per decade after 30 years of age, and 
muscle loss rapidly increases by about 25-30% after 60 years of age (English and 
Paddon-Jones, 2010). This loss of muscle mass, strength and function is the key 
cause of many diseases in elderly people, and the increased risk of injury and falls 
due to sarcopenia can also lead to continuous functional dependence and disability. 
The decreased muscle mass is also associated with a continuous increase in fat mass 
and consequently a change in body composition, and this in turn is associated with a 
higher incidence of insulin resistance in the elderly people (Jura and Kozak, 2016; 
Kalyani et al., 2014). Therefore, an increase of muscle mass in the elderly population 
is a promising approach to alleviate many of the symptoms of geriatric diseases (Dutt 
et al., 2015).  
Recent studies suggested that muscle loss can be prevented by exercise in both 
young and older people (Denison et al., 2015). Conversely, increased physical 
inactivity and obesity due to a sedentary lifestyle are associated with attenuated 
muscle mass and reduced AMP-activated protein kinase (AMPK) activity (Fu et al., 
2016; 2015). AMPK plays an important role in the regulation of cellular energy 
homeostasis, and the activation of AMPK promotes glucose uptake, fatty acid 
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oxidation, mitochondrial biogenesis and insulin sensitivity. In eukaryotes, there are 
three subunits of the AMPK, including the catalytic α-subunit (α1 and α2), regulatory 
E-subunit (E1 and E2) and J-subunit (J1, J2 and J3) (Ruderman et al., 2013) (Hardie 
et al., 2012). The regenerative process in skeletal muscle tissue generally involves a 
coordinated sequence of the activation of satellite cells, which  proliferate to produce 
a population of myogenic progenitors  (termed myoblasts) (Fu et al., 2015) (Asakura 
et al., 2002; Chen et al., 2007). Especially, the AMPKα1 isoform has an important 
role in enhancing Warburg-like glycolysis through non-canonical sonic hedgehog 
(Shh) signaling in myogenic cells during muscle regeneration. AMPKα1 knock-out 
in satellite cells reduces their activation and also inhibit the proliferation and 
differentiation of myogenic progenitor cells (Fu et al., 2015). Taken together, the 
activation of AMPK (especially AMPKα1) is a key mediator linking obesity and 
impaired muscle regeneration, providing an effective drug target to facilitate muscle 
regeneration in obese and elderly populations (Fu et al., 2016; 2015; Ruderman et 
al., 2013).  
Our ethnopharmacological investigation of medicinal plants with AMPK 
activation activity resulted in the selection of Gynostemma longipes, commonly 
called “That diep dom”, a Vietnamese traditional herb used widely by the local 
community for tonic, treatment of diabetes and health strengthening. A fraction from 
this plant was then found to show potential activity in accelerating the muscle 
proliferation in the myoblast C2C12 cell model. The main ingredients of G. longipes 
are known as dammarane triterpenes (Anh et al., 2015; Guo et al., 1997) similar to 
other species of Gynostemma genus (C. Lee et al., 2015; Nguyen et al., 2011). 
Dammarane triterpenes have been also reported to play a significant role in the 
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development of natural drugs for the treatment of different metabolic diseases such 
as diabetes mellitus, metabolic syndrome, aging and neurodegenerative diseases 
(Cao et al., 2015). In this study, bioassay-guided fractionation and isolation of G. 
longipes were performed, and resulted in the purification of nine 12,23-dione 
dammarane triterpenes (1–9), including 6 new compounds longipenosides A1-A6, 
longipengenol, 3-dehydro longipengenol and a known compound gypentonoside A. 
All isolates were evaluated for their enhancement effects on muscle proliferation 
through activation of the AMPK pathway using the C2C12 myoblast cell model. 
Purpose of research 
x Authenticate the scientific name of medicinal plant. 
x Identify the the chemical composition of Gynostemma longipes VK1. 
x Evaluate the muscle cell proliferation activities via activation of the AMPK 
pathway of the isolates. 
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2. Materials and methods 
2.1. Plant materials 
Plant material was collected in the Ha Giang province of Vietnam in March 
2016. The sample was identified as G. longipes C. Y. Wu based on the morphological 
characteristics by Prof. Tran Van On, Head of Department of Botany, Hanoi 
University of Pharmacy, Hanoi, Vietnam (Figure 44-A). A voucher specimen was 
deposited in the Medicinal Herbarium of Hanoi Univeristy of Pharmacy (HNIP) with 
the accession number HNIP.18500/16.  
  
Figure 44. Morphological and DNA authentication of G. longipes. 
(A) Authentication of G. longipes based on morphology (1) Whole plant with abaxial 
leaves, (2) adaxial leaf. (B) DNA analysis of G. longpipes with 4 DNA sequences 
ITS, rbcL, rpl20-rps12 and matK. All sequences of Gynostemma longipes were 
found to be at least 99.5% identical to sequences registered on Genebank. 
 118 
Total DNA was extracted from 200 mg of fresh plant leaves using the 
Dneasy Plant Mini Kit (QIAGEN, Germany) with some modifications. PCR 
amplification and sequencing were performed by Macrogen Inc. (Seoul, Korea) 
using 4 pairs of primers:  ITS1-F and ITS4-R for ITS1-5.8S-ITS2 region; matK8-F 
and matK710-R for partial maturase K gene, rbcL134-F and rbcL590-R for partial 
ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit (rbcL) gene,  rp143-
F and rp686-R for rpl20-rps12 intergenic spacer region. The sequences of all the 
primers were shown in Table 11. 
Table 11: Primers used to amplify and sequence 4 gene regions in G. longipes   
No. Gene sequence Primers sequences 
1 ITS1-5.8S-ITS2 
ITS1-F (5′-TCCGTAGGTGAACCTGCGG-3′) 
ITS4-R (5′- TCCTCCGCTTATTGATATGC-3′) 














All nucleotide sequence data were recorded in the GenBank database, 
National Center for Biotechnology Information (NCBI), with the accession numbers 
KX619478, KX619479, KX619480 and KX619481 respectively. DNA sequencing 
data were analyzed using the Geneious DNA sequencing analysis software (ver. 
8.1.8, Biomatters Ltd, New Zealand). DNA sequences were compared to published 
sequences available in Genbank using the Basic Local Alignment Search Tool 
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(BLAST). All analyzed sequences were matched with Gynostemma longipes at 
pairwise identity 99.9% (ITS1-5.8S-ITS2 region), 99.6% (rbcL gene), 99.8% (rpl20-
rps12 intergenic spacer region) and 99.9% (matK gene). This additional genetic 
information supported morphological authentication of Gynostemma longipes 
C.Y.Wu (Figure 44-B).  
2.2. Isolation and structure elucidation of compounds 
2.2.1. General experimental procedures 
 Optical rotations were measured in a JASCO P-2000 polarimeter (JASCO 
International Co. Ltd., Tokyo, Japan). IR data were recorded on a Nicolet 6700 FT-
IR spectrometer (Thermo Electron Corp., Waltham, MA, USA). NMR data were 
analyzed using an AVANCE 500 MHz spectrometer (Bruker, Germany) or a JNM-
ECA 600 MHz spectrometer (Jeol, Japan). HRESIMS values were analyzed using 
an Agilent Technologies 6130 Quadrupole LC/MS spectrometer equipped with an 
Agilent Technologies 1260 Infinity LC system (Agilent Technologies, Inc., Santa 
Clara, CA, USA) and an INNO C18 column (4.6 × 150 mm, 5 Pm particle size, 12 
nm, J.K.Shah & Company, Korea). Silica gel (particle size: 63200 Pm) and RP-C18 
(particle size: 40–63 Pm) were purchased from Merck (Darmstadt, Germany) and 
Sephadex LH-20 from Sigma-Aldrich (St. Louis, MO, USA) were used for column 
chromatography (CC). Silica gel 60 F254 and RP-18 F254 TLC plates were obtained 
from Merck (Darmstadt, Germany). A Gilson HPLC purification system, equipped 
with an Optima Pak C18 column (10 × 250 mm, 10 Pm particle size; RS Tech, Seoul, 
Korea), was used at a flow rate of 2 mL/min and UV detection at 205 and 254 nm.  
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2.2.2. Isolation scheme  
The aerial part of G. longipes (1.5 kg) was powdered, sonicated with 70% 
EtOH (3 × 3L), filtered and the solvent was evaporated in vacuo. The crude extract 
obtained (262 g) was suspended in water, absorbed onto Sephabeads SP70 resin and 
washed with water, 50% EtOH, 95% EtOH, 100% EtOH and acetone in a sequential 
elution process. The 95% EtOH fraction (75 g) was subjected to silica gel column 
chromatography (10 × 35 cm; 63–200 μm particle size) using a gradient of 
EtOAc:MeOH:H2O (from 20:1:0.1 to 4:1:0.1) to give 9 sub-fractions (C1-C9) based 
on the thin-layer chromatography profile. Compound 1 (50.5 g) was obtained by 
direct crystallization from sub-fraction C7.  
Sub-fraction 8 was chromatographed on C18- reversed phase silica gel (RP-
C18) column chromatography eluting with MeOH:H2O (from 1:1 to 1:0) and HPLC 
(Optima Pak C18, CH3CN:H2O (isocratic 2:3), flow rate 2 mL/min) to yield 
compounds 9 (16.0 mg) and 3 (21.3 mg).  
Sub-fraction C9 was chromatographed on RP-C18 column chromatography 
[CH3OH:H2O (from 1:1 to 1:0)] to yield 8 subfractions C9-1 to C9-8. Fraction C9.R3 
by preparative HPLC (Optima Pak C18, CH3CN:H2O (1:2), flow rate 2 mL/min) gave 
compounds 5 (10.5 mg) and 8 (18.5 mg). Fraction C9.R4 followed by HPLC (Optima 
Pak C18, CH3CN:H2O (2:3), flow rate 2ml/min) led to the isolation of compounds 2 
(12.5 mg), and 4 (20.4 mg).   
The 100% EtOH fraction was applied sequentially to Sephadex LH-20 using 
100% MeOH and HPLC (Optima Pak C18, CH3CN:H2O (7:3), flow rate 2 mL/min) 
to yield compounds  6 (22.2 mg) and 7 (17.1 mg). 
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Figure 45. Isolation scheme of compounds 1 – 9 from of G. longipes. 
2.2.3. Physical and chemical characteristics of isolated compounds 
Longipenoside A1 (1): white crystal; [α]25 D -32.0 (c 0.1, MeOH); UV (MeOH) 
λmax (log ε) 244 nm (3.8); IR (KBr) vmax 3404, 2973, 2938, 1697, 1616, 1073, 1055, 
1010 cm–1; 13C and 1H NMR data, Tables 12 and 13; HRESIMS m/z 925.5157 
[M−H]− (calcd for C48H77O17, 925.5166). 
Longipenoside A2 (2): white, amorphous powder; [α]25 D -37.5 (c 0.1, MeOH); 
UV (MeOH); λmax (log ε) 244 nm (3.8); IR (KBr) vmax 3400, 2970, 2938, 1698, 1617, 
1069, 1053, 1008  cm–1; 13C and 1H NMR data, Tables 12 and 13; HRESIMS m/z 
1087.5682 [M−H]− (calcd for C54H87O22, 1087.5694). 
Longipenoside A3 (3): white, amorphous powder; [α]25 D -35.2 (c 0.1, MeOH); 
UV (MeOH) λmax (log ε) 244 nm (3.8); IR (KBr) vmax 3402, 2971, 2938, 1702, 1616, 
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1060, 1054, 1010  cm–1; 13C and 1H NMR data, Tables 12 and 13; HRESIMS m/z 
967.5276 [M−H]− (calcd for C50H79O18, 967.5272). 
Longipenoside A4 (4): white, amorphous powder; [α]25 D -33.0 (c 0.1, MeOH); 
UV (MeOH) λmax (log ε) 244 nm (3.7); IR (KBr) vmax 3403, 2972, 2940, 1702, 1616, 
1060, 1054, 1010  cm–1; 13C and 1H NMR data, Tables 12 and 13; HRESIMS m/z 
779.4597 [M−H]− (calcd for C42H67O13, 779.4587). 
Longipengenol (6): white, amorphous powder; [α]25 D -33.0 (c 0.1, MeOH); UV 
(MeOH) λmax (log ε) 244 nm (3.9); IR (KBr) vmax 3403, 2972, 2940, 1702, 1616, 
1060, 1010 cm–1; 13C and 1H NMR data, Tables 12 and 13; HRESIMS m/z 471.3393 
[M−H]− (calcd for C30H47O4, 471.3480). 
 3-dehydro longipengenol (7): white, amorphous powder, [α]25 D -38.0 (c 0.1, 
MeOH); UV (MeOH) λmax (log ε) 244 nm (3.8); IR (KBr) vmax 3403, 2972, 2940, 
1702, 1616, 1060, 1054, 1010  cm–1; 13C and 1H NMR data, Tables 12 and 13; 
HRESIMS m/z 471.3452 [M+H]+ (calcd for C30H47O4, 471.3469). 
Longipenoside A5 (8):  white, amorphous powder, [α]25 D -32.5 (c 0.1, MeOH); 
IR (KBr) vmax 3403, 2972, 2940, 1702, 1616, 1060, 1054, 1010 cm–1; 13C and 1H 
NMR data, Tables 12 and 13; HRESIMS m/z 943.5374 [M-H]− (calcd for C48H79O18, 
943.5380). 
Longipenoside A6 (9): White amorphous powder, [α]25 D -33.0 (c 0.1, MeOH); 
UV (MeOH) λmax (log ε) 275nm (3.6); IR (KBr) vmax 3403, 2972, 2940, 1702, 1616, 
1060, 1054, 1010 cm–1; 13C and 1H NMR data, Tables 12 and 13; HRESIMS data at 
m/z 907.5066 [M−H]− (calcd for C48H75O16, 907.5061). 
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2.2.4. Acid hydrolysis 
20 mg of Longipenoside A1 (Compounds 1) was hydrolyzed with 1N HCl 
(MeOH 70%,  1 mL) at 90 °C  for 1 hours. The solution was neutralized by NaOH 
10%, dried and suspended in H2O and partitioned with EtOAc. The residual H2O 
layer was concentrated and dissolved in pyridine (1.0 mL) and 5.0 mg of L-cysteine 
methyl ester hydrochloride was added. The mixture was kept for 1 hours at 60 °C, 
and then 4.4 𝜇L of benzylisothiocyanate was added. This solution was filtered 
through a 0.2-µm Whatman hydrophilic membrane filter into an HPLC sample vials 
immediately before LC-MS analysis. Analysis was performed using an Agilent 1200 
HPLC system (Agilent Technologies, Palo Alto, CA, USA) with INNO C18 (4.6 × 
250 mm inner diameter, 5 μm particle size; Young Jin Bio Chrom Co., Ltd) at a 
column temperature of 30 °C. Chromatographic condition was carried out using a 
mobile phase of 27% CH3CN/H2O isocratic elution at a flow rate 0.6 mL/min in 60 
minutes. The sugar derivatives showed the retention time identical to the 
trimethylsilyl-L-cysteine derivatives of authentic D-glucose and L-rhamnopyranose, 
respectively. 
2.2.5. Quantitative analysis of Longipenoside A1 (compound 1) 
The plant extracts were prepared using different extraction solvents with water, 
30% EtOH, 50% EtOH, 70% EtOH, 100% EtOH and MeOH, respectively. After the 
extracts were dried in vacuo and lyophilized respectively, the extraction yield of each 
extract was calculated by the percentage of each extract in 1 g of raw material. For 
preparation of stock solutions, plant extracts were dissolved in extracted solvents at 
concentrations of 1 mg/mL. This solution was filtered through a 0.2-µm Whatman 
hydrophilic membrane filter into an HPLC sample vials immediately before LC-MS 
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analysis. Analysis and validation were performed using an Agilent 1200 HPLC 
system (Agilent Technologies, Palo Alto, CA, USA) with INNO C18 (4.6 × 250 mm 
inner diameter, 5 μm particle size; Young Jin Bio Chrom Co., Ltd) at a column 
temperature of 30°C. All chromatographic separations were carried out using a 
mobile phase of 10% to 100% CH3CN/H2O gradient elution at a flow rate 0.6 
mL/min. A calibration curve was drawn using the crystal form of compound 
Longipenoside A1 (1) at concentrations ranging from 0.025 mg/mL to 0.2 mg/mL. 
The regression equation is expressed as y = 11333x + 55.578 (correlation coefficient 
R2 = 0.9990), where y and x correspond to the peak area and concentration, 
respectively. The relative amount of compound in each of the extracts (mg/g of the 
extract) were calculated using this equation. 
2.3. Muscle regeneration activity of G.longipes extract and isolated compounds 
2.3.1. Cell proliferation assay 
C2C12 cell lines (mouse skeletal myoblasts) were maintained in growth 
medium consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) (Gibco, NY, USA), and cells were 
incubated at 37 °C and 5% CO2. The cell proliferation assay was carried out using 
the (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
(Sigma-Aldrich, St. Louis, MO, USA) or the WST-1 cell proliferation reagent 
(Roche, Mannheim, Germany). Briefly, C2C12 cells were seeded onto a 96-well 
plate at 4,000 cells/well and incubated for 8 hours. The cells were then treated with 
different concentrations of compounds or fraction dissolved in low-serum medium 
containing 5% FBS. After 24 hours or 48 hours of incubation, 2 mg/mL MTT 
solution (20 μL) was added to each well and incubated for 4 hours. Formazan was 
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dissolved in 100 μL of DMSO and then absorbance was measured with an 
Absorbance Microplate Reader (VersaMaxTM, Randor, PA, USA) at 550 nm. In 
addition, 10 μL of this reagent was added to each well to evaluate cell viability using 
the WST-1 cell proliferation reagent, and incubated for 2 hours, and absorbance was 
measured at 440 nm. For the cell counting assay, experiments were performed using 
36 mm cell culture dishes. After 48 hours of incubation with the tested compound, 
cells were harvested and evaluated with a CountessTM automated cell counter 
(Invitrogen, Eugene, OR, USA). For measuring the cell viability of cancer cell lines, 
MCF-7 and MDA-MB 231 cells were seeded onto 96-well plate at 4,000 cells/well 
and incubated for 8 hours. Next, cells were cultured in DMEM containing various 
compounds. After 2 days of incubation, cell viability was evaluated by the above 
procedure. 
2.3.2. Western blot analysis 
C2C12 myoblasts were seeded into 6-well plates and incubated until a 
confluence of 70-80%. To prepare C2C12 myotubes, cells were incubated with 
DMEM supplemented with 2% horse serum (Gibco, NY, USA). The differentiation 
medium was changed every 2 days until myotubes were formed. For Western blot 
analysis, myotubes or myoblasts were incubated with various concentrations of 
compounds or fractions for 30-60 minutes. The cells were washed with cold PBS 
and lysed using the lysis buffer [50 mM Tris-HCl (pH 7.6), 120 mM NaCl, 1 mM 
EDTA, 0.5% NP-40, 50 mM NaF] and centrifuged at 12,000 rpm for 20 minutes. 
The protein concentrations were determined using a protein assay kit (Bio-
Rad Laboratories, Inc., CA, USA). Aliquots of lysates were electrophoresed on 8% 
or 12% SDS-polyacrylamide gels and then transferred electronically to 
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polyvinylidene fluoride (PVDF) membranes (PVDF 0.45 µm, Immobilon-P, USA). 
Membranes were then incubated with primary antibodies for p-AMPKα Thr172, 
AMPKα, p-ACC Ser79, ACC (Cell signaling Technology, Inc., Beverly, MA, USA) 
or mouse monoclonal actin (Abcam, Cambridge, UK). After incubation with 
secondary antibodies, membranes were detected using an enhanced 
chemiluminescence Western blot detection kit (Thermo sci., Rockford, IL, USA).  
2.3.3. Immunochemical staining with BrdU antibody 
C2C12 myoblasts were grown on sterile glass coverslips and the cells were 
treated with test samples. After incubation for 8 hours, 50 µM BrdU labeling solution 
(Sigma-Aldrich, St. Louis, MO, USA) was added to the culture cells followed by 
incubation at 37 °C for 2 hours. The cells were then washed three times with PBS 
and fixed with 4% formaldehyde in PBS for 15 minutes at room temperature. After 
washing three times with PBS, the cells were permeabilized with Triton X-100 buffer 
(Sigma-Aldrich, St. Louis, MO, USA) for 20 minutes at room temperature. Next, the 
cells were incubated on ice for 20 minutes with 2N HCl solution. After removing the 
acid solution, the cells were incubated with phosphate/citric acid buffer (pH 7.4) for 
10 minutes at room temperature. Cells were washed three times with Triton X-100 
permeabilization buffer and incubated overnight with anti-BrdU monoclonal 
antibody (Santa Cruz, CA, USA) diluted 1:50 in PBS (pH 7.4). Cells were 
continuously incubated with FITC-conjugated goat anti-mouse lgG (Life 
technologies, Eugene, OR, USA) for 1 hour and then stained with 500 nM DAPI 
solution (Life technologies, Eugene, OR, USA) for 10 minutes at room temperature. 
The slides were fixed with a mounting medium for fluorescence detection 
(Vectashield®, Vector Lab, Inc., USA) and images were observed using fluorescence 
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microscopy (Olympus ix70 Fluorescence Microscope, Olympus Corporation, Tokyo, 
Japan). 
2.3.4. Flow cytometry analysis for BrdU and PI staining 
For flow cytometry with anti-BrdU antibody staining, C2C12 myoblasts 
were maintained in 36-mm culture dishes. After treatment with different 
concentrations of the test compounds, the cells were incubated for 8 hours. Next, 50 
µM BrdU labeling solution was added to the culture medium and incubated for 2 
hours. After removing BrdU medium, the cells were washed with PBS and harvested 
by trypsin solution. Cells were permeabilized using precooled 70% ethanol solution 
and further incubated at 4°C for 1 hour. After centrifugation at 1000 rpm for 2 
minutes, the pellet cells were continually added to a 2N HCl solution containing 0.5% 
Triton X-100 reagent and incubated at room temperature for 30 minutes. Cells were 
then washed with PBS containing 1% BSA (Sigma-Aldrich, St. Louis, MO, USA) 
and resuspended in PBS containing 0.5% Tween 20 and 1% BSA. Cells were 
incubated with anti-BrdU monoclonal antibody (Santa Cruz, CA, USA) for 4 hours 
at room temperature. Cells were resuspended in PBS containing 20 µg/mL 
propidium iodide (PI) (Merck Millipore, MA, USA) and kept in the dark for 30 
minutes. Then, double-stained cells were analyzed using a flow cytometer (BD, 
FACSCalibur, San Jose, CA, USA) and at least 10,000 cells were counted for each 
analysis.  
2.3.5. Flow cytometry of cell cycle status 
C2C12 myoblasts were maintained in 36-mm culture dishes and cells were 
treated with the test compounds. After 12 or 24 hour - incubation, cells were 
harvested using trypsinization and washed twice with pre-cooled PBS. Cells were 
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then fixed with pre-cooled 70% ethanol solution and incubated overnight at 4 °C. 
After washing with PBS, cells were stained sequentially with 20 µg/mL of PI in PBS 
solution and incubated at room temperature for 30 minutes. Cellular DNA content 
was analyzed using a flow cytometer (BD, FACSCalibur, San Jose, CA, USA). At 
least 10,000 cells were counted for each assay. At each phase of the cell cycle, cell 
distribution was displayed using a histogram.  
2.3.6. Glucose uptake assay 
C2C12 myoblasts were seeded into black 96-well plates at 104 cells/well 
using glucose-free medium containing 10% FBS. After 1 day of incubation, cells 
were treated with test samples or insulin (as a positive control) in the presence or 
absence of 2-NBDG (Invitrogen, Eugene, OR, USA). The cells were continually 
incubated for 1 hour at 37°C and they were then washed with cold PBS. The 
fluorescence intensity was measured with excitation/emission at 450/535 nm using 
a fluorescence microplate reader (Spectra Max Gemini XPS, Molecular Devices, San 
Jose, CA, USA).        
2.3.7. Measurement of ATP level 
Intracellular ATP production was evaluated using ATP bioluminescence 
determination assay kit (Invitrogen, Eugene, OR, USA). C2C12 myoblasts were 
grown on 24-well plates overnight and the cells were then exposed to test samples 
from 0 to 70 minutes. After that, the cells were lysed using lysis buffer (100 µL). The 
cell lysates and ATP standard dilutions (20 µL) were transferred to white 96-well 
plates and then luciferase mixture (80 µL) was added to each well. ATP levels were 
measured using a luminescence microplate reader (Spectra Max L, Molecular 
Devices, San Jose, CA, USA). 
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2.3.8. Statistical analysis 
All data were expressed as the mean ± SD of 2-3 independent experiments. 
The difference between group mean values was calculated by analysis of variance 
(ANOVA) followed by Duncan’s or Tukey’s post hoc test as appropriate, 
conducting in SPSS Statistics 23 (SPSS, Inc., Chicago, IL, USA). Statistical 
significance was accepted at * p < 0.05, and ** p < 0.01, *** p < 0.001.  
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3. Results and discussion 
3.1. Structural determination of new compounds  
Bioassay-guided fractionation and isolation of the bioactive fraction from the 
leaves of G. longipes afforded eight new dammarane triterpenes (1–3 and 5–9), along 
with one known compound gypentonoside A (4) (Figure 46). 
 
Figure 46. Nine compounds (1–9) isolated from Gynostemma longipes. 
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Table 12. 13C NMR spectroscopic data for new compounds 1–3 and 5–9  
(in Pyridine-d5).  
position 

















1 39.3, CH2 39.4, CH2 39.4, CH2 39.4, CH2 39.3, CH2 39.5, CH2 39.4, CH2 39.4, CH2 
2 26.9, CH2 26.9, CH2 27.0, CH2 27.1, CH2 29.0, CH2 34.4, CH2 26.9, CH2 28.7, CH2 
3 88.5, CH 88.6, CH 88.6, CH 88.8, CH 78.1, CH 216.2, C 88.7, CH 88.7, CH 
4 39.9, C 39.9, C 39.9, C 40.0, C 39.9, C 47.7, C 40.0, C 39.8, C 
5 56.6, CH  56.6, CH 56.7, CH  56.7, CH 56.7, CH  55.3, CH  56.7, CH 56.6, CH  
6 18.8, CH2 18.8, CH2 18.8, CH2 18.9, CH2 19.2, CH2 20.3, CH2 18.9, CH2 19.0, CH2 
7 34.8, CH2 35.0, CH2 34.8, CH2 34.9, CH2 34.9, CH2 34.1, CH2 34.9, CH2 34.8, CH2 
8 40.9, C  41.1, C 41.0, C  41.0, C 41.0, C  40.9, C  41.1, C 41.0, C  
9 54.6, CH 54.9, CH 54.8, CH 54.7, CH 54.9, CH 54.0, CH 54.7, CH 54.1, CH 
10 37.7, C 37.7, C 37.7, C 37.7, C 38.2, C 37.7, C 37.8, C 37.7, C 
11 40.1, CH2 40.3, CH 40.1, CH2 40.2, CH 40.3, CH2 40.3, CH2 40.2, CH 39.8, CH2 
12 211.7, C 211.4, C 211.8, C 211.8, C 211.9, C 211.2, C 211.9, C 209.9, C 
13 56.2, CH 56.5, CH 56.3, CH 56.3, CH 56.3, CH 56.8, CH 56.9, CH 59.0, CH 
14 56.5, C 56.5, C 56.5, C 56.7, C 56.7, C 56.3, C 56.3, C 55.3, C 
15 32.2, CH2 32.6, CH2 32.2, CH2 32.3, CH2 32.3, CH2 32.3, CH2 32.2, CH2 32.2, CH2 
16 25.2, CH2 25.3, CH2 25.2, CH2 25.2, CH2 25.2, CH2 25.2, CH2 25.2, CH2 28.7, CH2 
17 45.2, CH 43.5, CH 45.2, CH 45.3, CH 45.3, CH 45.2, CH 45.4, CH 45.7, CH 
18 16.0, CH3 16.2, CH3 16.0, CH3 16.1, CH3 16.1, CH3 15.7, CH3 16.0, CH3 16.1, CH3 
19 16.5, CH3 16.6, CH3 16.5, CH3 16.5, CH3 16.5, CH3 16.0, CH3 16.5, CH3 16.4, CH3 
20 74.0, C 80.7, C 74.1, C 74.1, C 74.1, C 74.1, C 73.9, C 159.7, C 
21 27.2, CH3 23.7, CH3 27.2, CH3 27.3, CH3 27.2, CH3 27.3, CH3 27.0, CH3 17.7, CH3 
22 54.8, CH2 55.1, CH2 55.0, CH2 55.0, CH2 55.0, CH2 55.0, CH2 55.1, CH2 126.3, CH 
23 201.7, C 199.8, C 201.7, C 201.7, C 201.8, C 201.7, C 212.9, C 191.7, C 
24 126.4, CH 126.6, CH 126.5, CH 126.6, CH 126.6, CH 126.5, CH 54.8, CH 127.5, CH 
25 154.9, C 154.5, C 154.9, C 154.9, C 154.9, C 155.0, C 70.0, C 154.1, C 
26 20.9, CH3 20.8, CH3 21.0, CH3 21.0, CH3 21.0, CH3 21.0, CH3 30.8, CH3 20.8, CH3 
27 27.7, CH3 27.6, CH3 27.7, CH3 27.7, CH3 27.7, CH3 27.7, CH3 30.4, CH3 27.7, CH3 
28 28.1, CH3 28.1, CH3 28.2, CH3 28.3, CH3 28.4, CH3 27.0, CH3 28.2, CH3 28.2, CH3 
29 16.9, CH3 16.9, CH3 16.8, CH3 17.2, CH3 16.6, CH3 21.5, CH3 17.0, CH3 17.1, CH3 
30 17.4, CH3 17.3, CH3 17.5, CH3 17.5, CH3 17.5, CH3 17.3, CH3 17.5.CH3 17.7, CH3 
1ʹ 105.3, CH 105.3, CH 105.1, CH 105.8, CH   105.3, CH 105.4, CH 
2ʹ 78.3, CH 78.5, CH 78.6, CH 78.1, CH   78.4, CH 78.5, CH 
3ʹ 87.5, CH 87.6, CH 87.8, CH 80.3, CH   87.8, CH 87.7, CH 
4ʹ 70.6, CH 70.4, CH 70.6, CH 72.5, CH   70.8, CH 70.8, CH 
5ʹ 78.3, CH 78.3, CH 78.6, CH 78.7, CH   78.4, CH 78.4, CH 
6ʹ 62.8, CH2 62.8, CH 62.8, CH2 63.3, CH2   63.0, CH2 63.0, CH2 
1ʹʹ 102.5, CH 102.4, CH 101.9, CH 102.1, CH   102.5, CH 102.6, CH 
2ʹʹ 72.2, CH 71.0, CH 70.3, CH 72.8, CH   72.4, CH 72.5, CH 
3ʹʹ 72.7, CH 72.7, CH 72.3, CH 72.9, CH   72.8, CH 72.9, CH 
4ʹʹ 73.9, CH 73.9, CH 76.0, CH 74.5, CH   74.1, CH 74.1, CH 
5ʹʹ 70.5, CH 70.6, CH 67.6, CH 69.9, CH   70.5, CH 70.6, CH 
6ʹʹ 18.9, CH3 18.9, CH3 18.2, CH3 19.1, CH3   18.9, CH3 18.9, CH3 
1ʹʹʹ 103.9, CH 104.0, CH 104.1, CH    104.0, CH 104.1, CH 
2ʹʹʹ 72.7, CH 72.6, CH 72.7, CH    72.9, CH 72.7, CH 
3ʹʹʹ 72.9, CH 73.0, CH 72.9, CH    73.0, CH 73.0, CH 
4ʹʹʹ 73.8, CH 73.8, CH 73.8, CH    73.9, CH 74.0, CH 
5ʹʹʹ 71.0, CH 71.0, CH 71.1, CH    71.1, CH 71.2, CH 
6ʹʹʹ 18.7, CH3 18.7, CH3 18.7, CH3    18.7, CH3 18.8, CH3 
 
# Chemical shift of 20-0-glc: C-1ʹʹʹʹ (98.8, CH), C-2ʹʹʹʹ (73.0, CH), C-3ʹʹʹʹ (72.9, CH), C-4ʹʹʹʹ (74.0, CH), C-5ʹʹʹʹ (78.2, CH), C-6ʹʹʹʹ 
(63.3, CH2); ## Chemical shift of 3ʹʹ-Acetyl: 171.9 (C=0); 21.4 (CH3).
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Table 13. 1H NMR spectroscopic data for compounds 1–3 and 5–9. 
position 
1 2# 3## 5 6 7 8 9 
δH, (J in Hz) 
500 MHz 
δH, (J in Hz) 
600 MHz 
δH, (J in Hz) 
600 MHz 
δH, (J in Hz) 
500 MHz 
δH, (J in Hz) 
600 MHz 
δH, (J in Hz) 
500 MHz 
δH, (J in Hz) 
500 MHz 
δH, (J in Hz) 
500 MHz 
















2. 2.11, overlap 
1.70, overlap  
2.12, overlap 













3. 3.25, overlap 3.26, dd (11.2, 4.4) 3.32, dd (11.2, 4.4) 3.32, dd (11.6, 4.0) 3.40, dd (10.8, 
5.4) 
3.28, dd (11.7, 
4.1) 
3.28, dd (11.7, 4.1) 3.30, dd (11.7, 4.2) 
5. 0.66, overlap  0.65, overlap  0.66, m  0.67, d (9.6)  0.80, overlap 1.35, m  0.69, m  0.69, overlap 
6. 1.50, overlap 




1.39, m  





1.41, m  
1.54, m  
1.41, m 
1.52, m 
1.42, m  
















9. 1.62, overlap 1.79, overlap 1.62, m 1.65 (dd, 13.0, 4.0) 1.62, overlap 1.78, m 1.66, overlap 1.62, m 
11. 2.24, overlap 





2.22, dd (10.5, 3.1) 
2.23, overlap (2H) 2.34, overlap 
2.32, overlap 
2.37, overlap 






13. 3.26, d (9.6) 3.66, d (9.4) 3.28, d (9.6) 3.27, d (10.0) 3.31, d (9.6) 3.31, d (9.6) 3.20, d (9.7) 3.04, d (10.5) 






1.16, m, overlap 
1.84, m, overlap 
1.17, overlap 
1.88, overlap 












2.10, m, overlap 









17. 2.77, td (10.0, 
5.1) 
3.12, td (10.0, 5.1) 2.80, td (10.0, 5.0) 2.80, td (10.0, 5.1) 2.80, td (10.0, 5.1) 2.8, td (5.2, 9.6) 2.78, td (10.1, 5.3) 3.20, ddd (17.0, 10.6, 
6.7) 
18. 1.12, s 1.28, s 1.11, s 1.13, s 1.19, s 1.19, s 1.12, s 1.15, s 
19. 0.76, s 0.76, s 0.82, s 0.79, s  0.85, s 0.83, s 0.78, s  0.81, s 
21. 1.50, s 1.80, s 1.53, s 1.53, s 1.54, s 1.54, s 1.53, s 2.34, s 
22. 2.90, d (14.2) 
2.72, d (14.2) 
3.38, d (14.2) 
3.21, d (14.2) 
2.90, d (14.2) 
2.72, d (14.2) 
2.93, d (14.2) 
2.74, d (14.2) 
2.94, d (14.2) 
2.74, d (14.2) 
2.94, d (14.2) 
2.75, d (14.2) 
3.11, d (15.6) 
2.83, d (15.6) 
6.47, s 
24. 6.28, s 6.22, s 6.30, s 6.31, brs 6.32, s 6.31, s 2.96, d (14.8) 
2.95, d (14.8) 
6.18, s 
26. 2.15, s 2.14, s 2.17, s 2.17, s 2.17, s 2.17, s 1.46, s 2.23, s 
27. 1.70, s 1.67, s 1.71, s 1.71, s 1.72, s 1.72, s 1.46, s 1.70, s 
28 1.17, s 1.17, s 1.19, s 1.24, s 1.23, s 1.14, s 1.19, s 1.22, s 
29 1.11, s  1.11, s  1.11, s  1.19, s 1.04, s  1.05, s  1.12, s 1.16, s  
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position 
1 2# 3## 5 6 7 8 9 
δH, (J in Hz) 
500 MHz 
δH, (J in Hz) 
600 MHz 
δH, (J in Hz) 
600 MHz 
δH, (J in Hz) 
500 MHz 
δH, (J in Hz) 
600 MHz 
δH, (J in Hz) 
500 MHz 
δH, (J in Hz) 
500 MHz 
δH, (J in Hz) 
500 MHz 
30. 0.84, s 0.83, s 0.86, s 0.86, s 0.88, s 0.89, s 0.83, s 0.89, s 
1ʹ 4.80, d (7.7) 4.82, d (7.5) 4.84, d (7.7) 4.96, d (7.7)   4.82, d (7.4) 4.86, d (7.7) 
2ʹ 4.01, overlap 4.01, overlap 4.06, overlap 4.30, overlap   4.03, overlap 4.07, overlap 
3ʹ 4.11, overlap 4.11, overlap 4.11, overlap 4.29, overlap   4.12, t (8.0) 4.11, t (8.0) 
4ʹ 4.01, overlap 4.01, overlap 4.01, overlap 4.16, t (9.1)   4.02, overlap 4.07, overlap 
5ʹ 3.85, overlap 3.87, overlap 3.89, overlap 3.98, overlap   3.85, m 3.89, m 






4.61, dd (12.0, 2.4) 
4.41, dd (12.0, 6.6) 
  4.46, dd (11.8, 3.4) 
4.32, dd (11.8, 5.4) 
4.60, overlap 
4.52, overlap 
1ʹʹ 5.92, br s 5.95, br s 5.99, br s 6.59, brs   5.94, br s 6.00, br s 
2ʹʹ 4.66, overlap 4.66, overlap 4.72, overlap 4.88, m   4.66, overlap 4.72, overlap 
3ʹʹ 4.45, overlap 4.45, overlap 4.48, overlap 4.70, dd (9.4, 3.4)   4.45, overlap 4.50, overlap 
4ʹʹ 4.26, overlap 4.28, overlap 5.79, t (10.0) 4.35, overlap   4.25, t (9.4) 4.31, overlap 
5ʹʹ 4.61, overlap 4.62, overlap 4.74, overlap 4.81, dq (9.5, 6.0)   4.66, overlap 4.68, overlap 
6ʹʹ 1.64, d (6.0) 1.65, d (6.0) 1.41, d (6.0) 1.73, d (6.0)   1.66, d (6.0) 1.70, d (6.0) 
1ʹʹʹ 5.70, br s 5.72, br s 5.72, br s    5.70, br s 5.77, br s 
2ʹʹʹ 4.87, br s 4.87, br s 4.84, br s    4.87, br s 4.93, br s 
3ʹʹʹ 4.53, overlap 4.52, overlap 4.53, overlap    4.53, dd (9.5, 3.1) 4.59, overlap 
4ʹʹʹ 4.28, overlap 4.30, overlap 4.30, overlap    4.26, t (9.4) 4.32, overlap 
5ʹʹʹ 4.70, overlap 4.69, overlap 4.72, overlap    4.66, overlap 4.75, overlap 
6ʹʹʹ 1.60, d (6.0) 1.62, d (6.0) 1.63, d (6.0)    1.61, d (6.0) 1.66, d (6.0) 
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3.1.1. Longipenoside A1 (1) 
Longipenoside A1 (1) was obtained as a white crystal with [D]25D -32.0 (c 0.1, MeOH).  
The molecular formula of compound 1 was deduced as C48H78O17 from the [M − H]− 
high resolution electrospray ionization mass spectrometry (HRESIMS) ion peak 
observed at m/z 925.5157 (calcd for C48H77O17, 925.5166). Infrared (IR) absorption 
at 1616 and 1697 cm–1 and ultraviolet–visible (UV) peak at 254 nm suggested the 
existence of an α, β-unsaturated carbonyl group. The IR broad peak at 3404 cm–1 
appeared in companion with the peak at 1035 cm–1 indicated the presence of a 
hydroxyl group. The proton nuclear magnetic resonance (1H NMR) spectrum 
demonstrated oxygenated methine proton at δH 3.25 (1H, H-3) and eight methyl 
singlets at δH 2.15, 1.71, 1.50, 1.17, 1.12, 1.11, 0.84, and 0.76 (each 3H). Its carbon-
13 nuclear magnetic resonance (13C NMR) spectrum revealed two ketone carbons 
(δC 211.7 and 201.7) and one oxygenated quaternary carbon (δC 74.0) (Figure 47). 
The above observations strongly suggested that compound 1 is a dammarane 
triterpenoid with one hydroxyl and two ketone groups. The position of hydroxyl 
group was confirmed at C-20 by heteronuclear multiple bond correlation (HMBC) 
correlations from H-17 (δH 2.77), H-21 (δH 1.50) and H-22 (δH 2.90 and 2.72) to C-
20 (δC 74.0). One ketone group was located at C-12 from the HMBC experiment 
showing cross-peaks from H-11 (δH 2.24 and 2.22), H-13 (δH 3.26, d, J = 9.6 Hz), 
and H-17 (δH 2.32) to C-12 (δC 211.7). As suggested by UV and IR spectra, an α,β-
unsaturated ketone moiety was further confirmed at C-23 (C=O) and C-24/25 
(CH=C) by HMBC cross peaks from H-22 (δH 2.90, 2.72), H-24 (δH 6.28) to C-23 
(δC 201.7), from H-22 (δH 2.90, 2.72), H-26 (δH 2.15), and H-27 (δH 1.71) to C-24 
(δC 126.4) (Figure 47). The nuclear overhauser effect spectroscopy (NOESY) 
correlation of H-3 (δH 3.25) and H-5 (δH 0.66) demonstrated an α orientation for H-
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3. Both H-17 and Me-21 were also determined as α orientation based on the coupling 
constant of H-13 (J = 9.6 Hz) and NOESY correlations from H-17 (δH 2.77) to H-21 
(δH 1.50) and H-30 (δH 0.84).  
The chemical shifts of the side chain of 1 are comparable with those of 
gypentonoside A, and the chemical shift of C-21 (27.1 ppm) is close to that of the 
typical chemical shift value of 20(S) dammarane derivatives. Also, proton H-17 and 
the methyl group at C-21 were determined as α oriented based on the coupling 
constant of H-13 (J = 9.7 Hz) and NOESY correlations from H-17 (δH 2.79) to H-
21 (δH 1.52) and H-30 (δH 0.86). Therefore, the aglycone of 1 was deduced as 
3β,20(S)-dihydroxydammar-24-en-12,23-dione. The diagnostic NMR data 
suggested the existence of three sugar units in compound 1. Acid hydrolysis of 1 
with HCl afforded D-glucopyranose and L-rhamnopyranose, based on liquid 
chromatography analysis following treatment with L-cysteine methyl ester 
hydrochloride and benzyl isothiocyanate derivatization. The coupling patterns of 
anomeric protons indicated β configuration for the glucopyranosyl (δH 4.80, J = 7.7 
Hz) unit and α configuration for the two rhamnopyranosyl (δH 5.92, 5.70, br s) units. 
The HPLC-MS experiment at the positive mode showed fragment ions at 909 [M + 
H − H2O (18)]+, 763 [M + H − H2O – rha (146)]+, 617 [M + H − H2O – rha – rha 
(146)]+, 455 [M + H − H2O – 2 × rha – glc (162)]+ corresponding to the presence of 
a sugar chain consisting of 2 rhamnoses and 1 glucose. The linkage patterns of three 
sugar units were analyzed based on the HMBC experiment (Figure 47) which also 
constructed the connection between H-1' (δH 4.80) and C-3 (δC 88.5), H-1'' (δH 5.92) 





Figure 47. Longipenoside  A1 
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3.1.2. Longipenoside A2 (2) 
Compound 2 was obtained as a white and amorphous powder. Its molecular 
formula of C54H88O22 was evident by the negative HRESIMS [M − H]− ion peak at 
m/z 1087.5682 (calcd for C54H87O22, 1087.5694). The high-performance liquid 
chromatography-mass spectrometry (HPLC-MS) experiment in the positive mode 
showed a similar fragmentation with compound 1 with extra neutral loss of one 
hexose (162). The 1H, 13C NMR data of 2 were similar in resonance to those of 1 
except for an additional β-glucopyranosyl unit which can be proved by the resonance 
of anomeric proton H-1ʹʹʹʹ (δH 5.16, d, J = 7.7 Hz) and the addition of 6 carbon 
resonances at C-1ʹʹʹʹ (δC 98.8), C-2ʹʹʹʹ (δC  73.0), C-3ʹʹʹʹ (δC 72.9), C-4ʹʹʹʹ (δC 74.0), C-
5ʹʹʹʹ (δC 78.2), and C-6ʹʹʹʹ (δC 63.3). When compared with 1, a downfield shift of C-
20 (δC 80.7, +6.7 ppm) and an upfield shift of C-21 (δC 23.7, −3.5 ppm) were 
observed, which supported the attachment of the glucopyranosyl unit to C-20. 
Further HMBC analysis also constructed a link between H-1ʹʹʹʹ (δH 5.16) and C-20 






Figure 48. Longipenoside  A2 
3.1.3. Longipenoside A3 (3) 
Compound 3 was obtained as a white and amorphous powder. The negative 
HRESIMS showed the deprotonated molecular ion peak at m/z 967.5276 [M − H]− 
(calcd for C50H79O18, 967.5272) indicating that the molecular formula is C50H80O18. 
HPLC-MS experiments at the positive mode showed the presence of an 
oligosaccharide chain consisted of 2 rhamnoses and 1 glucose similar with 
compound 1 together with an acetyl substitution. The 1H, 13C, and HSQC NMR 
spectroscopic data of 3 also showed similar resonances to those of 1, apart from an 
additional acetyl unit which can be deduced by the addition of 2 carbon resonances 
of one ketone (δC 171.9) and a methyl singlet (δC 21.4; δH 2.10).  When compared to 
1, a downfield shift of C-4ʹʹ (δC 76.0, +2.1 ppm) and an upfield shift of C-5ʹʹ (δC 67.6, 
−2.9 ppm) demonstrated the substitution of an acetyl moiety to C-4ʹʹ. The HMBC 
spectrum showed a cross peak from H-4ʹʹ (δH 5.79) to acetyl carbonyl (δC 171.9) 
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Figure 49. Longipenoside  A3 
3.1.4. Longipenoside A4 (5) 
Compound 5 was obtained as a white and amorphous powder. The negative 
HRESIMS showed a deprotonated molecular ion peak at m/z 779.4597 [M − H]− 
(calcd for C42H67O13, 779.4587) indicating the molecular formula to be C42H68O13. 
The HPLC-MS experiment at positive mode showed fragment ions at 763 [M + H − 
H2O (18)]+, 617 [M + H − H2O − rha (146)]+, 455 [M + H − H2O – rha − glc (162)]+ 
corresponding to the existence of a oligosaccharide chain [-glc-rha]. The 1H, 13C, 
HSQC and HMBC NMR spectroscopic data of 5 could be discriminated with 1 by 
the lack of resonances of the rhamnopyranosyl unit attached to C-3ʹ and the shielded 
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Figure 50. Longipenoside  A4 
3.1.5. Longipengenol  (6) 
Compound 6 was obtained as a white and amorphous powder. The negative 
HRESIMS showed a deprotonated molecular ion peak at m/z 471.3393 [M − H]− 
(calcd C30H47O4, 471.3480), representing the molecular formula C30H48O4. The 1H, 
13C NMR, HSQC and HMBC spectroscopic data shown that 6 is the aglycone of 
compounds 1−4. The NOESY correlations from H-3 (δH 3.40) to H-5 (δH 0.80) and 
H-28 (δH 0.77) suggested OH-3 to be β-oriented, which was also supported by the 
coupling pattern of H-3 (dd, J = 9.2 and 2.6 Hz). As a consequence, compound 6 




Figure 51. Longipengenol 
3.1.6. 3-dehydro longipengenol (7) 
Compound 7 was obtained as a white and amorphous powder. The negative 
HRESIMS showed a deprotonated molecular ion peak at m/z 471.3452 [M + H]+ 
(calcd for C30H47O4, 471.3469), which represents the molecular formula C30H46O4. 
The 1H, 13C, HSQC, and HMBC NMR spectroscopic data of 7 showed similar 
resonances to those of 6 except for the presence of the third ketone (δC 216.2) and 
the disappearance of H-3 resonance, together with the deshielded chemical shift of 
C-2 (δC 34.4, +5.4 ppm) and C-4 (δC 47.7, +7.8 ppm) suggested ketone oxidation of 
OH-3. Thus, 7 was identified as 20(S)-hydroxydammar-24-en-3,12,23-trione. 
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Figure 52. 3-dehydro longipengenol 
3.1.7. Longipenoside A5 (8) 
Compound 8 was obtained as an white, amorphous powder, and its molecular 
formula of C48H80O18 was evident on the basis of a negative [M − H]− HRESIMS ion 
peak at m/z 943.5374 (calcd for C48H79O18, 943.5380). HPLC-MS experiments at 
positive mode suggested the existence of a sugar chain similar with compound 1, 
together with the presence of two hydroxyl groups substituted on the its aglycone. 
The 1H, 13C NMR, HSQC spectroscopic data of 8 (Tables 11, 12) showed similar 
resonances to those of 1 except for the hydration of double bonds at C-24 and C-25. 
When compared with 1, an upfield shift of C-24 (δC 54.8, -71.6 ppm), C-25 (δC 70.0, 
-84.8 ppm) and a downfield shift of C-23 (δC 212.9, +11.2 ppm) were observed, 
which supported the attachment a hydroxyl group at C-25. Further HMBC analysis 
also established the connection between Me-26, Me-27 (each δH 1.46, s), and C-25 
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Figure 53. Longipenoside A5 
3.1.7. Longipenoside A6 (9) 
Compound 9 was obtained as a white and amorphous powder. The molecular 
formula of compound 9 was deduced as C48H76O16 from the [M − H]− HRESIMS ion 
peak observed at m/z 907.5066 (calcd for C48H75O16, 907.5061). The HPLC-MS 
experiment at positive mode also demonstrated the presence of a glycoside chain 
identical with compound 1. The 1H, 13C, and HSQC NMR spectroscopic data of 9 
(Tables 11, 12) showed a similar resonance to 1 with the lack of a hydroxy group 
signal at C-20 and contained a olefinic linkage resonance. Moreover, when 
compared with 1, an upfield shift of C-21 (δC 17.7, -9.5 ppm), and downfield shifts 
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of C-20 (δC 159.7, +85.7 ppm) and C-22 (δC 126.3, +71.5 ppm) were observed, 
suggesting the dehydration of this compound at C-20. The HMBC spectrum 
exhibited cross peaks from H-21 and H-17 to C-20 and C-22, respectively 
(CHARGÉ and Rudnicki, 2004; Hawke and Garry, 2001), further confirming the 




Figure 54. Longipenoside  A6 
3.2. Annotations of dammarane triterpenoids in G.latifolium using building block  
strategy 
A total of 19 compounds have been isolated from the sample of G. longipes,  
including 9 compounds isolated in this study and 10 compounds reported in our 
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previous publication (Pham et al., 2018). By analysis the structures of these 
compounds,  
six aglycones (Figure 55-A), two sugar types and one acyl mass fragments (Figure 
55-B) were identified to be building blocks of dammarane triterpenoids in G. 
longipes. Main construction rules can be proposed were oxidation of 3-hydoxy to 
ketone, ring cleavage at C3-4, and elongation of glycosyl chain at C-3. In the negative 
mode of MS1,  masses of precursor ions [M − H]− or [M + HCOO]− of all 
predicted structures were calculated. However signals of [M + HCOO]− could be 
detected with higher sensitivity for the triterpene compounds in G. longipes 
as shown in Figure 55-C.     
 
Figure 55. Building blocks of dammarane triterpenoids and the detection of 
targeted mass in the extract 
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 All the detected masses were analyzed by KIA and MFA techniques to 
consolidate the annotation of their structures. Consequently, a total of 45 peaks were 
detected and assigned. Besides 1 known compounds, 10 new compounds previously 
reported and 8 new compounds  
Table 14: Compound annotation for peaks detected in Gynostemma longipes  
Peak Rt m/z (-) Cald. m/z (-) 
Diff 
(ppm) Formula Ion type 
Building block compound 
assignment 
1.  14.123 517.3546 517.3529 3.3 C30H47O4 [M+H]⎯ [Ol-on-en] 
2.  14.861 515.3384 515.3373 2.1 C31H47O6 [M+HCOO]⎯ [Ol-on-en] – on 
3.  12.178 503.3387 503.3373 2.8 C30H47O6 [M+H]⎯ [Ol-on-en] – seco 
4.  10.362 679.4069 679.4057 1.8 C37H59O11 [M+HCOO]⎯ [Ol-on-en]+glc 
5.  9.862 825.4659 825.4636 2.8 C43H69O15 [M+HCOO]⎯ [Ol-on-en]+glc+rha 
6.  9.414 825.4661 825.4636 3.0 C43H69O15 [M+HCOO]⎯ [Ol-on-en]+glc+rha 
7.  9.528 971.5241 971.5216 2.6 C49H79O19 [M+HCOO]⎯ [Ol-on-en]+glc+rha+rha 
8.  10.038 971.5219 971.5216 0.3 C49H79O19 [M+HCOO]⎯ [Ol-on-en]+glc+rha+rha 
9.  8.441 1117.5793 1117.5795 -0.2 C55H89O23 [M+HCOO]⎯ [Ol-on-en]+glc+rha+rha+rha 
10.  8.941 1117.5787 1117.5795 -0.7 C55H89O23 [M+HCOO]⎯ [Ol-on-en]+glc+rha+rha+rha 
11.  9.397 1117.5795 1117.5795 1.0 C55H89O23 [M+HCOO]⎯ [Ol-on-en]+glc+rha+rha+rha 
12.  10.695 1013.5336 1013.5321 1.5 C51H81O20 [M+HCOO]⎯ [Ol-on-en]+glc+rha+rha+ace 
13.  10.774 1013.5338 1013.5321 1.7 C51H81O20 [M+HCOO]⎯ [Ol-on-en]+glc+rha+rha+ace 
14.  11.362 1013.5327 1013.5321 0.6 C51H81O20 [M+HCOO]⎯ [Ol-on-en]+glc+rha+rha+ace 
15.  14.291 485.3275 485.3267 1.6 C30H45O5 [M+H]⎯ [En-on-en] – seco 
16.  12.256 661.3958 661.3952 0.9 C37H57O10 [M+HCOO]⎯ [En-on-en]+glc 
17.  11.090 807.4534 807.4531 0.4 C43H67O14 [M+HCOO]⎯ [En-on-en]+glc+rha 
18.  11.572 807.4542 807.4531 1.4 C43H67O14 [M+HCOO]⎯ [En-on-en]+glc+rha 
19.  12.081 807.4535 807.4531 0.5 C43H67O14 [M+HCOO]⎯ [En-on-en]+glc+rha 
20.  11.563 953.5114 953.5110 0.4 C49H77O18 [M+HCOO]⎯ [En-on-en]+glc+rha+rha 
21.  10.748 1099.5682 1099.5689 -0.6 C55H87O22 [M+HCOO]⎯ [En-on-en]+glc+rha+rha+rha 
22.  11.861 995.5212 995.5216 -0.4 C51H79O19 [M+HCOO]⎯ [En-on-en]+glc+rha+rha+ace 
23.  12.361 995.5219 995.5216 0.3 C51H79O19 [M+HCOO]⎯ [En-on-en]+glc+rha+rha+ace 
24.  11.861 995.5212 995.5216 -0.4 C51H79O19 [M+HCOO]⎯ [En-on-en]+glc+rha+rha+ace 
25.  11.300 535.3658 535.3635 4.3 C31H51O7 [M+HCOO]⎯ [Ol-on-ol] 
26.  12.178 533.3487 533.3478 1.7 C31H51O7 [M+HCOO]⎯ [Ol-on-ol] – on 
27.  9.491 521.3496 521.3484 2.3 C30H49O7 [M+HCOO]⎯ [Ol-on-ol] – seco 
28.  8.195 697.4163 697.4163 0.0 C37H61O12 [M+HCOO]⎯ [Ol-on-ol]+glc 
29.  7.029 989.5342 989.5321 2.1 C49H81O20 [M+HCOO]⎯ [Ol-on-ol]+glc+rha+rha 
30.  7.529 989.5341 989.5321 2.0 C49H81O20 [M+HCOO]⎯ [Ol-on-ol]+glc+rha+rha 
31.  7.195 1135.5922 1135.5900 1.9 C55H91O24 [M+HCOO]⎯ [Ol-on-ol]+glc+rha+rha+rha 
32.  6.099 1135.5928 1135.5900 2.5 C55H91O24 [M+HCOO]⎯ [Ol-on-ol]+glc+rha+rha+rha 
33.  8.195 1031.5419 1031.5427 -0.8 C51H83O21 [M+HCOO]⎯ [Ol-on-ol]+glc+rha+rha+ace 
34.  8.643 1031.5424 1031.5427 -0.3 C51H83O21 [M+HCOO]⎯ [Ol-on-ol]+glc+rha+rha+ace 
35.  9.862 405.2524 405.2641 -1.7 C24H37O5 [M+H]⎯ [On] – seco 
36.  7.695 681.3843 681.3850 -1.0 C36H57O12 [M+H]⎯ [On]+glc+rha 
37.  8.143 681.3849 681.3850 -0.1 C36H57O12 [M+H]⎯ [On]+glc+rha 
38.  7.950 827.4439 827.4429 1.2 C42H67O16 [M+H]⎯ [On]+glc+rha+rha 
39.  7.503 1019.5089 1019.5063 2.6 C49H79O22 [M+HCOO]⎯ [On]+glc+rha+rha 
40.  7.695 827.4801 827.4793 1.0 C43H71O15 [M+HCOO]⎯ [Ol-en-ol]+glc+rha 
41.  7.397 973.5375 973.5372 0.3 C49H81O19 [M+HCOO]⎯ [Ol-en-ol]+glc+rha+rha 
42.  7.862 973.5386 973.5372 1.4 C49H81O19 [M+HCOO]⎯ [Ol-en-ol]+glc+rha+rha 
43.  8.028 973.5380 973.5372 0.8 C49H81O19 [M+HCOO]⎯ [Ol-en-ol]+glc+rha+rha 
44.  7.634 1119.5970 1119.5951 1.7 C55H91O23 [M+HCOO]⎯ [Ol-en-ol]+glc+rha+rha+rha 
45.  8.766 811.4844 811.4844 0.0 C43H71O14 [M+HCOO]⎯ [Ol-en]+glc+rha 
 
3.3. Dammarane triterpenes enhanced muscle proliferation through activating 
AMPK 
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Regeneration of damaged skeletal muscles depends on satellite cells (known as 
quiescent muscle precursor cells), which play an important role in the proliferation 
and differentiation of myoblasts to form or repair muscle fibers (Fu et al., 2015; Li 
et al., 2012). Recently, several studies have demonstrated that decreased  
proliferation of myoblasts and cytotoxicity can reduce  the number of muscle fibers 
(Li et al., 2012; Tews et al., 1997; Yen et al., 2012). Therefore, mouse C2C12 cells, 
also known as myoblastic cells, were chosen in this research because they are a valid 
model to study muscle cell proliferation (Fu et al., 2015; Li et al., 2012). In a search 
for new bioactive natural products with promising activity for muscle proliferation, 
we found that the 95% EtOH eluted fraction on SP70 resin of the total extract could 
potentially be a ‘hit’ using an in vitro screening method. This fraction stimulated an 
increase in proliferation of C2C12 myoblast cell about 20-30% compared to the 
negative control during 24 and 48 hours of treatment using 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and 4-[3-(4-iodophenyl)-2-
(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) methods 
(Figure 56-A,B). The proliferation also expressed dose-dependently using a cell 
counting method. As  AMPKα is an important regulator during the process of muscle 
proliferation,  we tested the effect of the G. longipes fraction on p-AMPKD 
stimulation in  C2C12 myotubes and myoblasts. As a result, this fraction stimulated 
the phosphorylation of AMPK significantly in a concentration-dependent manner 
(Figure 56-C,D). On the other hand, when the cells were pre-incubated with 
compound C (dorsomorphin – a reversible and potent AMPK inhibitor), the G. 




Figure 56. Effect of the SP70-EtOH 95% fraction from G. longipes on C2C12 
myoblast cell proliferation using the MTT method (A) or WST method (B) after 1 -
2 days incubation.  
Data are presented as the mean ± SD (n = 3), *, # p < 0.05 and **, ## p < 0.01, 
compared to the negative control group. (C) Gynostemma longipes induced 
phosphorylation (Thr172) of AMPKα in a concentration-dependent manner when 
C2C12 myotubes were incubated with the SP70-EtOH 95% fraction for 30 minutes. 
(D) C2C12 myotubes were preincubated for 15 minutes with or without compound 
C before treatment with fractions or Aicar as a positive control. After 30 minutes of 
incubation, cells were harvested and Western blot performed to evaluate the 
expression of p-AMPK. 
Bioassay-guided isolation from G. longipes resulted in the isolation of nine 
compounds (1–9) and all of the isolates were evaluated for their enhancing effect on 
muscle proliferation in C2C12 myoblast cells. After 48 hours of treatment, cell 
viability was assessed using the MTT and WST-1 methods. Seven compounds (1 
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and 3–8) increased cell viability by about 20-30% (Figure 57-A). Notably, 
compounds 6 and 7 exhibited the highest induction of cell proliferation at a value 
from 131.95 ± 2.54% to 136.19 ± 2.73%. Since compound 1 was identified as a 
major constituent of this plant (over 2.08% of the material), it was selected to 
examine the effects on the proliferation of two cancer cell lines, MCF-7 and MDA-
MB-231 breast cancer cells. Cell viability was not changed when the cells were 
incubated with a fraction of G. longipes (10 μg/mL) or compound 1 (10 μM) for 2 
days. These results suggested that the active fraction and major compound of G. 
longipes stimulate muscle cell proliferation selectively and do not induce the 
outgrowth of harmful cancer cell lines.   
A number of studies demonstrated that dammarane triterpenoids are potent 
classes of AMPK-activating agents (Cao et al., 2015; H. M. Lee et al., 2012; Nguyen 
et al., 2011). In order to evaluate the potential activities of compounds from G. 
longipes, nine isolates (1–9) were measured the stimulatory effects on the p-AMPK 
and p-ACC expressions using mouse C2C12 myotubes. Compounds 5, 6, and 7 
increased the phosphorylation of AMPK and ACC proteins strongly, while 
compounds 1, 3, 4, and 8 exhibited less efficient. Therefore, potential candidates (1, 
5, 6, and 7) were further confirmed the activation effect on p-AMPK in C2C12 
myoblasts. These compounds clearly increased the phosphorylation of the target 
protein compared to Aicar as a positive control. 
Because compound 1 is the major constituent of the active fraction, it was 
selected for further evaluating the activation of p-AMPK in a time-dependent 
manner using the mouse C2C12 myoblast model. Remarkably, compound 1 up-
regulated the phosphorylation of AMPK from 30 to 90 minutes (Figure 57-B). 
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Besides, compound 1 also induced the expression of AMPK slightly at 24 hours after 
treatment. These results suggested that triterpenoids from G. longipes could 
significantly stimulate the p-AMPK expression in both mouse C2C12 myotubes and 
myoblasts.  
Considering the structures and activities of all nine isolates, the core structure 
of the dammarane skeleton might contribute mainly to the AMPK activation effect. 
Further examination of structure-activity relationships (SAR) revealed that 
compounds with a longer saccharide side chain at C-3 showed lower AMPK 
inhibition effects: 4 (4 sugar units) < 1 (3 sugar units) < 5 (2 sugar units) < 6 and 7 
(no sugar). It was also noteworthy that with the same number of sugar units, the 
attachment of a sugar unit to C-20 remarkably reduced the activity (2 < 4). 
Furthermore, the hydration of olefinic bond at C-20 and C-24 slightly increased the 
effect in the following order: 9 (two double bonds) < 1 (one double bond) < 8 (no 
double bond). The change of hydroxy (6) and ketone substitutions (7) at C-3 did not 
cause any difference in activity.  
Finally, to assess the effects of compound C during muscle proliferation, the 
cell growth and expression of p-AMPK were analyzed using the mouse C2C12 
myoblast model. Interestingly, co-treatment of compound C with the active fraction 
or compound 1 decreased the percentage of cell viability after 48 hours of incubation, 
compared to the number of C2C12 cells exposed to the fraction or compound 1 alone 
(Figure 57-C). The decline of the p-AMPK expression was also observed after 1 
hour of incubation. Similarly, the stimulation effect of compound 1 on p-AMPK was 
down-regulated by co-treatment with compound C (Figure 57-D). Consequently, 
the activation of the AMPK signaling pathway by G. longipes’s fraction and 
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compound 1 contributes relatively to muscle proliferation by inducing the growth of 
C2C12 myoblasts. 
 
Figure 57. (A) Effect of isolated compounds (1–9) on the proliferation of myoblast 
cells. C2C12 cells were incubated with tested compounds for 48 hours and cell 
viability was assessed using the MTT or WST method.  
Each value is expressed as the mean ± SD (n=3); * p < 0.05 and ** p < 0.01, 
compared to negative control group using the WST method; while # p < 0.05 and ## 
p < 0.01, compared to the vehicle group using the MTT method. (B) C2C12 myoblast 
cells were exposed to compound 1 (20 μM) and incubated for 15 to 120 minutes. 
Phosphorylation of AMPK protein in the cells was assessed by Western blot analysis. 
Values are expressed as the mean ± SD (n = 3), * p < 0.05 and ** p < 0.01, compared 
to the negative control group. (C) The effect of co-treatment compound C with the 
active fraction and compound 1 on the cell viability. C2C12 myoblasts were re-
treated with compound C (20 μM) for 15 minutes and then the cells were 
continuously incubated with test samples for 2 days. After that, the percentage of 
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cell viability was evaluated using MTT method. Results are presented as the mean ± 
SD (n=3); * p < 0.05 and ** p < 0.01, compared to negative control group (without 
compound C treatment); while # p < 0.05 and ## p < 0.01 compared to co-treatment 
with compound C and test samples group, respectively. (D) Down-regulatory effect 
of compound C on p-AMPK (Thr172) when co-treatment with the active fraction or 
compound 1. After 15 minutes re-incubated with compound C (20 μM), mouse 
C2C12 myoblasts were then exposed to test samples for 1 hour. Phosphorylation of 
AMPK protein was measured by Western blotting. Data were calculated as the mean 
± SD (n=3); ** p < 0.01 compared to the negative control, while ## p < 0.01 compared 
to co-treatment with compound C and test samples group, respectively. 
3.4. Effects of dammarane triterpenes on DNA synthesis during cell proliferation.  
It has been previously reported that 5-bromo-2′-deoxyuridine (BrdU) can be 
used to label the DNA of cells in the S-phase. This method is useful for quantifying 
the degree of DNA synthesis during cell proliferation (Staszkiewicz et al., 2009). 
Therefore, in order to confirm whether compound 1 from G. longipes induces cell 
proliferation, immunochemical staining analysis with a BrdU antibody was 
performed. In the first experiment, C2C12 myoblast cells were treated with 
compound 1 (20 μM) or the SP70-EtOH 95% fraction (20 μg/mL) and incubated for 
8 hours. Next, the cells were incubated for 2 hours with or without BrdU. The BrdU 
incorporation into the nucleus was assessed using a fluorescein isothiocyanate 
(FITC)-conjugated anti-BrdU antibody and DAPI staining. As shown in Figure 58-
A, the number of BrdU-positive cells was significantly increased in the group treated 
with the active fraction of G. longipes or compound 1 compared to DMSO treatment 
alone. We also evaluated the BrdU-labeled cells using a flow cytometer for BrdU 
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and PI staining. When C2C12 cells were incubated with or without BrdU treatment, 
the fluorescence intensity was significantly increased from 33.46 r 0.58% to 55.41 
r 0.88%. In order to confirm the concentration dependence in the cells, compound 1 
was treated for 8 hours at different concentrations (20, 10, and 5 μM) and then 
incubated with BrdU for 2 hours. The BrdU positive cell population increased in a 
concentration-dependent manner to 65.22 r 3.43%, 59.90 r 0.84% and 56.00 r 
0.81%, respectively (Figure 58-B). 
Moreover, to better understand the effects of co-treatment compound C with 
test samples on DNA synthesis during cell proliferation, immunofluorescence 
detection and flow cytometry analysis for BrdU staining were carried out. For 
qualitative analysis, the number of red stained cells notably reduced in the groups 
co-treated with compound C compared to the active fraction or compound 1 alone 
(Figure 58-A).  To further examine the fluorescence intensity of each group, the 
BrdU-labeled cells were determined using flow cytometry for BrdU staining only. 
This result indicated that co-treatment of compound C with the active fraction or 
compound 1 failed to increase the number of BrdU-positive cells.            
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Figure 58. Increased DNA synthesis in C2C12 myoblasts cells by dammarane 
triterpenes from G. longipes. (A) C2C12 myoblast cells were re-treated with 
compound C (20 μM) for 15 minutes and the cells were then incubated with the 
active fraction (20 μg/mL) or compound 1 (20 μM) for 8 hours. 
Cells were then incubated for 2 hours in the presence or absence of BrdU. 
After fixation and permeabilization, the cells were incubated with antibodies and 
stained with the DAPI solution. Cells images were observed by fluorescence 
microscopy. (B) C2C12 myoblast cells were incubated with compound 1 at different 
concentrations for 8 hours. After incubation for 2 hours with or without BrdU, the 
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cells were harvested and flow cytometric analysis for BrdU and PI staining was 
performed. The cell distribution was displayed using a histogram. Data presented as 
the mean ± SD (n = 2), * p < 0.05 and ** p < 0.01, compared to the DMSO group. 
(C) Stimulation effects of the active fraction or compound 1 on glucose uptake in 
C2C12 myoblasts using the 2-NBDG probe. The cells were incubated with test 
samples or insulin (as a positive control) for 1 hour. The fluorescent intensity was 
observed at ex/em = 450/535 nm using a fluorescence microplate reader. Each value 
is represented as the mean ± SD (n = 3), * p < 0.05 compared to negative control. 
(D) Dammarane triterpenes from G. longipes increased intracellular ATP level of 
C2C12 myoblasts. The cells were treated with the active fraction (20 μg/mL) or 
compound 1 (20 μM) from 0 to 70 minutes. Mitochondrial ATP synthesis was 
measured using ATP bioluminescence determination assay. Data were calculated as 
the mean ± SD (n = 3); the p value for compound 1 (* p < 0.05, ** p < 0.01) and 
total fraction (# p < 0.05) compared to negative control. 
3.5. Effects of dammarane triterpenes on glucose uptake and ATP levels 
Recent studies suggested the importance of AMPKD enhances glucose uptake 
and ATP production during the process of muscle proliferation (Wagatsuma and 
Sakuma, 2013). Considering that the glucose uptake level was evaluated using a 
fluorescent-tagged glucose analogue, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino]-2-deoxy-D-glucose (2-NBDG), to monitor intracellular glucose uptake. 
As illustrated in Figure 58C, the active fraction and compound 1 as well as insulin 
(as a positive control) increased glucose uptake in mouse C2C12 myoblasts.  
The effects of dammarane triterpenes from G. longipes on the mitochondrial 
ATP synthesis was examined by treatment mouse C2C12 myoblasts with the active 
fraction and compound 1 in approximately 70 minutes. The ATP levels of the active 
fraction and compound 1 increased drastically from 30 to 50 minutes comparison 
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with the vehicle group (Figure 58-D). However, the rate of ATP production reduced 
rapidly after 1 hour of incubation with these samples. During the proliferation of 
myoblasts, the production of ATP is an essential downstream target of glycolysis, 
and cells used these ATP (approximately 30%) which is supplied by oxidative 
phosphorylation (OXPHOS) as the major source of metabolic energy (Medema and 
Macůrek, 2012). Taken together, the role of triterpenoids from G. longipes, which 
regulate muscle proliferation by increasing glucose uptake and ATP production, 
could be suggested. 
3.6. Enhancement of cell proliferation by dammarane triterpenes through cell cycle 
regulation 
Several previous studies have proposed that ginseng root extract promotes 
glucose uptake in muscle cells and also induces the proliferation of β-cells, and 
ginsenoside Rg1 from Panax ginseng enhances myoblast differentiation and myotube 
growth (Cha et al., 2010; Go et al., 2017). In this study, the effect of dammarane 
triterpenoid from G. longipes on cell proliferation through regulation of cell cycle 
was also evaluated using propidium iodide (PI) staining method (Medema and 
Macůrek, 2012). C2C12 myoblasts were exposed to compound 1 (20 PM) for 12 and 
24 hours. The cell cycle distributions at different phases were significantly changed, 
compared to the vehicle group. After 12 hours of incubation with compound 1, the 
cells with 2N DNA content (G0/G1 phases) decreased remarkably from 72.07 r 0.63% 
to 65.09 r 2.49%, while the cells with >2N DNA content (S or G2/M phases) 
increased about 8% compared with negative control. Moreover, the proportion of 
G2/M phases increased significantly from 13.64 r 1.47% to 22.41 r 0.81% when the 
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cells were incubated with compound 1 for 24 hours in comparison with the group 




In this study, we reported the findings of eight new 12,23-dione dammarane 
triterpenes from G. longipes, a traditional Vietnamese medicinal plant. Seven of the 
compounds (1 and 3–8) activated significantly AMPK phosphorylation in mouse 
C2C12 cell lines. The result of AMPK activation by compound 1 could stimulate 
glucose uptake into the cells and increase mitochondrial ATP synthesis. The effect 
of dammarane triterpenes on DNA synthesis during cell proliferation also showed 
that compound 1 increased the BrdU positive cell population in a dose-dependent 
manner. Analysis of cell cycle using flow cytometry displayed clearly that 
compound 1 reduced the 2N DNA content (G0/G1 phases) while the ratio of G2/M 
phases was significantly increased. These results suggested strongly that compound 
1 enhances significantly the proliferation of C2C12 myoblast cells (Figure 59). 
Furthermore, a considerable amount of active compound l (over 2.08% per dried raw 
plant) in G. longipes suggested that it may be a promising candidate for development 
of functional food or botanical drug. These results also indicated that new 
dammarane-type compounds are promising candidates for muscle proliferation via 
activation of AMPK signaling pathways and could be further studied and developed 
as therapeutics for geriatric diseases. 
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Figure 59. The proposed mechanism for enhancing cell proliferation by 
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Gymnema sylvestre      
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         oleanane 
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 PTP1B   .      
Gymnema latifolium     .    
14   oleanane triterpene  Gymlatinosides (1-14)  6  
  . Gymlatinoside GL2  GL3     
IC50  28.66±2.57  19.83±0.40   PTP1B   




Gynostemma longipes  8   12,23-dione dammarane 
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(1, 3-8)    AMPK    . 
 1      2.08%      
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주요어: Gynostemma longipes, Gymnema sylvestre, Gymnema latifolium, oleanane 
triterpenes, dammarane triterpenes, building block 전략, PTP1B, 근육세포증식.  
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